
Title: An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and 
Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic 
Colorectal Cancer, and Other Advanced Solid Tumors
Study ID: [REMOVED]
Protocol Approve Date: 16 July 2018 
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
PROTOCOL
An Open -Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and 
Activity of TAK -931 Single Agent in Patients With Metastatic Pancreatic Cancer, 
Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Sponsor: Millennium Pharmaceuticals, Inc, a who lly owned subsidiary o f Takeda 
Pharmaceut ical Co mpany Limited
40 Landsdowne Street
Cambridge, MA 02139 USA
Telephone: +1 (617) 679 -7000
Please note: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited, may be referred to in this protocol as “Millennium,” 
“sponsor,” or “Takeda.”
Study Number: TAK -931-2001
IND Number: 127,176 EudraCT Number: Not applicable
Compound: TAK -931
Date: 16 July 2018 Amendment Number: 04
Amendment History : 
Date Amendment Number Region
22 May  2017 Initial Protocol Global
14 July  2017 01 Global
30 October 2017 02 Global
26 June 2018 03 Global
16 July 2018 04 Global
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 2of 99
Protocol Incorporating Amendment 04 16 July 2018
1.0 ADMINISTRATIVE 
1.1 Contacts 
A separate contact informat ion list will be provided to each site.
Serious adverse event and pregnancy reporting information is presented in Section 10.0 , as is 
inform ation on reporting product complaints. 
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role Contact
Serious adverse event and pregnancy reporting See Section 10.2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-931
Study No. TAK-931- 2001 Page 3 of 99
Protocol Incorporating Amendment 04 16 July 2018
1.2 Approval 
REPRESENTATIVES OF TAKEDA This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic Signatures may be found on the last page of this document.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedance ance
g:g
olidatedlidate
a privacpriva
other sigther si
s docs do
nd Subjethihi
r Non-Commercial Use Only and
TAK -931
Study No. TAK -931-2001 Page 4of 99
Protocol Incorporating Amendment 04 16 July 2018
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, and any 
other product information provided by the sponsor. I agree to conduct this study  in accordance 
with the requirements of this protocol and also to protect the rights, safet y, privacy, and well -being 
of study  patients in accordance with the fo llowing:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.0 of this 
protocol .
Terms outlined in the Clinical Study  Site Agreement.
Responsibilit ies o f the Invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signatu re of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 5of 99
Protocol Incorporating Amendment 04 16 July 2018
1.3 Protocol Amendment 04 Summary of Changes
Rationale for Amendment 0 4
This sectiondescribes the changes to the protocol incorporating Amendment 04. The primary 
reason for this amendment is change the method from SAE reporting from electronic data capture 
(EDC) -based to paper -based . 
Minor grammat ical, editorial, formatting, and adminis trative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only.
For specific descript ionsoftextchanges and where the changes are located, seeAppendix F
.
Changes inAmendment 04
1.SAE reporting requirements were changed fro m EDC -based reporting to 
paper/e -mail/fax -based reporting.  
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 6of 99
Protocol Incorporating Amendment 04 16 July 2018
TABLE OF CONTENTS
1.0 ADMINISTRATIVE ....................................................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Ame ndment 04 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 11
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 16
3.1 Study -Related Responsibilit ies................................................................................. 16
3.2 Principal Invest igator/Coordinating Invest igator ...................................................... 16
3.3 List of Abbreviat ions............................................................................................... 17
3.4 Corporate Identificat ion........................................................................................... 20
4.0 INTRODUCTION ......................................................................................................... 21
4.1 Background ............................................................................................................. 21
4.1.1 Nonclini cal Experience ...................................................................................... 21
4.1.2 Clinical Experience ............................................................................................ 25
4.1.3 Risks and Benefits .............................................................................................. 27
4.2 Rationale for the Proposed Study ............................................................................. 28
4.2.1 Predi ctive Bi omarkers and Explorat ion of Indicat ions........................................ 28
4.2.2 Colorectal  Cancer ............................................................................................... 29
4.2.3 Pancreat ic Cancer ............................................................................................... 30
4.2.4 Squam ous Esophageal Cancer ............................................................................ 30
4.2.5 Squam ous NSCLC ............................................................................................. 31
5.0 STUDY OBJECTIVES AND ENDPOINTS ................................
.................................. 32
5.1 Object ives................................................................................................................ 32
5.1.1 Primary Object ives............................................................................................. 32
5.1.2 Secondary  Object ives......................................................................................... 32
5.1.3 Exploratory /Additional Object ives..................................................................... 32
5.2 Endpoints ................................................................................................................. 33
5.2.1 Primary Endpo ints............................................................................................. 33
5.2.2 Secondary  Endpo ints.......................................................................................... 33
5.2.3 Exploratory /Additional Endpoints ...................................................................... 33
6.0 STUDY DESIGN .......................................................................................................... 35
6.1 Overview of Study  Design ....................................................................................... 35
6.2 Number of Patients .................................................................................................. 36
6.3 Durati on of  Study .................................................................................................... 36
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 7of 99
Protocol Incorporating Amendment 04 16 July 2018
6.3.1 Durati on of  an Individual Pat ient’s Study  Parti cipati on...................................... 36
6.3.2 End of Study /Study  Com pletion Definit ion and Pl anned Reporting .................... 37
6.3.3 Total  Study  Durati on.......................................................................................... 37
7.0 STUDY POPULATION ................................................................................................ 38
7.1 Inclusion Criteria..................................................................................................... 38
7.2 Exclusio n Cri teria.................................................................................................... 39
8.0 STUDY DRUG ............................................................................................................. 42
8.1 Study  Drug Administration ...................................................................................... 42
8.2 Definit ions of Dose -Limit ing Toxi city..................................................................... 42
8.3 Dose Modificat ion Guidelines .................................................................................. 43
8.3.1 Criteria for Beginning or Delaying a Subsequent Treatment Cy cle..................... 44
8.3.2 Criteria for Treatment Interruption and Dose R educti on..................................... 44
8.3.3 Criteria for Di scontinuati on of  TAK -931............................................................ 46
8.4 Management of Specific Adverse Events .................................................................46
8.4.1 Hem atologic Toxi cities...................................................................................... 46
8.4.2 Gastrointestinal Adverse Events ......................................................................... 47
8.4.3 Hepatobiliary  Disorders ..................................................................................... 48
8.4.4 Cardi ac Toxici ties.............................................................................................. 48
8.4.5Hypotensi on....................................................................................................... 48
8.5 Excluded Conco mitant Medi cations and Procedures ................................................ 49
8.6 Permi tted Concomitant Medications and Procedures ................................................ 50
8.7 Precauti ons and Restri ctions.................................................................................... 50
8.7.1 Pregnancy and Contraception ............................................................................. 51
8.7.2 Females Who Are Lactating or Breastfeeding .................................................... 51
8.7.3 Patients Wi th Prior Exposure to Hepatitis B or Hepatit is C.................................51
8.7.4 Photosafet y........................................................................................................ 52
8.8 Blinding and Unblinding .......................................................................................... 52
8.9 Descript ion of Invest igational Agents ...................................................................... 52
8.10 Preparati on, Reconstitution, and Dispensat ion.......................................................... 52
8.11 Packaging and Labeling ................................
........................................................... 52
8.12 Storage, Handling, and Accountabilit y..................................................................... 53
8.13 Other Protocol -Specified Materials .......................................................................... 53
9.0 STUDY CONDUCT ...................................................................................................... 54
9.1 Study  Personnel and Organizations .......................................................................... 54
9.2 Arrangements for Recruit ment of Patients ................................................................ 54
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 8of 99
Protocol Incorporating Amendment 04 16 July 2018
9.3 Study  Procedures ..................................................................................................... 54
9.3.1 Inform ed Consent ............................................................................................... 54
9.3.2 Patient Dem ographi cs........................................................................................ 54
9.3.3 Medical History .................................................................................................54
9.3.4 Physical Examinat ion......................................................................................... 55
9.3.5 Patient Hei ght and Weight ................................................................................. 55
9.3.6 Vital Signs ......................................................................................................... 55
9.3.7 Pregnancy Test ................................................................................................... 55
9.3.8 Concomitant Medications and Procedures .......................................................... 56
9.3.9 Adverse Events .................................................................................................. 56
9.3.10 Enrollment ......................................................................................................... 56
9.3.11 Electrocardiogram .............................................................................................. 56
9.3.12 Eastern Cooperative Oncology  Group Perform ance Status .................................57
9.3.13 Echocardi ogram  or Mul tiple Gated Acquisit ion Scan ......................................... 57
9.3.14 Clinical Laboratory  Evaluat ions......................................................................... 57
9.3.15 Disease Assessment ........................................................................................... 58
9.3.16 Biomarker and Pharmacodynamic Samples ........................................................ 58
9.3.17 Pharmacokinet ic Measurements ......................................................................... 60
9.3.18 EORTC QLQ -C30............................................................................................. 61
9.4 Com pletion of Study  Treatm ent (f or Individual Patients) ......................................... 61
9.5 Com pletion of Study  (for Individual Pat ients).......................................................... 61
9.6 Discontinuati on of  Treatment Wi th Study  Drug and Pati ent Repl acement ................ 61
9.7 Withdrawal o f Patients From  Study ......................................................................... 62
9.8 Study  Com pliance .................................................................................................... 62
9.9 Posttreatm ent Follow -up Assessments (Progression -Free Survival and Overall 
Survival) .................................................................................................................. 63
10.0 ADVERSE EVENTS .................................................................................................... 64
10.1 Definitions............................................................................................................... 64
10.1.1 Adverse Event Definit ion................................................................................... 64
10.1.2 Serious Adverse Event Definit ion...................................................................... 64
10.2 Procedures for Recording and Reporting Adverse Events and Serious Adverse 
Events...................................................................................................................... 65
10.3 Moni toring of Adverse Events and Period of Observat ion........................................ 66
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 66
10.5 Procedures for Reporting Product Complaints or Medicat ion Errors (Including 
Overdose) ................................................................................................................ 66
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 9of 99
Protocol Incorporating Amendment 04 16 July 2018
10.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties........... 67
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 68
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 69
12.1 eCRFs ...................................................................................................................... 69
12.2 Record Retention ..................................................................................................... 69
13.0 STATISTICAL METHODS .......................................................................................... 71
13.1 Statistical and Analyt ical Plans ................................................................................ 71
13.1.1 Analysis Sets ...................................................................................................... 71
13.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 71
13.1.3 Efficacy Analysis ............................................................................................... 71
13.1.4 Pharmacokinet ic Analysis .................................................................................. 72
13.1.5 Safety Analysis .................................................................................................. 73
13.1.6 Pharmacodynamic Analysis ............................................................................... 74
13.1.7 Biomarker Analysis ............................................................................................ 74
13.1.8 Analysis of Patient -Reported Outcomes ............................................................. 74
13.2 Interim Analyses and Criteria for Early Terminat ion................................................ 74
13.3 Determinat ion of Sample Size .................................................................................. 75
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 76
14.1 Study -Site Moni toring Visit s................................................................................... 76
14.2 Protocol  Deviat ions.................................................................................................. 76
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 77
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 78
15.1 IRB and/or IEC Approval ........................................................................................ 78
15.2 Patient Inform ation, Inform ed Consent, and Patient Authorizat ion........................... 79
15.3 Patient Confident iality............................................................................................. 80
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................80
15.4.1 Publicat ion......................................................................................................... 80
15.4.2 Clinical Trial Registration .................................................................................. 80
15.4.3 Clinical Trial Result s Disclosure ........................................................................ 81
15.5 Insurance and Co mpensation for Injury .................................................................... 81
16.0 REFERENCES .............................................................................................................. 82
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 10of 99
Protocol Incorporating Amendment 04 16 July 2018
LIST OF IN -TEXT TABLES
Table 6.a Primary and Secondary  Endpo ints for Di sclosures ............................................. 37
Table 8.a TAK -931 Dose Reductions ................................................................................ 44
Table 8.b Dose Modificat ion Reco mmendations for TAK -931 Toxi cities.......................... 45
Table 8.c TAK -931 Dose Adjustments for Hematologic Toxicit ies.................................... 47
Table 9.a Clinical Chemistry  and Hematol ogy Tests .......................................................... 57
Table 9.b Clinical Urinalysis Tests .................................................................................... 58
LIST OF IN -TEXT FIGURES
Figure 4.a Kaplan -Meier Pl ot of TAK -931 Versus Vehicle in Pancreat ic Cancer 
Xenografts (n=25) .............................................................................................. 22
Figure 4.b Different ial Activity of TAK -931 (n=26) in MSS CRC Versus MSI (n=13) 
Tumors.............................................................................................................. 23
LIST OF APPENDICES
Appendix ASchedule of Events ............................................................................................. 84
Appendix BResponsibilit ies o f the Invest igator ..................................................................... 93
Appendix CInvest igator Consent to Use of Personal Informat ion.......................................... 95
Appendix DEastern Cooperative Oncology  Group (ECOG) Scale for Performance Status .....96
Appendix ECockcroft -Gaul t Equati on.................................................................................. 97
Appendix F Detailed Descript ion of Amendments to Text ..................................................... 98
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 11of 99
Protocol Incorporating Amendment 04 16 July 2018
2.0 STUDY SUMMARY 
Name of Sponsor:
Millennium Pharmaceuticals, IncCompound:
TAK -931
Title of Protocol: An Open -Label, Phase 2, Parallel Arm Study to 
Evaluate the Safety, Tolerability, and Activity of TAK -931 Single 
Agent in Patients with Metastatic Pancreatic Cancer, Metastatic 
Colorectal Cancer, and Other Advanced Solid Tumors IND No.: 127,176 EudraCT No.:
Not applicable
Study Number: TAK -931-2001 Phase: 2
Study Design: 
Phase 2, multicenter, single agent, uncontrolled, open -label, parallel arm trial in advanced cancer indications. The 
study will also enroll a lead-in safety cohort of Western patients (United States [US] only) with locally advanced or 
metastatic solid tumo rs to determine the safety, tolerability and pharmacokinetics (PK) of TAK -931 50 mg QD for 
14days in 21 -day cycles in this patient population.
Primary Objectives:
To confirm the safety and tolerability of TAK -931 in a cohort of Western patients with meta static solid tumors. 
To evaluate the anti -tumor activity of TAK -931 in patients with metastatic pancreatic cancer, colorectal cancer 
(CRC), squamous esophageal cancer (sqEC), and squamous non –small - cell lung cancer (sqNSCLC) 
Secondary Objectives:
To characterize the PK of TAK -931 in a cohort of Western patients with metastatic solid tumors. 
To contribute to evaluation of population PK using a limited sampling strategy in tumor -specific cohorts .
To assess additional measures of antitumor activity, including overall response rate (ORR), duration of response 
(DOR), progression -free survival (PFS), and overall survival (OS). 
To further characterize the safety of TAK -931 as a single agent in patients with metastatic pancreatic cancer, 
CRC, sqEC, and s qNSCLC.
Patient Population : Patients with one of the following diagnoses:
Pathologically confirmed metastatic pancreatic adenocarcinoma that has progressed after, at least, a first line of 
standard systemic chemotherapy for metastatic disease.
Pathologica lly confirmed metastatic adenocarcinoma of the colon or rectum who have progressed to at least 2 
lines of standard systemic chemotherapy for the metastatic disease.
Pathologically confirmed locally advanced or metastatic sqEC that has progressed after at l east a first line of 
standard systemic therapy for metastatic disease. First -line patients can be enrolled if a platinum doublet is 
contraindicated or refused by the patient.
Pathologically confirmed locally advanced or metastatic sqNSCLC that has progress ed after at least 2 lines of 
standard systemic therapy for metastatic disease .
Number of Patients:
It is expected that up to ~33 response -evaluable patients in the 
metastatic pancreatic cancer cohort and ~35 response -evaluable 
patients in the metastatic CRC cohort will be enrolled in the study in 
3 stages, each with 2 futility evaluations. Additionally, up to 40
response -
evaluable patients with locally advanced or metastatic 
sqEC and up to 40 response - evaluable patients with locally 
advanced or metastatic sqNSCLC may be enrolled in 2 stages, with 
1futility evaluation for each cohort. Number of Sites: 
Approximately 2 -4 sites for the Western safety 
cohort in the US; approximately 18 sites total 
(2-3 sites in Japan and approximately 15 in the 
US).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 12of 99
Protocol Incorporating Amendment 04 16 July 2018
Dose Level:
TAK -931 50 mg QD 14 days on and 7 days off study drug in a 
21-day  cycle. Route of Administration:
Oral. 
Duration of Treatment:
Until a discontinuation criterion is met or 1 year of dosing. Patients 
with clinical benefit may continue after 1 year upon sponsor 
approval.Period of Evaluation:
Patients will be followed for safety for 
approximately 30 days after their last dose of 
study drug or until the start of subsequent 
anticancer therapy, whichever occurs first .
All patients will be followed for P FS and, in 
tumor -specific cohorts, for OS.
It is anticipated that this study will last for 
approximately 24 months.
Main Criteria for Inclusion:
Adult male or female patients aged ≥20 y ears (Japan) or ≥18 years (US). 
Eastern Cooperative Oncology Group (ECOG) performance status of 0 -1.
Patients with one of the following:
–Pathologically confirmed metastatic pancreatic adenocarcinoma that has progressed after, at least, a first line 
of standard systemic chemotherapy for metastatic disease.
–Pathologically c onfirmed metastatic adenocarcinoma of the colon or rectum who have progressed to at least 2 
lines of standard systemic chemotherapy for the metastatic disease.
–Pathologically confirmed locally advanced or metastatic sqEC that has progressed after at least a first line of 
standard systemic therapy for metastatic disease. First -line patients can be enrolled if a platinum doublet is 
contraindicated or refused by the patient.
–Pathologically confirmed locally advanced or metastatic sqNSCLC that has progressed af ter at least 2 lines of 
standard systemic therapy for metastatic disease .
For the Western safety cohort only: patients with locally advanced or metastatic solid tumor for whom no 
standard treatment with an established survival benefit is available or if t he patient refuses other standard therapy. 
For disease -specific cohort patients: measurable disease per Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.1. 
Adequate bone marrow reserve and renal and hepatic function based on the following laboratory parameters: 
Absolute neutrophil count ≥1500/mm3, platelet count ≥100,000/mm3, and hemoglobin ≥9 g/dL.
Total bilirubin ≤1.5×the institutional upper limit of normal (ULN).
Serum alanine aminotransferase or aspartate aminotransferase ≤3.0×the institutional ULN (<5 ×ULN if liver 
enzyme elevations are due to hepatocellular cancer, biliary tract cancer, or metastatic disease in liver).
Creatinine <1.5 ×the institutional ULN or estimated creatinine clearance using the Cockcroft -Gault formula ≥50 
mL/minute for patients with serum creatinine concentrations above institutional limits.
Left ventricular ejection fraction >50% as measured by echocardiogram or multiple gated acquisition scan within 
4 weeks before receiving the first dose of study drug.
Recovered to Grade 1 or Baseline from all toxic effects of previous therapy (except alopecia or neuropathy).
For the Western safety cohort only: willingness to un dergo serial skin tissue biopsies. 
For disease -specific cohort patients: Must have an archival (banked) tumor sample or agree to have a new (fresh) 
tumor biopsy during the screening period. If a new tumor sample is needed, the disease should, in the opini on of 
the investigator, be accessible. For patients in the Western safety cohort, this biopsy is optional. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 13of 99
Protocol Incorporating Amendment 04 16 July 2018
Main Criteria for Exclusion:
Patients who require continuous use of proton pump inhibitors (PPIs) or histamine -2 receptor antagonists and 
patients who are taking PPIs within 5 days before the first dose of study drug.
Treatment with clinically significant enzyme inducers, such as phenytoin, carbamazepine, phenobarbital, 
rifampin, rifabutin, rifapentine, or Saint John’s wort within 14 days before the first dose of study drug.
Treatment with any systemic anticancer treatment (including investigational products) within 30 days or 
5half-lives, whichever is shorter, before the first dose of study drug. 
Histor yof any  of the following within the last 3 mo nths before administration of the first dose of study drug:
–Ischemic myocardial event including angina requiring therapy and artery revascularization procedures, 
myocardial infarction, and unstable symptomatic ischemic heart disease.
–Ischemic cerebrovascul ar event, including transient ischemic attack and artery revascularization procedures.
–Significant, uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or 
ventricular tachycardia).
–Placement of a pacemaker for control of cardiac rhythm.
–New York Heart Association Class II to IV heart failure.
–Any other cardiac condition that, in the opinion of the investigator, could pose an additional risk for 
participation in the study (eg, pericardial effusion or restrictive cardiomyopathy ). 
–Baseline prolongation of the QT interval corrected for heart rate (HR) using Fridericia’s formula ([QTcF] eg, 
repeated demonstration of QTcF interval >480 ms, history of congenital long QT syndrome, or torsades de 
pointes).
Patients with hypertension that is unstable or not controlled by medication.
Histor y of uncontrolled brain metastasis unless:
–Previously treated with surgery, whole -brain radiation, or stereotactic radiosurgery, AND
–Stable disease (SD) for ≥30 days, without steroid use (or stable steroid dose established for ≥14 days before 
the first dose of TAK -931).
Known history of human immunodeficiency virus infection.
Known he patitis B virus (HBV) surface antigen seropositive or detectable hepatitis C infection viral load. Note: 
Patients who have positive HBV core antibody or HBV surface antigen antibody can be enrolled but must have an 
undetectable HBV viral load. 
Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption of study drug, 
such as total gastrectomy or GI conditions that could substantially modify gastric pH.
Prior treatment with radiation therapy involving ≥25% of the hematopoietically active bone marrow within 
3months before the first dose of study drug. 
Patients with known MSI-H genotype or known wild type TP53 per local testing. 
Western Lead -in Safety Cohort Only
Patients with Japanese heredity.
Main Criteria for Evaluation and Analyses:
The primary endpoints for this study are: 
Frequency of treatment -emergent adverse events (TEAEs) per National Cancer Institute Common Terminology 
Criteria for Adverse Events version 4.03: dose -limiting toxicities (DLTs), serious adverse events (SAEs), TEAEs 
leading to dose modifications, and TEAEs leading to treatment discontinuation in the Western safety cohort. 
Disease control rate (DCR) per RECIST version 1.1 in both disease -specific cohorts: complete response (CR) + 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 14of 99
Protocol Incorporating Amendment 04 16 July 2018
partial response (PR) + SD; SD has to be ≥6 weeks from treatment initiation to qualify for DCR.
Secondary endpoints for this study are:
PK parameters after the first dose of TAK -931 o n Cy cle 1 Day  1 (C1D1): C max, time to first occurrence of 
maximum (peak) concentration (t max); AUC from time 0 to 24 hours (AUC 24), AUC from time 0 to the time of the 
last quantifiable concentration (AUC last); and renal clearance (CLr). PK parameters following multiple doses of 
TAK -931 (C1D8): C max, tmax, AUC 24, AUC last, terminal disposition phase half -life (t 1/2z), steady -state apparent 
oral clearance ( CL ss/F), and accumulation ratio based on AUC over the dosing interval ( AUC τ) (R ac(AUC) ). 
ORR (CR+PR), DOR, PFS, and OS in disease -specific cohorts. ORR, DOR, and PFS will be measured in the 
Western safety cohort. 
Percentage of patients with TEAEs: Grade ≥3 TEAEs, serious AEs (SAEs), TEAEs leading to treatment 
discontinuation or dose modifications, and clinically significant changes in laboratory values and vital sign 
measurements in the tumor -specific cohorts.
Statistical Considerations:
Sample size considerations for tumor -specific cohorts are based on a Bayesian predictive probability approach with 
interim analyses for futility (see Section 13.2) with the fol lowing parameters: 
AssumptionsPancreatic Cancer 
CohortMetastatic 
CRC CohortSqEC CohortsqNSCLC 
Cohort
Ineffective DCR (H o) 13% 23% 30% 30%
Effective DCR (H a) 30% 40% 50% 50%
Type 1 erro r 10% 10% 10% 10%
Power 80% 80% 80% 80%
Prior beta distribution 
parametersa0=0.2, b0=0.8 a0=0.2, b0=0.8 a0=0.2, b0=0.8 a0=0.2, b0=0.8
Abbreviations: CRC, colorectal cancer; DCR, disease control rate, H o, null hypothesis, H a, alternative hypothesis; 
sqEC, squamous esophageal cancer; sqNSCLC, squamous non –small - cell lung cancer.
Metastatic Pancreatic and CRC Cohorts
Two interim futility analyses will be conducted for both cohorts. In the metastatic pancreatic cancer cohort, the first 
interim futility analysis will be carried out after the first 16 response -evaluable patients. If no patients with disease 
control (CR, PR, or SD ≥6 weeks) are observed in the first stage, the study will be stopped for futility; otherwise, the 
study will continue to the second stage. The second interim futility analysis will be carried out after 25 
response -evaluable patients. If ≤2 patients have achieved disease control, the study will be stopped for futility; 
otherwise, the study will continue into the third stage to more fully characterize the DCR in a total of 33 
response -evaluable patients and the null hypothesis will be rejected if there are more than 7 patients with disease 
control. Similarly, the 2 interim futility stopping bounds for DCR in the metastatic CRC cohort will be ≤1/15 and 
≤4/25 in a total of 35 response -evalua ble patients, and the null hypothesis will be rejected if there are more than 11 of 
35 patients with disease control. 
Squamous Esophageal Cancer and Squamous Non –Small-Cell Lung Cancer Cohorts 
One interim futility analysis will be conducted for both cohorts. The interim futility stopping bound for DCR will be 
≤6 patients with disease control in a total of 20 response -evaluable patients, and the null hypothesis will be rejected if 
there are more than 16 of 40 patients with disease control.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 15of 99
Protocol Incorporating Amendment 04 16 July 2018
Sample Size Justification: It is expected that the study will enroll up to ~33 response -evaluable patients in the 
metastatic pancreatic cancer cohort, ~35 response -evaluable patients in the metastatic CRC cohort, up to 40 
response -evaluable patients in the sqEC cohor t, and up to 40response - evaluable patients in the sqNSCLC cohort. 
With a potential drop -out rate of 10%, as many as approximately 76 patients may be enrolled in the pancreatic and 
CRC cohorts . Approximately 8 0patients may be enrolled in the sqEC cohort a nd sqNSCLC cohorts.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 16of 99
Protocol Incorporating Amendment 04 16 July 2018
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Clinical Study  Supplier List or equivalent. The ident ified vendors for spe cific study -related 
activit ies will perform these act ivities in full or in partnership wi th the sponsor. 
3.2 Principal Investigator/Coordinating Investigator
Takeda will select a signatory  coordinat ing invest igator from the invest igators who participate in 
the study . Selection criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study  medicat ion, thei r experti se in the therapeutic area and the conduct of clinical 
research as well as study participation. The signatory coo rdinating invest igator will be required to 
review and sign the clinical study report (CSR) and by doing so agrees that it accurately describes 
the resul ts of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 17of 99
Protocol Incorporating Amendment 04 16 July 2018
3.3 List of Abbreviations
%CV coefficient of variation
5-FU 5-fluourouracil
5-HT 3 5-hydroxy tryptamine 3 serotonin
AE adverse event
ALK anaplastic lymphoma kinase
ALT alanine aminotransferase
ANC absolute neutrophil count
ASCO American Society of Clinical Oncology
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the plasma concentration -time curve
AUC τ area under the plasma concentration -time curve over the dosing interval
AUC 24 area under the plasma concentration -time curve from the time 0 to 24 hours
AUC last area under the plasma concentration -time cur ve from time 0 to the time of the last quantifiable 
concentration
BP blood pressure
C1D1 Cycle 1 Day  1
CA19 -9 carbohydrate antigen 19 -9
CDC7 cell division cycle 7
CEA carcinoembryonic antigen
CLr renal clearance
CL ss/F steady state apparent oral clearance
Cmax maximum observed plasma concentration
CR complete response
CRC colorectal cancer
CRO contract research organization
CSR clinical study report
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
ctDNA circulating tumor DNA
CxDx Cycle x, Day  x
CV cardiovascular
CYP cytochrome P -450
DCR disease control rate
DDI drug-drug interaction
DDR DNA damage response
DLT dose-limiting toxicity
DOR duration of response
ECHO echocardiogram
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 18of 99
Protocol Incorporating Amendment 04 16 July 2018
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EGFR epidermal growth factor receptor
EORTC European Organisation for Research and Treatment of Care
EOT End-of-Treatment (visit)
EU European Union
FDA Food a nd Drug Administration
FFPE formalin -fixed, paraffin -embedded
FIH first-in-human
FOL folinic acid
FOLFOX folinic acid + 5 -fluorouracil + oxaliplatin
GCP Good Clinical Practice
G-CSF granulocyte colony -stimulating factor
GI gastrointestinal
GM-CSF granulocyte -macrophage colon y-stimulating factor
H2 histamine -2 (receptor)
HBV hepatitis B virus
HCV hepatitis C virus
HR heart rate
HRQOL health -related quality of life
IC50 the concentration producing 50% inhibition
ICF informed consent form
ICH International Conference on Harmonisation
IEC independent ethics committee
IHC immunohistochemistry
IND investigational new drug
IRB institutional review board
MCM2 minichromosome maintenance complex 2
MedDRA Medical Dictionary for Regulatory Activities
MHRA Medicines and Healthcare products Regulatory Agency
MRI magnetic resonance imaging
MSI microsatellite instability
MSI-H microsatellite instability -high
MSS microsatellite stability
MTD maximum tolerated dose
MUGA multiple gated acquisition scan
NA nucleoside antagonist
NCI Natio nal Cancer Institute 
NGS next generation sequencing
NSAID nonsteroidal anti -inflammatory drug
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 19of 99
Protocol Incorporating Amendment 04 16 July 2018
NSCLC non–small -cell lung cancer
ORR overall response rate
OS overall survival
PD progression of disease
PD-L1 programmed death -ligand 1
PFS progression -free survival
P-gp P-glycoprotein
PK pharmacokinetic(s)
PMDA Pharmaceuticals and Medical Devices Agency of Japan
pMCM2 phosphorylation of MCM2 at serine -40
PO per os (orally )
PPI proton pump inhibitor
PR partial response
PRO patient -reported outcome
QD once daily
QLQ -C30 Core Quality of Life Questionnaire
QTc QT interval corrected for heart rate
QTcF QT interval corrected for heart rate using Fridericia’s formula
Rac(AUC) accumulation ratio based on AUC τ
RBC red blood cell
RECIST Response Evaluation Criteria in Solid Tumors
SAE serious adverse event
SD stable disease
SUSAR suspected unexpected serious adverse reaction
sqEC squamous esophageal cancer 
sqNSCLC squamous non–small -cell lung cancer
TAS -102 LONSURF
TEAE treatment -emergent adverse event
t1/2z terminal disposition phase half -life
tmax time to first occurrence of C max
ULN upper limit of normal
US United States
WBC white blood cell
WHO World Health Organization
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 20of 99
Protocol Incorporating Amendment 04 16 July 2018
3.4 Corporate Identification 
Millennium Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited.
TDC Japan Takeda Development Center Japan
TDC Asia Takeda Development Center Asia ,Pte Ltd
TDC Europe Takeda Development Centre Europe Ltd.
TDC Americas Takeda Development Center Americas , Inc.
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda Millennium Pharmaceuticals, Inc, TDC Japan, TDC Asia, TDC Europe and/or TDC 
Americas, as applicable
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 21of 99
Protocol Incorporating Amendment 04 16 July 2018
4.0 INTRODUCTION
4.1 Background
TAK -931 i s a highly potent and selective inhibitor of the cell divisio n cycle 7 (CDC7) kinase. 
CDC7 is a serine/threonine kinase that contributes to init iation of DNA replicat ion by 
phosphorylat ing the mini chrom osom e maintenance complex 2 (MCM2) [1,2] . Kinase act ivity of 
CDC7 is controlled by its binding protein DBF4 in a cell cycle -dependent m anner [
3]. Recent 
studi es revealed that CDC7 is also invo lved in DNA damage response (DDR) and DNA 
replicat ion, suggest ing that CDC7 plays important roles in both cell pro liferat ion during the S 
phase and geno mic stabilit y in DDR [
4-7]. 
Furtherm ore, el evated CDC7 expressio n has been reported in various cancers and correlates with 
poor prognosis, such as in diffuse large B
-cell lympho ma, oral squamous carcino ma, and breast, 
colon, col orectal , ovari an, and lung tumors [8-11] . However, it is not clear to what extent this 
increased expressio n reflects proliferat ive potential [
12].
In vitro inhibi tion of  the CDC7/DBF4 kinase complex arrests cell pro liferat ion and induces 
apoptosis in cancer cell lines [
13]. The major reason why t he inhibit ion of the CDC7/DBF4 kinase 
complex is highly relevant for cancer is that activation of diverse oncogenes and loss of some 
tumor suppressors evoke replication stress and consequent DNA damage that triggers the 
checkpoint responses of specific sig naling cascades, as demonstrated in cell culture experiments 
and in analyses o f clinical specimens fro m a range of human malignancies [14]. Taken togeth er, 
these data suggest that CDC7 kinase inhibitors present a novel class of mo lecular targets for cancer 
therapy  [
15].
Given that CDC7 is responsible for two key  functions of DNA replicat ion and DDR, CDC7 
appears to be a critical gene for proliferat ion and survival o f cancer cells, and inhibit ion of CDC7 
is expected to be ant iproliferat ive and induce apoptosis in a broad range of cancers. Based on its 
dual mechanism of act ion, CDC7 inhibitors may also produce clinically meaningful efficacy both 
as a single agent and in co mbination wit h other DNA -damaging drugs. 
4.1.1 Nonclinical Experience
4.1.1.1 Nonclinical Pharmacology
In vitro and in vivo pharmacology  studi es indicate that TAK -931 is a highly  potent and sel ective 
inhibitor of CDC7 kinase with a concentration producing 50% inhibit ion (IC 50) of l ess than 
0.3nM. Time -dependent inhibit ion assays in the presence of high and low adenosine 
5’
-triphosphate (ATP) concentrations revealed that TAK -931 is an ATP -competitive inhibitor 
with slow-binding kinet ics to CDC7 kinase. The specificit y of TAK -931 was evaluated at 1 M 
against a panel of kinases. Of the 308 kinases tested, TAK-931 at 1M inhibited 10 kinases by 
80% or more. The IC 50values for these kinases —DAPK3, DAPK1, CDK9/Cyclin T1, DMPK, 
CDK8/Cyclin C, MAPK12, STK17A, CLK4, DYRK1A, and GSK3B—ranged from  36.9 to 
338nM. TAK -931 exhibited >120 -fold select ivity for CDC7 kinase i nhibit ion compared wit h the 
other kinases in this panel.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 22of 99
Protocol Incorporating Amendment 04 16 July 2018
TAK -931 causes DNA replication stress by inhibit ing the phosphorylat ion of MCM2 at serine -40 
(pMCM2). In the colorectal adenocarcino ma cell lines COLO205, SW48, HCT116, and RKO, 
TAK -931 suppressed MC M2 phosphorylation in a dose dependent manner with IC 50values 
ranging from 18 to 170 nM. 
The in vivo ant itumor activit y of TAK -931 administered orally as either a single agent or in 
combinat ion (wi th irradiat ion, irinotecan, or topotecan) was evaluated in female BALB/c nude 
mice bearing COLO205 human co lorectal  adenocarcino ma o r OC -11-JCK human primary ovaria n 
adenocarcino ma xenografts. Single treatments with TAK -931 using ei ther continuous or 
intermittent dosing schedules demonstrated significant dose -
dependent antitumor activit y against 
COLO205. In COLO205, TAK
-931 combined wit h irradiat ion or irinotecan also exhibited 
additive antitumor activit y compared with eit her single treatment alone. In the OC -11-JCK 
xenograft, the combinat ion of TAK -931 and topo tecan produced synergy  com pared wi th either 
treatm ent al one.
The in vivo ant itumor activit y of TAK -931 was further characterized using 94 primary  human 
xenograft tumors. In this nonclinical phase 2 like study , mice were treated with TAK -
931 
60mg/kg orally (PO) wi th a 3 days on and 4 days off weekly schedule for 21 day s. In thi s study , 
TAK -931 was m ore acti ve in pancreat ic and colorectal tumors ( Figure 4.aand  Figure 4.b). 
In addit ion, microsatellite -instable (MSI) ty pe of  colorectal  tumors appeared to show worse 
response to TAK -931 compared with microsatellit e stabl e (MSS) type of CRC ( Figure 4.b). These 
in vivo data were consistent with the in vitro cancer cell line screen results where the data 
suggested that the MSS group was more sensit ive to TAK -931 than the MSI group in CRC cell 
lines. 
Figure 4.a Kaplan -Meier Plot of TAK -931 Versus Vehicle in Pancreatic Cancer 
Xenografts (n=25)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 23of 99
Protocol Incorporating Amendment 04 16 July 2018
Figure 4.b Differential Activity of TAK -931 (n=26) in MSS CRC Versus MSI (n=13) 
Tumors
Abbreviations: CRC, colorectal cancer; MSI, microsatellite instable; MSS, microsatellite stable; PDX, patient -derived 
xenografts; TGI, tumor growth inhibition. 
4.1.1.2 Nonclinical Pharmacokinetics and Pharmacodynamics
The pharmacokinet ic (PK) and pharmacodynamic response of TAK -931 was evaluated after a 
single oral  administrati on of  10, 20, 40, 60, and 80 mg/kg to female BALB/c nude mice bearing 
COLO205 human colorectal adenocarcino ma xenografts. Plasma and tumor samples were 
obtained and analyzed for TAK- 931 concentrations and derived PK parameters. pMCM2, which 
CDC7 kinase phosphorylates directly, was used as a target -engagement pharmacodynamic 
marker. Pharmacodynamic analysis was performed using Western blot and immunohistochemistr y 
(IHC). The plasma and tumor exposures of TAK -931 are increased in an approximately 
dose-proporti onal manner in female BALB/c nude mice bearing COLO205 xenografts. Both 
Western blot and IHC analysis dete cted modulat ions of the pharmacodynamic bio marker pMCM2 
in xenograft tumors and mouse skin in a dose -and time -dependent manner. Furthermore, 
antitumor activit y and durat ion of saturated pMCM2 suppressio n in tum or was well correlated in 
nude mice bearing C OLO205 xenografts. These results indicate the potential utilit y of pMCM2 as 
clinical pharmacodynamic bio markers to evaluate the pharmacodynamic response of TAK -931.
TAK -931 exposure after a single oral administration demonstrated that the compound is rapid ly 
absorbed in vivo, with 35.1% and 21.6% oral bioavailabilit y in Sprague -Dawley  rats and beagle 
dogs, respectively. After a single intravenous dose, TAK -931 demonstrated high plasma clearance 
in rats (3260 mL/hr/kg) and dogs (2630 mL/hr/kg), and high vo lume of distribut ion at steady state 
in both species (rats: 2460 mL/kg; dogs: 3060 mL/kg). Both rats and dogs exhibited nonlinear oral 
PK.
TAK -931 exhibited nonlinear pharmacokinet ics following oral dosing in rats and dogs with 
single- dose m aximum  observed c oncentrati on (C max) and area under the plasma 0 5 10 15 200255075100125MSI T AK-931
MSS T AK-931MSI vehicle
MSS  vehic le
Days after treatmentPercent survivalMSS vehicle vs. TAK-931:p<0.001
MSI veh icle vs. TAK-931:n.s.
CRC_MSS CRC_MSI050100150TGI (%)
MSS CRC MSI 
CRCp<0.05
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 24of 99
Protocol Incorporating Amendment 04 16 July 2018
concentration -time curve (AUC) from time 0 to 24 hours (AUC 24) increasing in a greater than 
dose-proporti onal manner at hi gher doses. No accumulat ion of TAK -931 was observed in eit her 
species. 
TAK -931 has high perm eabili ty and is a substrate for breast cancer resistance protein, but is not 
likely  a substrate for P -glycoprotein (P -gp) on the basis of transcellular transport invest igations 
across Caco -2 cell mo nolayers. Addit ionally , TAK -931 m ay have a weak inhib itory effect on 
P-gp–mediated efflux activit y (IC 50>100 M). The drug -drug interaction (DDI) potential o f 
TAK -931 wi th P-gp substrates and inhibitors is low.
In an in vitro study , plasma protein binding was 59% to 62% in mice, 73% to 74% in rats, 57% to 
58% in dogs, and 73% to 74% in humans, with no concentration dependency observed fro m 0.01 
to 1 g/mL.
The in vitro oxidative metabo
lism of TAK -931 was evaluate d using liver microsomes from CD -1 
mice, Sprague -Dawl ey rats, beagl e dogs, cyno molgus monkeys, and humans. TAK -931 was 
metabo lized primarily to the unident ified metabo lite UK -1 and, to a lesser extent, UK -2. There 
was no m etabo lite unique to human liver mi crosomes through oxidat ive metabo lism.
Evaluat ion of the in vitro metabo lism of TAK -931 in the presence of uridine -5'-
diphosphategl ucuroni c acid showed that the compound is metabo lized through glucuronidation by 
liver microsomes from all species except do gs (mice, rats, monkeys, and humans).
Invest igations into cytochrom e P450 (CYP) enzyme -mediated metabo lism showed that CYP2D6 
and CYP3A are the main CYPs invo lved in the metabolism o f TAK -931. There is a DDI potential 
with UDP -glucuronosyltransferase induc ers; however, the DDI potential wit h CYP inhibitors, 
though they  are involved in metabolism, is unlikely . TAK -931 is unlikely to cause DDIs with 
concomitant medicat ions metabo lized via CYP isozymes at C maxvalues <800 ng/mL . 
Details on these studies are provi ded in the current TAK -931 Investi gator’s Brochure (IB).
4.1.1.3 Nonclinical Toxicology
The toxi cologic profile and systemic toxic potential o f TAK -931 has been well defined in 
Sprague -Dawl ey rats and beagle dogs.
The primary  dose -limit ing toxicit ies (DLTs), particularly in the dog, appear to be associated with 
Cmaxand are closely associated with the observed cardiovascular (CV) changes. These CV effects 
were dose dependent and plasma co mpound concentration dependent, occurring in rats and dogs 
when TAK -931 pl asma concentrations exceeded approximately  1000 ng/mL. It has been 
confirmed that the effects of TAK -931 on HR and BP are monitorable and reversible upon 
clearance of TAK -931.The CV effects may be related to TAK -931 inhibitory  activit y at off -target 
kinase s. In addi tion, renal injury  (obstructive nephropathy ) was confirmed to be a DLT in rats, 
although similar changes were not observed in dogs. Renal effects of TAK -931 were m onitorabl e 
with clinical  and urine chemistry
, and renal  tubular dam age is considere d reversible. 
The target organ toxicit ies after the repeated dosing of TAK -931 were largely similar in rats and 
dogs and were generally consistent with inhibit ion of CDC7 act ivity. Test arti cle-related findings 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 25of 99
Protocol Incorporating Amendment 04 16 July 2018
included the hematopoi etic and lympho id syst ems, gastrointestinal (GI) mucosa, and reproductive 
organs. Decreased white blood cell (WBC) count or single cell necrosis in the GImucosa appeared 
with minimal degree atlower dose s and severit y increased with dose level. All target organ 
toxicities obse rved in the repeated- dose studies were generally mo nitorable and reversible, except 
for the effect on germ cells.
Based on these results, the toxico logy studi es conducted wi th TAK -931 support the proposed 
clinical program in adult patients with advanced ma lignancies. The nonclinical toxico logy profile 
demonstrated target organ toxicit y that was generally considered to be monitorable and reversible. 
The primary C max-related toxi city was CV effects (decreased BP with reflect ing tachycardia). The 
DLTs rel ated to total exposure were effects on the GI mucosa and lympho id systems consistent 
with pharm acology-mediated CDC7 inhibit ion. 
Details on these studies are provided in the current TAK -931 IB. 
4.1.2 Clinical Experience
All prior clinical experience is fro m the first-in-human (FIH) phase 1 study  (TAK -931-1002) in 
Japanese patients with advanced so lid malignancies . The data cut -off used for the safet y analysis 
and PK analysis was 04 January 2018 and included 49 patients who had received at least 1 dose of 
TAK -931 as a single agent. This trial in pat ients wit h advanced nonhematologic cancer has 
enrolled 16 patients in Schedule A (14 days on/7 days off in 21 -day) in 4 dose levels (14 patients 
DLT -evaluable). The MTD was defined at 50 mg QD with this schedule. Twelve pat ients were 
enrolled into Schedule B (7 days on/7 days o ff twice in 28 -day cycles), 3 patients at 60 mg QD and 
9 pati ents at 80 m g. Currently this schedule is ongoing and enro lling patients at 100 mg QD. 
Twelve pat ients have been enro lled into Schedule D (c ontinuous QD administration), 6 patients at 
20 m g and 6 pati ents at 30 m g. Current ly pat ients are being enro lled in this schedule at 40 mg.
4.1.2.1 Safety
The MTD has been defined per the protocol at 50 mg QD for Schedule A because there were no 
DLTs in the 14 DLT -evaluable patients receiving this dose in the escalat ion plus the expansi on 
phases. Neutropenia has been the only reported DLT. Neutropenia was dose -dependent, 
noncumulat ive, and reversible, with the nadir usually occurring at the end of the dosing period . 
Neutropenia has not been accompanied by other toxicit ies such as thrombocytopenia, mucosit is, or 
diarrhea. 
Two of 3 patients receiving 60 mg QD in Schedule A had DLTs (Grade 4 neutropenia lasting 
longer than 3 days that, per the protocol, was considered a DLT). The first patient presented with 
an abso lute neutrophil count (ANC) nadir o f 190/mm3and l ow-grade fever that prompted the 
investigator to use prophylact ic antibiot ics and granulocy te-colony stimulating factor (G -CSF). 
The second pat ient’s ANC nad ir was 30/mm3, and prophylact ic antibiot ics and G- CSF were al so 
used. No Grade 4 neutropenia was observed at 50 mg. In Schedule B, 2 out of 9 patients in the 
80-mg cohort had DLTs of Grade 3 febrile neutropenia; 1 of these 2 patients presented with 
concomi tant ileus and the other wi th a peri toneal abscess. Both pati ents were di scontinued as a 
consequence o f the events. Escalat ion in this cohort is ongoing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 26of 99
Protocol Incorporating Amendment 04 16 July 2018
In the 49 patients treated with TAK -931 in the FIH study , nausea was reported in 24 (49%) 
patients. Ot her GI AEs included vo miting (n = 10 [20%]), diarrhea (n = 9 [18%]), constipation (n = 
5 [10%]), abdominal pain (n = 4 [8%]), ileus (n = 2 [4%]), dysgeusia (n = 1 [2%]), and pancreat itis 
(n = 1 [2%]). In addit ion, 13 (27%) patients reported AEs of decrease d appet ite. Seri ous GI AEs 
included ileus (2 [4%]) and nausea (1 [2%]). Grade ≥3 GI AEs included decreased appet ite (2 
[4%]), abdominal abscess (1 [2%]), and ileus (1 [2%]). In general, GI tolerabilit y was good with a 
low frequency of severe nausea, vomit ing, and di arrhea, and there was no significant impact on 
treatm ent com pliance. Nausea and vomit ing were successfully managed with standard 
antiemetics.
Hypotensi on is considered a key  nonclinical risk (Section 4.1.1.3 ). In the FIH trial, 2 patients 
presented with an AE of drug -related Grade 1 (asymptomat ic, intervention not indicated) 
hypotension. One patient dosed with 40 mg in Schedule A presented with Grade 1 hyp otensi on in 
Cycle 1 that started on Day  2 and l asted until the end of the dosing period in Cycle 1. No action 
was taken with study  drug. Another patient treated at 50 mg QD presented with Grade 1 
hypotension for 2 consecut ive days (Cycle 1 Day 12 predose a nd Cycle 1 Day  13 predose); thus, 
TAK -931 doses were held for these 2 days. The low BP recovered without intervent ion. Both 
episodes of asymptomat ic hypotension were not recorded as correlated with t max(2 hours 
postdose). TAK -931 C maxin pat ients dosed with 50 mg QD in the FIH trial had a median 
concentration of 214 ng/mL wit h an interpatient CV of 39.6%. Hy potensi on in animals was 
observed wit h C maxabove 1000 ng/mL. Based on clinical safet y and PK, the risk o f clinically 
relevant hy potensi on at a 50 m g dose i s considered to be very  low.
Alopecia has been reported in the study  TAK -
931-1002. As of 04 January 2017, 4 of the 12 
patients who received treatment with TAK -
931 reported Grade 1 or 2 alopecia. None of the 
reported TEAEs for alopeci a were designated as serious.
The current study  (TAK -931- 2001) i s the second trial with TAK -931. The enrollment of the 
Western cohort safet y (n = 12) has been completed. One patient presented with Grade 3 
neutropeni a as a DLT. The PK profile on Days 1 a nd 8 is comparable to that obtained for the same 
dose in the previous FIH study  in Japanese patients with so lid tumors. 
4.1.2.2 Pharmacokinetics
Absorpti on of  TAK -931 was fast fo llowing single or mult iple oral dose administrations, with a 
median time to first occ urrence of C max(tmax) of 1 to 4 hours. Systemic exposures (AUC) of 
TAK -931 increased in approximately a dose -proporti onal manner over the range of 30 to 60 mg 
QD. The C maxand AUC of TAK -931 hadrelatively low inter -patient variabilit y (<50% for C max
and coefficient of variat ion [%CV] ≤30% for AUC). TAK -931 showed minimal accumulat ion 
following once -daily dosing wi th a mean terminal  disposi tion phase half -life ( t1/2z)of 4.3to 
6.2hours. These results suggested that TAK -931 showed PK properties that suppo rt routine oral 
administration. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 27of 99
Protocol Incorporating Amendment 04 16 July 2018
4.1.3 Risks and Benefits
The safet y of Schedule A at 50 mg QD has been adequately studied in the FIH trial in Japan. This 
dose and schedule have demonstrated safe and comparable in a similar cohort of Western patients 
with metast atic cancer (Section 4.1.2.1 ). The main clinical toxicit y is neutropenia that is monitored 
routi nely in this trial. The overall tolerabilit y and safet y of TAK-931 i s adequate for an oral drug to 
be self -administered by the patient at home. 
Early signs of clinical act ivity include PRs in duodenal cancer at 30 mg, squamous esophageal 
cancer at 50 mg, and squamous cervical cancer at 60 mg, prolonged SD (9 months) in 1 patient 
with pancreat ic cancer at 30 mg, and bio marker response (CA125) in 1 pat ient with ovarian cancer 
at 60 m g.
In the nonclinical setting, TAK -931 suppressed MCM2 phosphorylat ion in a dose -dependent 
manner in various cancer cell lines. TAK -931 also dem onstrated significant inhibit ion of pMCM2 
in human xenograft tumors and mouse skin which correlated well wit h the pl asma concentrations 
of TAK -931 observed in the nonclinical xenograft models. In the FIH study , strong pMCM2 
inhibit ion in skin was observed in pat ients treated with TAK -931 (all dose levels) which correlated 
well with the drug exposures in these pat ients. Thus, pMCM2 appears to be a viable 
pharmacodynamic marker to monitor target engagement of TAK -931 in the clinic in skin t issue 
and possibly in tum ors. 
Based on these encouraging data, it is reasonable to continue the development of TAK -931 and 
test its init ial activit y in pat ients with metastatic CRC who have progressed after at least 2 lines o f 
previous standard chemotherapy , pati ents wi th metastati c pancreatic cancer who have progressed 
after at l east 1 line of standard chemotherapy , pati ents wi th metastati c sqNSCLC who have 
progressed after at least 2 lines o f standard treatment, and patients with metastatic sqEC who have 
progressed after a t least 1 line of standard chemotherapy . Enrollments in the CRC and pancreat ic 
cohorts will fo llow a 3 -stage desi gn wi th 2interim analyses for fut ility using di sease control  rate 
(DCR). Enrollments in sqNSCLC and sqEC will follow a 2- stage design wit h 1 interim fut ility 
analysis using DCR (see Sect ions 4.2and 13.2 for details). 
Trial parti cipants are requi red to provi de bi opsies for predi ctive biomarker assessment. This 
activit y is crucial for a successful pat ient selection in future tri als. 
Patients in the Western safet y cohort are requested to provide low -risk pretreatment and 
posttreatment skin tissue biopsies to demonstrate target engagement and to establish 
PK-pharm acodynamic rel ationships to further confirm the data obtained in the Japan ese 
patient popul ation from the FIH tri al (TAK -
931-1002). Skin t issue biopsies are optional for 
patients undergoing or scheduled to have pre and on -treatment tum or biopsies to establish a 
correl ation between target engagement in skin and tumor. 
All pat ients in the disease
-specific cohorts are required to provide a pretreatment tumor biopsy 
for predi ctive bio marker evaluation. It can be eit her a fresh tumor biopsy  obtained during the 
screening period or an archival one. Because biopsy procedures have risks, the biopsy  
sampling plan and rationale are outlined in Sect ion 9.3.16.4 . If a fresh biopsy is required and 
the pati ent gives consent, the lesio n should be accessible in the opinio n of the invest igator. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-931
Study No. TAK-931- 2001 Page 28 of 99
Protocol Incorporating Amendment 04 16 July 2018
These tumor biopsies will be used to evaluate mo lecular biomarkers and their relationship with 
clinical response.
!Paired baseline predose and postdose tumor biopsies in Cycle 1 after exposure to TAK-931 to 
evaluate target engagement in the tumor tissues by measuring pMCM2 levels are optional in this trial. Patients undergoing paired biopsies will specifically consent to the procedure, which 
must be considered of nonsignificant risk in the opinion of the investigator (see 
Section 9.3.16.4) . The predose Cycle 1 Day 1 (C1D1) fresh tumor biopsy can be replaced by 
banked tumor tissues obtained at the time of the last PD if there has been no intervening 
anticancer treatment. For these patients, a skin tissue biopsy may also be collected (optional).
4.2 Rationale for the Proposed Study
This trial has 2 principal objectives:
!To confirm the dose and schedule of 50 mg QD for 14 days in 21-day cycles in Western 
patients of non-Japanese ethnicity. This objective has been achieved.
!To evaluate the antitumor activity of TAK-931 in patients with metastatic pancreatic 
adenocarcinoma, patients with metastatic CRC, patients with locally advanced or metastatic squamous esophageal cancer, and patients with locally advanced or metastatic sqNSCLC. The 
selection of the 2 additional indications is based in the identification of an enrichment 
signature that it is described in Section  4.2.1.
The trial will enroll patients at sites in the United States (US) and in Japan. To achieve the 
objectives, the study is divided into 2 parts. In the first part, a limited safety cohort of ~12 patients 
with metastatic solid tumors that progressed after appropriate prior therapy were enrolled only in 
the US. Safety, PK, and skin pharmacodynamic information was used to confirm the 50 mg QD 
dose in Western patients. To achieve this, a descriptive comparison with a similar population with 
a Japanese ethnicity treated in the FIH study (TAK-931-1002, [STUDY_ID_REMOVED]) was performed. In 
this cohort of 12 patients, the number of patients with  DLTs had to be 3 or fewer to consider the 
dose safe. However, to accept that the 50 mg QD dose is therapeutically sufficient in Western 
patients, other factors, including the TEAE rate, PK parameters, antitumor activity, and pMCM2 
changes in skin, were considered. If there ha d been potential clinically meaningful differences 
from the Japanese patients, the tumor-specific cohorts would not have started enrolling and the 
trial could have been amended to evaluate othe r dosing alternatives. This objective has been 
already achieved and 50 mg QD is considered comparable between Japanese and Western cancer 
patients.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use to o 
nal in al in 
re, whicre, whi
be replace repl
interveinterv
coollectellect
in 21n 21-d
en achien ach
atients wtients w
atietientntsw
h locallyh locall
ased in ased in
2.11..
he Unitee Uni
parts. Inparts. I
rogresseogress
armacormac
achievechiev
d in thed in th
ts, the ns, the 
to acceto acc
ctors, inors, 
n, were  wer
panese panes
d have d have
dy achiedy achi
ients.ents.
operty oII
TAK-931
Study No. TAK-931- 2001 Page 29 of 99
Protocol Incorporating Amendment 04 16 July 2018
4.2.2 Colorectal Cancer
The second part of the study will assess in a noncontrolled manner the anticancer activity of 
TAK-931 in patients with metastatic pancreatic adenocarcinoma that progressed after at least a 
first line of chemotherapy and in patients with metastatic CRC progressing after at least 2 lines of 
standard chemotherapy. Based on nonclinical research, TAK-931 is expected to be more active in 
MSS colorectal tumors. For this reason, the trial excludes patients with known MSI-H genotype. 
The selection of these indications is based on nonclinical efficacy models as described in Section 
4.1.1.1.  
The FIH study TAK-931-1002 has confirmed 50 mg QD as the MTD for 21-day cycle dosing (14 
days on followed by 7 days of rest). For this reason, Japanese sites will enroll patients directly in 
the tumor-specific cohorts. If the same dose is confirmed in the US, US sites will begin to enroll 
patients with pancreatic cancer and CRC with the char acteristics specified in the inclusion criteria 
(Section 7.1). 
The selection of DCR as the primary endpoint for activity is based on the recent phase 3 
registration trial in CRC and pancreatic cancer. In these trials, ORR (CR+PR) per RECIST was 
minimal in a similar pretreated patient population; however, there were differences in DCR 
(defined as the sum of CR+PR+SD ≥6 weeks) (see Sections  13.2 and 13.3) . 
Regorafenib (STIVARGA) single agent was approved by the US Food and Drug Administration 
(FDA) in patients with metastatic CRC previously treated with 2 lines of chemotherapy. The phase 
3 placebo-controlled trial enrolled 760 patients with a 2:1 randomization scheme. The trial 
demonstrated benefits in OS and PFS (hazard ratios of 0.77 and 0.49, respectively). Only 1% of 
patients achieved a PR status per RECIST; however, DCR (defined as PR+SD assessed at least 6 CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea nonca non
ancreatncrea i
tients wents w
n nonclinoncl
is reasos reas
attioions nsi
931-931-101
byby 7 da7 yy
cific cohfic co
hh pancr panh
7.11)). 
electelect ioi
gistratiistrat
minimminim
(def(defy and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 30of 99
Protocol Incorporating Amendment 04 16 July 2018
weeks after randomizat ion) was achieved in 207 patients (41%) assigned to regorafenib and in 
38(15%) patients assigned to plac ebo (p<0.0001) [16]. Similarly, TAS -102 (LONSURF) was 
approved in Japan and the European Union (EU) in a similar pa tient popul ation with a 
placebo -controlled phase 3 trial (N = 800, 2:1 randomizat ion). The trial demo nstrated a significant 
OS and PFS advantage (hazard ratios of 0.69 and 0.48, respectively). PR was achieved in only 
1.6% of patients with TAS -102; however, DCR was reached in 221 pat ients (44%) in the TAS -
102 
group and in 42 patients (16%) in the placebo group (p<0.0001) [17].
4.2.3 Pancreatic Cancer
Liposom al irinotecan (Onivyde) single agen t was init ially com pared wi th 5-fluorouracil/fo linic 
acid (5-FU/FOL) for treatment of pat ients with metastatic pancreat ic cancer that had progressed 
after gemcitabine (liposomal irinotecan n = 151; 5 -FU/FOL n = 149). The trial was amended once 
started to i nclude an arm using triplet liposomal irinotecan/5 -FU/FOL, which was approved in the 
US in 2015 and in the EU in 2016. Nine patients (6%) allocated to liposomal irinotecan 
monotherapy  achieved an object ive response compared with one patient (1%) assigned t o 
5-FU/FOL (difference of 5.3%, 95% CI 1.3 to 9.3; p = 0.02). Forty - one percent of patients in the 
irinotecan arm achieved a PR or SD versus 24.2% treated with 5 -FU/FOL. Twenty -nine of 123 
patients (24%) allo cated to liposo mal irinotecan monotherapy  had a carbohydrate antigen 19 -9 
(CA19 -9) response versus 12 of 105 patients (11%) assigned to 5- FU/FOL (p = 0.024) [18,19 ]. 
The DCR endpo int was selected over PFS or OS because it can be used as an early indicator of 
futilit y in a mult istage design; however , for future studi es other time -to-event indicators will be 
considered. 
4.2.4 Squamous Esophageal Cancer 
sqEC i s the m ost comm on histol ogical  subty pe of esophageal cancer and is of particularly  high 
incidence in Japan. There are no sy stemic treatm ents approved specifically for the metastatic 
squamous indication. With few except ions (HER2 -positive adenocarcino mas), the same 
treatm ents are recommended for esophageal adenocarcino ma, sqEC, gastroesophageal junct ion 
carcino ma (GEJC), and gastric cancer. The standard first-line therapy is a doublet containing a 
platinum plus a fluoropyrimidine. After recurrence, single -agent chemotherapy  with a taxane or 
irinotecan is indicated in patients with a good performance status [18] [20] .
Seven pat ients with esophageal cancer have been dosed in the FIH trial TAK -
931-1002, 1 at 
20mg, 4 at 30 mg, 1 at 40 mg using a continuous QD administrati on schedule, and 1 patient at 50 
mg QD with a 2 weeks on/1 week off schedule. One patient presented a RECIST 1.1 PR until 
progressing at Cy cle 7. Three pati ents presented wit h PD in Cycle 3, 2 stay ed on treatm ent until 
Cycle 6 (1 had a target lesio n reduct ion of -
20%), and 1 is ongoing in Cycle 10+. 
There are no published clinical trials evaluat ing the effect of any single -agent chemotherapy  as 
second -line treatment in sqEC. As a reference, we used the control arm in the RAINBOW trial: 
paclitaxel plus ramu cirumab versus paclitaxel plus placebo in patients with gastric cancer or GEJC 
in second line (n = 665). In this trial, computed tom ography (CT) scans were done every  6 weeks 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 31of 99
Protocol Incorporating Amendment 04 16 July 2018
[3]. The ORR in the paclitaxel arm was 16% (95% CI:13 -20%), and the DCR was 64% (95% CI: 
58-69) wi th a median durati on of  response of 2.8 mo nths (interquartile range 1.4 to 4.4).
4.2.5 Squamous NSCLC 
There are many  approved opti ons for patients with metastatic NSCLC in the first 2 lines of 
treatm ent. However, m ost pati ents wi th metastati c disease will  eventually progress after available 
therapi es. Approximately 30% of NSCLC patients are fit enough to receive further treatment, 
which is ty pically m onotherapy  with either chemotherapy or a targeted agent [
21]. Although 
targeted agents are a valid option for some patients whose tumors express anaplast ic lympho ma 
kinase (ALK), epidermal growth factor receptor ( EGFR ), B Raf -proto -oncogene, serine/threonine 
kinase (BRAF ), 
c-ros oncogene 1 or programmed death -ligand 1 (PD-L1), many of these patients 
fail to respond to targeted agents. In this context, a clinical trial wit h an oral single -agent drug is a 
reasonable option for sqNSCLC in third -line treatment and beyo nd. 
There are no specific published references of clinical trials in the sqNSCLC third -line setting and 
beyond. Establishing an acceptable comparator to retrospectively evaluate activit y is even m ore 
complicated because of the recent introduction of several checkpo int inhibitors in first -and 
second -line treatment. 
In a single -arm phase 2 trial , 444 pati ents with metastati c NSCLC that progressed after at least 
2previous lines of standard treatment received durvalumab as a single agent. The trial enro lled 3 
cohorts of patients, depending on ALK, EGFR and PD-L1expression. The subset of patients of 
interest as a reference for this trial were enro lled in cohort 2: tumors EGFR −/ALK −with <25% 
cells expressing PD-L1. In this group of patients (n = 93), ORR was 7.5% (95% CI: 3.1 -14.9) with 
a DCR at 6 months of 20.4% (95% CI: 12.8- 30.1).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-931
Study No. TAK-931- 2001 Page 32 of 99
Protocol Incorporating Amendment 04 16 July 2018
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objectives
!To confirm the safety and tolerability of TAK-931 in a cohort of Western patients with 
metastatic solid tumors. 
!To evaluate the antitumor activity of TAK-931 in  patients with metastatic pancreatic cancer, 
CRC, sqEC, and sqNSCLC. 
5.1.2 Secondary Objectives
!To characterize the PK of TAK-931 in a cohort of Western patients with metastatic solid 
tumors. 
!To contribute to evaluation of population PK using a limited sampling strategy in 
tumor-specific cohorts. 
!To assess additional measures of antitumor activity, including ORR, duration of response 
(DOR), PFS, and OS. 
!To further characterize the safety of TAK-931 as a single agent in patients with metastatic 
pancreatic cancer, CRC, sqEC, and sqNSCLC. 
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith with 
ancreatancrea
ients wients w
mited saited s
ity,y, i inclnc
931 as931 a
NSCLCNSCL
perty of Takeda: For Non-Commercial U
TAK-931
Study No. TAK-931- 2001 Page 33 of 99
Protocol Incorporating Amendment 04 16 July 2018
5.2 Endpoints
5.2.1 Primary Endpoints
!Frequency of TEAEs per National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.03: DLTs, SAEs, TEAEs leading to dose modifications, 
and TEAEs leading to treatment discontinuation in the Western safety cohort.
!DCR per RECIST version 1.1 [22] in disease-specific cohorts: CR+PR +SD; SD has to be 
≥6 weeks from treatment initiation to qualify for DCR.
5.2.2 Secondary Endpoints
!PK parameters after the first dose of TAK-931 on C1D1: C max, tmax; AUC 24, AUC from time 0 
to the time of the last quantifiable concentration (AUC last); and renal clearance (CLr). PK 
parameters following multiple doses of TAK-931 (C1D8): C max, tmax, AUC 24, AUC last, t1/2z, 
steady-state apparent oral clearance (CL ss/F), and accumulation ratio based on AUC over the 
dosing interval (AUC τ) (R ac(AUC) ). 
!ORR (CR+PR), DOR, PFS, and OS in tumor-specific cohorts. ORR, DOR, and PFS will be 
measured in the Western safety cohort. 
!Percentage of patients with TEAEs: Grade ≥3 TEAEs, SAEs, TEAEs leading to treatment 
discontinuation or dose modifications, and clinically significant changes in laboratory values and vital sign measurements in the tumor-specific cohorts.CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicammon Temmon 
Es leadiEs lea
Western estern
ic cohorc coho
DCR.DCR.
AKK--931 931
ncentratncentra
ses of TAses of T
ance (Cnce (C
(AUC)AUC)). ). 
PFS, andFS, an
tern safrn sa
tients wtients of Use
n or door doicable Terms of
gn mean mea
operty of Takeda: Fo
TAK-931
Study No. TAK-931- 2001 Page 34 of 99
Protocol Incorporating Amendment 04 16 July 2018
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecable Terms of
TAK -931
Study No. TAK -931-2001 Page 35of 99
Protocol Incorporating Amendment 04 16 July 2018
6.0 STUDY DESIGN
6.1 Overview of Study Design
This is a phase 2, mult icenter, single -agent, uncontrolled, open -label, parallel -arm trial in patients 
with metastati c cancer (CRC, pancreas cancer, sqNSCLC and sqEC). The study  will also enroll a 
safet y cohort of ~12 Western patients of non -Japanese ethnicit y with metastati c solid tumors with 
locally advanced or metastatic solid tumors for whom no standard treatment with an established 
survival benefit is available or if the pat ient refuses other standard therapy to determine the safet y, 
tolerabilit y, and PK of 50 mg QD for 14 days fo llowed by  a 7-day rest peri od in 21- day cycles. In 
this cohort, init ially 6 pati ents will  be enrolled for safet y and PK evaluat ion. These 6 patients can 
be enrolled concurrent ly. If no more than 2 patients present with a DLT (Section 8.2), the 
remaining 6 pati ents will be enrolled. If the final number of patients wi th a DLT i s 4 or m ore, the 
50mg QD dose will be considered unsafe for Western patients and enro llment of the 
disease -specific cohorts will not start in the US until the protocol is amended and a safe path to 
evaluate the dose and schedule is ident ified. Bef ore deciding that the 50 mg QD dose is adequate to 
proceed into the disease -specific cohorts in Western patients, a complete review o f available 
safet y, PK, and ant itumor activit y will be perform ed. These resul ts will  be com pared wi th those 
from Japanese patients who were treated in the FIH study  TAK -931- 1002 ([STUDY_ID_REMOVED]). Dose 
comparabili ty will not be established using formal statist ical methods. If TAK -931 exposures at 50 
mg QD in Japanese and Western populat ions are considered comparable, the trial w ill start 
enrolling pat ients with metastati c pancreat ic adenocarcino ma and CRC in the US. In Japan, the 
proposed dose has been considered the MTD of 50 mg QD for the 14 days on/7 days off schedule; 
therefore, Japanese sites will enro ll disease -specific coh orts fro m the beginning. The 
comparabili ty of dose and schedule between Japanese and Western patients wasachieved at the 
time of Protocol Amendment 03.
AEs will be assessed according to CTCAE, version 4.03, effect ive date 14 June 2010 [
20], and 
laboratory  values, vi tal signs, and ECGs will be obtained to evaluate the safet y and tol erabili ty of 
TAK -931.
HRQOL will be evaluated using the patient -reported outcome (PRO) measure, the EORTC 
QLQ -C30.
Serial blood sam ples f or determination o f the plasma concentration of TAK -931 will be obt ained 
at prespecified time points as described in the Pharmacokinet ic Sampling Schedule ( Appendix A). 
An intensive PK co llection with time-matched triplicate ECGs will be perform ed in the Western 
safet y cohort and first 10 patients in the pancreatic cancer and CRC cohorts in the US to allow 
comparison wi th a similar Japanese populat ion. All other patients, including all pat ients in the 
sqEC and sqNSCLC cohorts, will undergo sparse PK sampling. 
Serial blood sam ples will  be collected in the Western safet y cohort for tumor -specific markers 
(CEA in the CRC cohort and CA19 -9 in the pancreatic cancer cohort).
An evaluat ion of disease response using the modified RECIST version 1.1 [22] will be performed 
at Baseline and every other cy cle o f treatm ent.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 36of 99
Protocol Incorporating Amendment 04 16 July 2018
In the Western safety cohort only, predose and postdose skin biopsies will be collected in Cycle 1 
for pharmacodynamic bio marker (pMCM2) assessment and PK -pharmacodynamic relat ionships 
for target engagement evaluation and co mpar ison with simil ar data obtained in the FIH trial. 
Relationships between plasma exposures o f TAK -931 and pMCM2 (Ser40) levels in pretreatment 
and posttreatment tumor biopsies will be explored to evaluate PK/pharmacodynamic -efficacy 
relationships. Paired baseline predose and postdose tumor biopsies in Cycle 1 after exposure to 
TAK -931 are optional for patients in the disease -specific cohorts to evaluate target engagement in 
the tumor tissues by measuring pMCM2 levels. Other potential bio markers (to be determined) will 
be assessed in the same way.
Serial plasma sam ples will  be collected for NGS characterizat ion of ctDNA in patients to ident ify 
molecular determinants of TAK-931 efficacy. 
For the discovery  of other potenti al predict ive biomarkers, the trial requires all pat ients in the 
disease -specific cohorts to provide a pretreatment tumor biopsy, eit her fresh (during the screening 
period) or archival (obtained at any  time since the init ial diagnosis). A fresh biopsy or an archival 
one obtained after last tumor progression i s preferred. 
6.2 Number of Patients
Initially, ~12 Western patients with metastatic solid tumors are expected to be enrolled in the US to 
confirm the dose of 50 mg QD for 14 day s in 21 -day cycles based on the safet y, tolerabilit y, and 
PK of TAK -931 in Western patients of non -Japanese ethnicit y. 
It is expected that up to ~33 response -evaluable patients in the metastatic pancreat ic cancer cohort 
and ~35 response -evaluable patients in the metastatic CRC cohort will be enro lled in the study in 3 
stages, each with 2 futility evaluat ions. Addit ionally , up to 40 response -evaluable pat ients with 
locally advanced or metastatic sqEC and up to 40 response- evaluable pat ients with locally 
advanced or metastatic sqNSCLC may  be enrolled in 2 stages, with 1 futilit y evaluat ion for each 
cohort (see Sections 13.2 and 13.3). 
6.3 Duration of Study
6.3.1 Duration of an Individual Patient’s Study Participation
Patients may receive TAK -931 unt il they experience PD or unacceptable toxicit y or until any other 
discontinuat ion criterion is m et (Secti on 8.3.3 ). The maximum scheduled duration of treatment 
will be 1 year; however, patients with clinical benefit (per invest igator and as agreed by the 
sponsor’s medical monitor) can continue treatmen t beyo nd 1 year with the explicit approval of the 
sponsor’s medical mo nitor. 
All patients will attend an End -of-Treatm ent (EOT) vi sit 30 days (+10 day s) after receiving their 
last dose of study  drug or before the start of subsequent sy stemic ant icancer th erapy , whichever 
occurs first, to permit detection of any delayed TEAEs and resolut ion of ongo ing events. Patients 
with unresolved TEAEs will cont inue the periodic safet y follow-up until com plete resol ution or 
stabilization (established as sequelae) occurs . 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 37of 99
Protocol Incorporating Amendment 04 16 July 2018
Patients who discont inue study  treatm ent for reasons other than PD will continue PFS follow-up 
every 12±1 weeks fro m the EOT vi sit until the occurrence of PD, loss to follow -up, consent 
withdrawal , death, the start of subsequent sy stemic antineopl astic therapy , study  terminat ion 
(Secti on 9.4), or until 6 months after the discont inuation of study treatment, whichever occurs first. 
Patients in tum or-specific cohorts will be fo llowed f or OS every  12±1 weeks until death, loss to 
follow-up, consent withdrawal, study  terminat ion, or any  of the ci rcumstances described in 
Secti on 9.7. 
6.3.2 End of Study/Study Completion Definition and Planned Reporting
The final data cutoff for the CSR will be conducted after all pat ients have been discont inued fro m 
treatm ent or transferred to a long -term safety  study, a single -patient invest igational new drug 
applicat ion, or a similar program. 
The estimated time frame for study complet ion is 18 to 24 months. Alternat ively, if fut ility criteria 
are met for any  disease -specific cohort(s), the study  will be considered co mplete (see 
Secti on13.2)
. 
Refer to Table 6.afor disclosure information for all primary  and secondary  endpoints. 
Table 6.a Primary and Secondary Endpoints for Disclosures
Endpoint Definition Maximum Time Frame
Primary :Frequency of TEAEs. Includes DLTs, SAEs, TEAEs leading to dose 
modifications, and TEAEs leading to treatment 
discontinuation in the Western safety cohort (see 
Section 5.2.1 ). 1 year
Primary :DCR See Section 5.2.1 1 year
Secondary: PK of TAK -931 See Section 5.2.2 1 year
Secondary: ORR See Section 5.2.2 1 year
Secondary: DOR See Section 5.2.2 1 year
Secondary: PFS See Section 5.2.2 1 year
Secondary: OS See Section 5.2.2 1 year
Secondary: Percentage of 
patients with TEAEsIncludes Grade ≥3 TEAEs, SAEs, TEAEs leading to 
treatment discontinuation or dose modifications, and 
clinically significant changes in laboratory values 
and vital sign measurements in the tumor -specific 
cohorts (see Section 5.2.2 )1 year
6.3.3 Total Study Duration
It is ant icipated that this study  will last approximately 18 to 24 months. Alternat ively, if futilit y 
criteria are met for any  disease -specific cohort(s), the study  will be considered complete (see 
Secti on13.2). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 38of 99
Protocol Incorporating Amendment 04 16 July 2018
7.0 STUDY POPULATION
7.1 Inclusion Criteria
Each patient must meet all of the fo llowing inclusion criteria to be enr olled in the study :
1.Adult male or female pat ients aged ≥20 years (Japan) or ≥18 years (US). 
2.Eastern Cooperative Oncology Group (ECOG) performance status of 0 -1.
3.Patients wi th one of the fo llowing diagnoses:
Pathol ogically  confirmed m etastati c pancreat ic adenocarcino ma that has progressed after, 
at least, a first line of standard systemic chemotherapy  for metastati c disease.
Pathol ogically  confirmed m etastati c adenocarcinoma of the colon or rectum who have 
progressed to at least 2 lines of standard systemic chem otherapy  for m etastati c disease.
Pathol ogically  confirmed l ocally advanced or metastatic sqEC that has progressed after at 
least a first line of standard systemic therapy  for metastati c disease. First -line patients can 
be enrolled if a plat inum doublet is contraindicated or refused by the patient.
Pathol ogically  confirmed l ocally advanced or metastatic sqNSCLC that has progressed 
after at l east 2 lines of standard systemic therapy  for m etastati c disease .
4.For the Western safet y cohort only : patients with locally advanced or metastatic so lid tumor 
for who m no standard treatment with an established survival benefit is available or the patient 
refuses other standard therapy . 
5.For di sease -specific cohort patients: measurable disease per RECIST version 1.1. [22]
6.Adequate bone marrow reserve and renal and hepatic funct ion based on the following 
laboratory  parameters: 
–ANC ≥1500/mm3, platelet coun t ≥100,000/mm3, and hem oglobin ≥9g/dL.
–Total  bilirubin ≤1.5 ×the institutional upper limit of normal (ULN). 
– Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0 ×the 
institutional ULN (<5 ×ULN if liver enzyme elevations are due to hepatocellular cancer, 
biliary  tract cancer, or m etastati c disease in liver). 
–Creatinine <1.5 ×the insti tutional ULN or estimated creatinine clearance using the 
Cockcroft -Gaul t formula ≥50 mL/minute for patients with creatinine concentrations above 
institutional limits.
7.Left ventricular eject ion fraction >50% as measured by echocardiogram (ECHO) or mult iple 
gated acquisit ion (MUGA) scan within 4 weeks before receiving the first do se of study  drug.
8.Recovered to Grade 1 or Baseline from all toxic effects of previous therapy (except alopecia or 
neuropathy ).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 39of 99
Protocol Incorporating Amendment 04 16 July 2018
9.Female pat ients who:
–Are postm enopausal  for at l east 1 y ear before the screening visit, OR
–Are surgically  sterile, OR
–If they  areof childbearing potential, agree to practice one highly effective method of 
contraception and one additional effect ive (barrier) method at the same time, fro m the time 
of signing the informed consent through 30 days after the last dose of study  drug, OR
– A gree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the patient. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulatio n 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
10.Male patients, even if surgically  sterilized (ie, status postvasectomy), who:
–Agree to practice effective barrier contraception during the ent ire study  treatm ent peri od 
and through 120 days after the last dose of study  drug, OR
–Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the patient. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulatio n
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
–Agree not to donate sperm during the course of this study  and f or 120 day s after receiving 
their last dose of study  drug. 
11.Voluntary  written consent must be given before performance of any study -related procedure 
not part of standard medical care, with the understanding that consent may be withdrawn by 
the pati ent at any  time wi thout prej udice to future medical care.
12.Suitable venous access for the study -requi red bl ood sam pling. 
13.For the Western safet y cohort only : willingness to undergo serial skin t issue biopsies. 
14.For di sease -specific cohort patients: Must have an archival (banked) tumor samp le or agree to 
have a new (fresh) tumor biopsy during the screening period. If a new tumor sample is needed, 
the disease should, in the opinio n of the investigator, be accessible. For patients in the Western 
safet y cohort, this biopsy  is opti onal.
7.2 Exclusio n Criteria
Patients meet ing any o f the following exclusio n criteri a are not to be enrolled in the study .
1.Patients who requi re continuous use of proton pump inhibitors (PPIs) or histamine -2 (H 2) 
receptor antagonists and patients who are taking PPIs within 5 days before the first dose of 
study  drug.
2.Treatment with clinically significant enzyme inducers, such as phenyto in, carbamazepine, 
phenobarbital, rifampin, rifabut in, rifapentine, or Saint John’s wort within 14 days before the 
first dose of study  drug.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 40of 99
Protocol Incorporating Amendment 04 16 July 2018
3.Treatment with any systemic anticancer treatment (including investigat ional products) within 
30 day s or 5 half -lives, whichever is shorter, before the first dose of study  drug.
4.History  of any of the fo llowing wit hin the last 3 months before administration of the first dose 
of study  drug:
Ischemic myocardial event including angina requiring therapy and artery revascularizat ion 
procedures, myocardial infarct ion, and unstable symptomat ic ischemic heart disease.
Ischemic cerebrovascular event, including transient ischemic attack and artery  
revascularization procedures.
Significant, uncontrolled cardiac arrhy thmia (including atrial flutter/fibrillat ion, 
ventri cular fibrillat ion, or ventricular tachy cardi a).
New York Heart Associat ion Class III to IV heart failure.
Any other cardiac condit ion that, in the opinio n of the invest igator, could pose an 
additional risk for parti cipati on in the study  (eg, peri cardial  effusi on or restri ctive 
cardi omyopathy ). 
Baseline prolongat ion of the QT interval corrected for HR using Fr idericia’s formula 
([QTcF], eg, repeated demonstration of QTcF interval >480 ms, history of congenital lo ng 
QT syndrome, or torsades de pointes). 
5.Hypertensio n that is unstable or not controlled by  medicat ion.
6.History of uncontrolled brain metastasis unles s:
Previously  treated wi th surgery , who le-brain radiatio n, or stereotactic radiosurgery , AND
SD for ≥30 days, without steroid use (or stable steroid dose established for ≥14 days before 
the first dose of TAK -931).
7.Known history  of human immunodeficiency  virus infect ion.
8.Known hepat itis B virus (HBV) surface ant igen seroposit ive or detectable hepat itis C virus 
(HCV) infect ion viral load. Note: Patients who have posit ive HBV core antibody or HBV 
surface ant igen antibody can be enrolled but must have an undete ctabl e HBV vi ral load. 
9.Known GI disease or GI procedure that could interfere with the GI absorption of study drug, 
such as total gastrectomy or GI condit ions that could substant ially m odify gastri c pH. 
10.Female pat ients who are lactating and breastfeeding or who have a posit ive serum pregnancy 
test during the screening period or a positive urine pregnancy test on Day 1 before the first dose 
of study  drug. 
11.Any serious medical or psy chiatri c illness that could, in the invest igator’s opinio n, potenti ally 
interfere wi th the com pletion of treatment according to this protocol.
12.Prior treatm ent wi th radiation therapy  involving ≥25% of the hematopoiet ically active bone 
marrow within 3 mo nths before the first dose of study  drug. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 41of 99
Protocol Incorporating Amendment 04 16 July 2018
13.Patients wi th known MSI -H genoty pe or known wild type TP53 per local testing. 
Western Safet y Cohort Only
14.Patients wi th Japanese heredit y. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 42of 99
Protocol Incorporating Amendment 04 16 July 2018
8.0 STUDY DRUG
8.1 Study Drug Administration
All protocol -specific criteria for administration o f study drug must be met and documented before 
drug administratio n. Study  drug will be administered only  to eli gible pat ients under the 
supervisio n of the invest igator or ident ified subinvestigator(s).
TAK -931 will be administered to patients on an empty stomach. Patients should not eat for 2 hours 
before taking the study drug with at least 8 ounces (230 mL) of water. Patients should be instructed 
to eat a m eal or snack >1 hour after taking the study  drug. 
Patients shoul d be instructed to take their study  medication at approximately  the same time each 
day and not to take m ore than the prescribed dose at any  time. Pati ents shoul d swall ow the study  
medicat ion who le and not chew it, open it, or manipulate i t in any way before swallo wing. If a 
patient fails to take the TAK -931 dose wi thin the time frame specified (±12 hours), that dose 
shoul d be skipped. Pati ents shoul d record any  skipped doses in their dosing diary  (see Study  
Manual) and resume dosing at the next scheduled time with the prescribed dosage.
If severe emesis or mucosit is prevents the patient from taking a TAK -931 dose, that dose will be 
skipped. If emesis occurs after study medicat ion ingestion and if who le capsule(s) are visible in the 
vomitus,replacement capsule(s) should be taken; otherwise the dose will not be re -administered 
and pat ients should simply adhere to the dosing schedule and resume dosing at the next scheduled 
time with the prescribed dosage. Patients should record the time of the emesis in their dosing diar y 
(see Study Manual). Except for the case of emesis with visible capsules in the vomitus as described 
above, patients should never repeat a dose or double -up on doses.
TAK -931 will be administered only during Days 1 to 14 of eac h 21-day cycle of study  
participat ion. TAK -931 doses missed due to any  reason, including treatment interruption due to 
toxicity, will  not be m ade up by extending the 14 -day treatment peri od during the 21 -day cycle.
8.2 Definitions of Dose -Limiting Toxicity
Inthis study , DLTs will be evaluated only in pat ients enro lled in the safety cohort of Western 
patients wi th metastati c solid tumors. Initially, up to 6 evaluable Western patients will be dosed. 
These pat ients can be enro lled concurrent ly. If 2 or fewer pat ients have DLTs, then 6 more patients 
will be enro lled to complete the safet y cohort of 12 evaluable patients. If the final number of 
patients wi th DLTs is 4 or m ore, enrollment will be interrupted un til the clinical, PK, and 
pharmacodynamic data are evalu ated. In this cohort, the number of patients with DLTs should be 
3or fewer for the dose of 50 mg QD to be considered safe. 
Toxicit y will be evaluated according to the NCI CTCAE, versio n4.03, effective 14 June 2010. A 
DLT will be defined as any of the fo llowing events occurring during Cycle 1 that are considered by 
the invest igator to be at least possibly related to therapy with TAK -931:
Nonfebrile Grade 4 neutropenia (ANC <500 cells/mm3) lasting m ore than 7 consecutive days. 
If myelo id growth factors are used, the event will be considered a DLT irrespect ive of the 
durati on.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 43of 99
Protocol Incorporating Amendment 04 16 July 2018
Febrile neutropenia: Grade ≥3 neutropenia (ANC <1000 cells/mm3) with fever and/or 
infect ion, where fever is defined as a single temperature >38.3°C or sustained temperature of 
≥38°C fo r more than 1 hour.
Grade 4 thrombocy topeni a.
Grade ≥3 thrombocy topeni a of any durati on accompanied by  Grade 2 bleeding or requiring 
transfusio n.
Delay in the ini tiation of  Cycle 2 by  more than 14 days due to a lack of adequate recovery  of 
treatm ent-relate d hematol ogical or nonhematol ogic toxici ties.
Grade 2 ejection fraction decreased by ECHO or MUGA scan.
Grade 4 laboratory  abnorm alities—even if asymptomat ic—of any duration.
Other Grade 2 nonhematologic toxicit ies that are considered by the investigator to be related to 
study  drug and dose -limiting. 
Patients receiving <50% of doses (<7 doses) of the planned TAK -931 dosing in Cycle 1 due to 
study  drug -related AEs. 
Grade ≥3 nonhematologic toxicit y with the f ollowing except ions:
–Grade 3 arthralgia/myalgia t hat responds to nonsteroidal ant i
-inflammatory  drugs 
(NSAIDs) within 1 week.
–Grade 3 fat igue that lasts less than 1 week.
–Asymptomat ic Grade 3 laboratory abnormalit ies, if improved to Grade ≤2 in ≤48 hours. 
Adequate test(s) must be repeated at least every 2 days until the event is Grade ≤2. Grade 3 
nausea and/or emesis that can be controlled to Grade <3 in ≤3 days with the use o f optimal 
antiemetics (defined as an ant iemetic regimen that emplo ys both a 5 -hydroxytryptamine 3 
serotonin [5-HT 3]receptor antago nist and a corticosteroid given in standard doses and 
according to standard schedules).
–Grade 3 diarrhea that can be controlled to Grade <3 in ≤3 days wit h appropriate treatment. 
Patients not receiving at least 11 daily  doses of  TAK -931 in Cycle 1 for rea sons other than 
drug-related AEs will be replaced within the cohort. 
8.3 Dose Modification Guidelines
Dose m odificat ion gui delines for toxi cities are described below for TAK -931 based on the ty pe 
and severit y of AEs and causalit y determinat ion by invest igator s. Further clarificat ion can be 
obtained in consultation wit h the sponsor clinician (or designee). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 44of 99
Protocol Incorporating Amendment 04 16 July 2018
Table 8.a TAK -931 Dose Reductions
Dose Reduction Levels TAK -931
Standard dose 50 mg
–1 dose level 40 mg
–2 dose levels 30 mg
8.3.1 Criteria for Beginning or Delaying a Subsequent Treatment Cycle
Before starti ng a new treatment cy cle, TAK -931 related AEs or laboratory  abnorm alities must 
have returned to Grade ≤1 or baseline levels. 
If there is a delay o f a subsequent cy cle longer than 2 weeks because of an AE, the patient may be 
withdrawn from  treatm ent unl ess there i s clinical benefit as assessed by the invest igator, with 
agreem ent by the sponsor’s medical mo nitor. TAK -931 dosing may be cont inued at a reduc ed dose 
level.
Treatment with TAK -931 will use a cyc le length of 21 days. For a new cycle o f treatm ent to begin, 
the pati ent m ust m eet the following criteria:
ANC m ust be ≥1500/mm3.
Platelet coun t must be ≥100,000/mm3.
For therapy  to resum e, toxi city considered to be related to treatment with TAK -931 must have 
resolved to Grade 1, to the patient’s baseline values, or to a level considered acceptable by the 
physician (eg, hypophosphatemia that can be managed by oral repl acement). 
If the patient fails to meet the above -cited cri teria for retreatm ent, ini tiation of the next cy cle of  
treatm ent shoul d be delayed until the criteria for retreatment have been met. The patient must be 
retested or re -evaluated at least once a wee k at the investigator's discretion. The patient can be 
retreated once recovery  is achieved. 
Only for Western patients in the safet y lead-in cohort: Should the start of the next cycle need to be 
delayed for m ore than 2 weeks because of inco mplete recovery  from treatment -related toxicit y, 
this will be considered a DLT. If the patient is to receive addit ional treatment with TAK-931 
despite this DLT, the dose will be reduced by one dose level when treatment resumes (see 
Secti on8.3). 
8.3.2 Criteria for Treatment Interruption and Dose Reduction
All toxicit ies that occur during the study  will be actively  managed foll owing the standard of care 
unless otherwise specified in the protocol . Pati ents experiencing AEs attributed to TAK -931 may 
continue study treatm ent wi th the sam e dose, may  have TAK -931 treatm ent hel d, may have thei r 
dose reduced, or may  be permanent lydiscontinued from  the study . Patients who have study  drug 
held be cause of treatment -related or possibly related AEs may resume study  drug treatm ent af ter 
resol ution of the AE at the same dose level or at a reduced dose depending on the nature and 
severit y of the AE and whether i t is the first occurrence or it is recurre nt.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 45of 99
Protocol Incorporating Amendment 04 16 July 2018
Refer to Table 8.bfor general dose modificat ion recommendat ions. When the dose of TAK -931 is 
withheld based on these criteria, clinical and laboratory  reevaluati on shoul d be repeated at l east 
weekly or more fr equent ly, depending on the nature of the toxicit y observed until the toxicit y 
resolves to Grade ≤1 or Baseline. For transi ent laboratory abnormalit ies that, based on invest igator 
assessment, are not clinically significant or drug- related, continuat ion of t herapy wit hout dose 
modificati on is permissible upon discussio n with the sponsor. See details for the management of 
specific TEAEs in Sect ion 8.4. 
Table 8.b Dose Modification Recommendations for TAK -931 Toxicities
Criteria Action
Grade 1 AEs No dose reductions or interruptions 
Grade 2 AEs Treat according to local practice. Whether to hold treatment or continue it at the 
same or at a reduced dose is at the discretion of the investigator.
Patients experiencing Grade 2 AEs considered related to study treatment that are not 
easily  managed or corrected and are not tolerable to the patient, or AEs that are not 
accepta ble in the investigator’s judgment, should have study treatment interrupted 
until the AE resolves to Grade ≤1 or Baseline and then restarted at the same dose or, 
depending on the toxicity, at a reduced dose level. 
Grade 3 AEs Hold TAK -931 until resolution to Grade ≤1 or Baseline, then resume treatment at 
either the same dose or a reduced dose level at the discretion of the investigator.
Grade 4 (life -threatening) AEs Consider permanently withdrawing the patient from the study, except when the 
investigator determines that the patient is receiving clinical benefit and has 
discussed this with the sponsor, then treatment may be restarted at a reduced dose 
level or below when toxicity recovers to Grade ≤1 or Baseline.
AEs of all grades If treatment h as been held for >14 consecutive days without resolution of the 
toxicity (to Baseline or Grade ≤1), consider permanently discontinuing study 
treatment unless there is clinical benefit for the patient as assessed by the 
investigator and with sponsor's appro val. Treatment can be resumed at a reduced 
dose level after resolution of AEs to Grade ≤1 or Baseline.
Dose reductions are shown in Table 8.a. If initial dose adj ustment does not provide sufficient 
relief, the dose of TAK-931 can be further reduced by  an addi tional dose l evel if the treating 
physician considers that the patient is receiving benefit. In general, after a dose is reduced it should 
not be re -escalated even if there is minimal or no toxicit y with the reduced dose. However, if 
further evaluation reveals that the AE that led to the dose reduction was not study drug -related , the 
dose may be re -escalated to the original dose level. Up to 2 dose level reduct ions of TAK -931 due 
to AE are generally recommended. If a third dose reduction is needed, it must first be discussed 
with and approved by  the sponsor’s m edical mo nitor. 
Only for the safet y cohort in Western patients: The dose of TAK -931 will not be reduced for an 
individual pat ient during Cycle 1 unless a DLT has been declared and it is st ill possible for the 
patient to receive treatment within the 2 -week dosing period sche duled. In this case, the patient can 
complete the rem ainder of Cycle 1 at a reduced dose level. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 46of 99
Protocol Incorporating Amendment 04 16 July 2018
8.3.3 Criteria for Discontinuation of TAK-931
TAK -931 shoul d be discont inued in pat ients experiencing an AE meet ing the criteria for a DLT 
(see Section 8.2) for whi ch the investigator considers that retreatment of the patient could be 
dangerous. For Grade 4 life -threatening TEAEs, c onsider permanent ly wit hdrawing the patient 
from the study; however, if the invest igator determines that the patient is receiving clinical benefit  
and has discussed this wit h the sponsor, treatment may be restarted at a reduced dose level when 
toxicity recovers to Grade ≤1 or baseline.
If more than 2 dose reductions are required , orif the next cycle of TAK -931 is del ayed f or 
>14days because of TAK -931–related toxi cities, study  treatm ent shoul d be di scontinued unless 
theinvest igator considers that the patient will benefit from cont inuing in the study .Further dose 
reducti on must be discussed wit h, and approved by, the sponsor’s medical mo nitor. If the patient is 
discontinued fro m treatment, the end -of-treatm ent visit should be completed within 30 to 40 day s 
of the l ast administration o f TAK -931 or bef ore initi ation of new ant icancer therapy  (whichever 
comes first). 
8.4 Management of Specific Adverse Events
Therapies that are required to manage AEs and control cancer symptoms are allowed based on 
standard clinical pract ice, unless specifically  excluded. Su pportive care agents, such as 
erythropoi etin and G -CSF are permitted as needed per the American Societ y of Clinical Onco logy 
(ASCO) guidelines. [23] Blood products (red blood cell [RBC] and platelet transfusions) and pain 
medicat ions are permitted per local inst itutional practi ce. For pati ents enrolled in the Weste rn 
safet y cohort, these agents (excluding NSAIDs) should be avo ided at Baseline to meet inclusio n 
criteria or to mit igate toxicit y during Cycle 1 before DLT declaration. Each treatment intervent ion 
shoul d be clearly docum ented.
8.4.1 Hematologic Toxicities
Refer to
 Table 8.cfor dose delay  and reduct ion recommendat ions for hematol ogictoxicities. 
Dosing wit h TAK -931 shoul d be held if significant treatment -emergent cy topenia or bleeding is 
suspected to be related to, or can be worsened by, study treatment. Precautionary measures should 
be taken to prevent bleeding and overwhelming infections. Blood transfusions (RBC or platelets) 
and hematopoiet ic or thrombopoie tic stimulating factors may be used to treat cytopenia/ 
thrombocy topenia at the discret ion of the invest igator per standard clinical pract ice. It should be 
noted that use of myelo id growth factors (eg, G -CSF and granulocyte -macrophage 
colony-stimulat ing factor [GM -CSF]) are not allo wed in Cycle 1 before DLT confirmat ion. For a 
first event, a dose reduction is preferred over the use of myelo id growth factors [
3].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 47of 99
Protocol Incorporating Amendment 04 16 July 2018
Table 8.c TAK -931 Dose Adjustments for Hematologic Toxicities
Criteria Action
Neutropenia (ANC)
Grade 1 (ANC <LLN to 1500 cells/mm3) Continue TAK -931 at the same dose level.
Grade 2 (ANC 1000 -1499 cells/mm3) Continue TAK -931 at the same dose level.
Grade 3 (ANC 500 -999 cells/mm3)
without feverWithhold dose until resolved to Grade ≤1 or Baseline, then:
If resolved in ≤7 days, resume treatment at the same dose level;
If resolved in >7days, resume treatment at a reduced dose level;
If it is a repeat occurrence, resume treatment at a reduced level.
Grade 4 (ANC <500 cells/mm3) Withhold dose until resolved to Grade ≤1 or Baseline, then resume 
treatment at a reduced dose level.
Febrile neutropenia (ANC <1000 cells/mm3, 
with a single temperature of >38.3°C or 
sustained temperature of ≥38°C for more than 1 
hour)Withhold dose until fever/infection have recovered, then resume 
treatment at a reduced dose level.
Thrombocytopenia (PLT)
Grade 1 (PLT < LLN to 75,000 cells/mm3) Continue TAK -931 at the same dose level.
Grade 2 (PLT 50,000 -74,999 cells/mm3) Continue TAK -931 at the same dose level.
Grade 3 (PLT 25,000 -49,999 cells/mm3)
without bleedingWithhold dose until resolved to Grade ≤1 or Baseline, then:
If resolved in ≤7 days, resume treatment at the same dose level;
If resolved in >7 days, resume treatment at a reduced dose level.
Grade 4 (PLT <25,000 cells/mm3)
without bleedingWithhold dose until resolved to Grade ≤1 or Baseline, resume 
treatment at a reduced dose level.
Platelets <10,000 cells/mm3, thrombocytopenia 
Grade ≥3 associated clinically significant 
bleedingConsider permanently withdrawing the patient from the study, 
except when the investigator determines that the patient is 
obtaining clinical benefit and has discussed this with the sponsor.
Abbreviations: ANC, absolute neutrophil count; LLN, lower limit of normal; PLT, platelets.
8.4.2 Gastrointestinal Adverse Events
Nausea and/or Vomit ing
This study  will not ini tially emplo y prophylact ic ant iemetics; however, a patient who develops 
nausea and/or vomit ingwill be act ively managed by  employing optimal ant iemetic treatment per 
local standard practi ce. Additionally, antiemetics may be used prophylact ically as clinically 
indicated following the occurrence of the first event of TAK -931–related or possibly related 
nausea and/or vomit ing. An optimal ant iemetic regimen is defined as one that emplo ys both a 
5-HT 3antagonist and a corticosteroid given in standard doses and according to standa rd schedules. 
PPIs and histamine H 2receptor antagonists are not allowed during treatment. 
Diarrhea
Prophylactic ant idiarrheals will not be used in this study; however, diarrhea should be managed 
according to clinical pract ice, including the administratio n of ant idiarrheals once infect ious causes 
are excluded. Fluid intake should b e maintained to avo id dehydration. Fluid deficit should be 
corrected before init iation oftreatm ent and during treatment.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 48of 99
Protocol Incorporating Amendment 04 16 July 2018
8.4.3 Hepatobiliary Disorders
Liver function tests should be m onitored throughout participat ion in the study  (AST, ALT, 
alkaline phosphatase, and bilirubin). If abnormalities are observed, the patient should be assessed 
for causes other than the TAK -931. Transaminase elevat ions shoul d be managed according to 
locally accepted clinical practice including frequent monitoring of appropriate laboratory  
funct ions (2 to 3 times per week). If possible, hepatotoxic conco mitant m edicat ions should be 
discontinued in patients who develop elevated transaminases.
Dose interruption shoul d be considered in any  patient who devel ops Grade 2 el evated 
transaminases last ing longer than 2 weeks or at any t ime if pat ient develops Grade ≥3. Treatm ent 
shoul d be restarted at a reduced dose level (after transaminase levels reso lve to Grade ≤1 or
Baseline), provided that this occurs within 14 days of dose interruption.
Patients who develop AST or ALT >3 × ULN in conjunct ion with bilirubin >1.5 × ULN must be 
perm anent ly discont inued fro m study  treatm ent, unless a correctable non –drug -related cause of 
hepat ic injury  is identified. 
8.4.4 Cardiac Toxicities
A MUGA scan or ECHO will be performed at the time points indicated in the Schedule of Events 
(Appendix A)
. An ECHO or MUGA scan will also  be performed if symptoms o f heart failure are 
noted. Patients with significant abnormalit ies should be treated per standard of care at their 
institution and the treatment should be documented in the electronic case report forms (eCRFs). If 
Grade ≥2 decrease in cardiac eject ion fraction occurs, treatment should be discont inued unt il 
resol ution to Grade ≤1, then the study drug will be resumed at a reduced dose l evel. 
If Grade 3 QTcF prolongat ion or arrhy thmia occur, treatment should be discont inued unt il 
resol ution to Grade ≤1. An evaluat ion by a cardio logist must be performed and adequate patient 
management and fo llow-up (including hospitalizatio n if necessary )shoul d be put in pl ace 
immediately  after observat ion of a QTcF prolongatio n or arrhy thmia. Review of concomitant 
medicat ions and electroly te abnorm alities for QT effects is also required. Upon resolution o f the 
event to Grade ≤1, the study drug will be re sumed at a reduced dose level. For Grade 4 QTcF 
prolongati on or arrhy thmia, treatment should be permanent ly discontinued. If the patient shows a 
clinically significant benefit and is willing to resume treatment, treatment can be resumed at a 
reduced dose l evel after consul tation wi th a cardi ologistand approval fro m the sponsor (see 
Secti on 8.3.3 ).
8.4.5 Hypotension
Transient hy potensi on with reflex tachycardia was observe d in toxi cology studi es wi th dogs at 
tmax. Thi s risk has not been substant iated in Japanese patients dosed up to 80 mg QD in the FIH 
trial. With the current experience of pat ients being dosed at 50 mg QD, the risk of clinically 
meaningful hypotensio n can b e reasonably discharged (Section 4.1.2.1 ). However, guidance on 
the event of hypotensio n is maintained as fo llows.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 49of 99
Protocol Incorporating Amendment 04 16 July 2018
Patients shoul d be advised of the possibilit y of orthostati c hypotensi on and recommended to lie 
down and seek assistance if symptoms occur, and, if possible, to measure HR and BP. The patient 
also should be advised not to perform dangerous activit ies or to drive an automobile during t max
(1to 3 hours af ter administration). If the hypotensive event recurs, the patient should be advised to 
contact the site for instructions. BP and HR monitoring should be performed at home, if indicated 
by the investigator, and values recorded in the patient’s diary. 
If a hypotensive event occurs at the site, the patient can be discharged only if no clinically relevant 
BP or HR changes occurred during the observation period. If the invest igator notes changes in 
BP/HR and/or symptoms of concern, subsequent doses of TAK -931 s hould be administered at the 
site wi th the same m onitoring as for Cy cle 1, Day  1 until the ri sk is confirmed or discharged. 
Grade 1 hy potensi on:Hypotensi on (at l east 20 mmHg systolic BP drop and/or at least 
10mmHg diastolic BP drop versus individual pat ient’s baseline BP) without symptoms and no  
reflex tachycardia at rest. No treatment modificat ion or m onitoring is indicated. 
Grade 2 hy potensi on:Hypotensi on wi th com patible symptom s and/or reflex tachy cardi a (or 
Grade 2 presyncope). BP, HR, ECG, and blo od draw for TAK -931 concentration will be 
perform ed prom ptly. Repeated assessments should be performed as clinically indicated. 
Treatment should fo llow local pract ice. After recovery  and norm alizat ion to Baseline, the 
patient can continue receiving treatme nt at the same dose if it is the first occurrence or at a 
reduced dose if it is a reoccurrence. 
Grade ≥3 hypotensio n:Stop treatment. Treatment for the event should fo llow local pract ice. 
Consider continuous electronic monitoring of HR, BP, and ECG until complete normalizat ion 
of vital signs. Take a blood sample for measurement of TAK -931 concentration. Depending on 
the seriousness of the event, associated pathologies and recovery, consider either discont inuing 
the pati ent’s treatm ent or continuing treatme nt at a reduced dose level. 
8.5 Excluded Concomitant Medications and Procedures
All prescript ion and over -the-counter medicat ions, including influenza vaccines, taken by a patient 
as of the first study  drug administrati on through the EOT visit or init iation of new ant icancer 
therapy  (whichever com es first) will be recorded in the designated eCRF. Patients must be 
instructed not to take any  medicat ions, including over -the-counter m edicat ions and herbal 
supplements, without first consult ing with the investigator .
The fo llowing m edicat ions and procedures are prohibited during the study :
Patients currently on chronic ery thropoi etin support for anemia may cont inue to receive 
erythropoi etin, but init iation of new er ythropoiet in therapy is not allowed during the first cycle[3].
Note: ery thropoi etin has not been approved for the treatment of anemia associated with cancer 
chemotherapy in Japan. 
Any invest igational agent other than TAK -
931.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 50of 99
Protocol Incorporating Amendment 04 16 July 2018
Any concurrent ant ineoplastic therapy (eg, chemotherapy, hormonal therapy, immunotherapy, 
radiation therapy  except for palliat ive radiat ion therapy  and once PD i s ruled out), or standard 
or investigational agents for treatment of cancer . 
Clinically significant CYP enzyme inducers, such as the enzyme -inducing ant iepileptic drugs 
phenyto in, carbamazepine, or phenobarbital, or rifampin, rifabut in, rifapent ine, or Saint John's 
wort wi thin 14 days before the first dose of TAK -931 and during the study .
Chronic conco mitant administration of any  PPI i s not allowed during the study . Pati ents 
receiving PPI therapy  must stop using the PPI for 5 day s before thei r first dose of TAK -931. 
Examples of PPIs include omeprazo le, esomeprazole, pantoprazole, lansoprazole, vonoprazan, 
and rabeprazo le. During study participat ion, patients who develop new clinical symptoms that 
may require treatment with PPIs should be discussed with the sponsor to determine the dose, 
schedule, and suitabilit y of the pati ent forcontinued study  parti cipat ion. 
H2receptor antagonists (eg, cimet idine, nizat idine, and ranit idine) are not permitted from the 
day before the first dose (Day  -1) through the last day  of TAK -931 dosing in the treatment 
cycle. Intermi ttent use m ay be consi dered especially  during the 1 -week rest period if needed. 
Patients who requi re addi tional therapy  with H2receptor antagonists during the act ive 
treatm ent peri od wi th TAK -931 shoul d be discussed with the sponsor to determine the dose, 
schedule, and suitabilit y of the pati ent for continued study  parti cipat ion. 
8.6 Permitted Concomitant Medications and Procedures
Other medications considered necessary  for the safety  and wellbeing of the patient may be 
administered at the discret ion of the invest igator. Any conco mitant m edicati ons added or 
discontinued during the study should be recorded in the eCRF. Use of myelo id growth factors (eg, 
G-CSF, GM -CSF) m ay be administered to manage patients who experience severe and/or febrile 
neutropeni a if clinically  indicated in accordance wit h ASCO guidelines and/or institutional 
practi ces. For the first episode of neutropenia, dose reduction is preferred [24]. 
Over -the
-counter antacid preparations such as calcium carbonate are allowed, but should not be 
taken from 2 hours before and un til 2 hours after administration of TAK -931. They are allowed as 
needed on non -dosing days. 
8.7 Precautions and Restrictions
Patients shoul d be advised of the possibilit y of orthostati c hypotensi on and recommended to lie 
down and seek assistance if symptoms o ccur, and, if possible, to measure HR and BP. The patient 
also should be advised not to perform dangerous activit ies or to drive an automobile between 1 and 
3 hours from intake. If the hypotensive event recurs, the patient should be advised to contact the 
site for instructions. In these cases, BP and HR mo nitoring should be inst ituted at home and values 
recorded in the patient’s diary . 
Because of the risk of neutropenia, the patient should be instructed to measure axillary temperature 
at least daily  and to foll ow local procedures if their body  temperature reaches 38ºC. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 51of 99
Protocol Incorporating Amendment 04 16 July 2018
8.7.1 Pregnancy and Contraception
It is not known what effects TAK -931 has on human pregnancy  or devel opment of the embry o or 
fetus; therefore, female patients participat ing in this study  shoul d avoi d becoming pregnant, and 
male pat ients should avo id impregnat ing a female partner. Nonsterilized female pat ients of 
reproducti ve ag e and male patients should use effective methods of contraception throughout 
defined periods during and after study  treatment as specified below. 
Female pat ients must m eet 1 of  the fo llowing:
Postmenopausal  for at l east 1 year before the screening visit, OR
Surgically sterile, OR
If they  are of  childbearing potential, agree to practice one highly effective method of 
contraception and one addit ional effect ive (barrier) method at the same time, from the time of 
signing of the informed consent form (ICF) thro ugh 30 days after the last dose of study drug, 
OR
Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the patient. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulatio n 
methods], withdrawa l, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
Male patients, even if surgically  sterilized (eg, status postvasectomy) must agree to one of the 
following:
Agree to practi ce effective barrier contraception during the ent ire study  treatm ent peri od and 
through 120 day s after the l ast dose of study  drug, OR
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the pati ent. (Peri odic abst inence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods for the female partner], withdrawal spermicides only, and lactational amenorrhea are 
not acceptable methods of contraception. Female and male condoms should not be used
together.)
Agree not to donate sperm during the course of this study and for 120 days after receiving their 
last dose of study  drug.
8.7.2 Females Who Are Lactating or Breastfeeding
Female pat ients who are lactating must refrain from breastfeeding from the star t of study  
participat ion (Section 7.2, excl usion criterion #10) throug h 30 days after the last dose of study 
drug.
8.7.3 Patients With Prior Exposure to Hepatitis B or Hepatitis C
Patients who have detectable HBV or HCV viral loads are excluded from study  parti cipat ion (see 
Secti on
 7.2, excl usion criterion 8). Pati ents wi th prior exposure to HBV or HCV who have 
subsequent ly cleared the infection (bas ed on a negative viral load) are allowed on study, but should 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 52of 99
Protocol Incorporating Amendment 04 16 July 2018
be monitored for reacti vation every  2 months. Patients who develop detectable HBV or HCV 
levels will have TAK- 931 treatm ent hel d with administrati on of  a nucleoside antagonist (NA) per 
institutional guidelines and a consultation with a hepatologist should be considered. 
Restarti ng TAK -931 after HBV or HCV is no longer detected may be considered in the setting of 
continued NA prophylaxis and after a discussio n wit h the Takeda medical mo nitor to r eview the 
potenti al benefi t versus risk to the patient in the setting of a controlled HBV or HCV infect ion. 
8.7.4 Photosafety
In the photoabsorption spectrum, TAK -931 exhibit s a peak at 294 nm, which is wit hin the zone of 
concern for potential phototoxicit y and/or photoallergy . A photosafet y assessment of TAK -931 
has not y et been performed; therefore, patients should be cautioned to take protective measures 
(eg, avoi dance o f exposure to direct sunlight, use of sunglasses and long sleeves).
8.8 Blinding and Unblindi ng
Not applicable. This is an open- label study . 
8.9 Description of Investigational Agents
TAK -931 will be supplied as capsules for oral administration. TAK- 931 is available in 2 dose 
strengths, 10 and 25 mg of TAK -931 in addit ion to the fo llowing inact ive ingredients: mannito l 
(filler), collo idal silicon dio xide (flow aid), and hard gelat in cap sule. 
The dose strength in each capsule is different iated by size and color, as listed in the fo llowing:
10-mg TAK -931 capsules: white opaque color, size 4 capsule.
25-mg TAK -931 capsules: Swedish orange opaque color, size 4 capsule.
Refer to the TAK -
931 Investi gational Brochure for full details.
8.10 Preparation, Reconstitution, and Dispensation
TAK -931 dosage forms will be provided in labeled bottles in accordance wit h all applicable 
regul ations. Materials provided by the sponsor should be dispensed to patien ts wi th clear 
administration instructions from the invest igator.
TAK -931 i s an anticancer drug, and as with other potentially  toxic com pounds, caution should be 
exercised when handling TAK -931 capsules. 
8.11 Packaging and Labeling
TAK -931 will be provided by T akeda and will be handled at the invest igative site as open -label 
materi al.
TAK -931 will be provided in high- densi ty polyethylene bottl es wi th polypropylene, 
child -resistant caps, and an induct ion seal.
TAK -931 i s packaged and labeled in accordance wit h all applicable regulations.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 53of 99
Protocol Incorporating Amendment 04 16 July 2018
8.12 Storage, Handling, and Accountability
Upon recei pt at the invest igative site, TAK -931 shoul d be stored in the original bottles unt il use 
and stored at 2°C to 8°C (refrigerated). The study  drug should be stored at home in a refrige rator. 
All temperature excursio ns at the site pharmacy will be reported to the sponsor for assessment and 
authori zation for continued use. All invest igational supplies must be stored in a secure area with 
controlled access and will be stored in original pa ckaging. All TAK -931 should be used before the 
retest expiry  date.
A drug dispensing log, including records of drug received fro m the sponsor and drug dispensed to 
the pati ents, will be provided and kept at the study  site. Storage area temperature conditio ns m ust 
be monitored and recorded daily . A daily tem perature l og will also be kept at the study  site.
Because TAK -931 i s an invest igational agent, it should be handled wit h due care. In case of 
contact wi th broken capsules, raising dust should be avo ided d uring the clean -up operati on. The 
product may be harmful if inhaled, ingested, or absorbed through the skin. Gloves and protective 
clothing shoul d be worn during the clean -up operatio n. The area should be ventilated and the spill 
site washed after m aterialcleanup is com plete. The spilled material should be disposed of as 
hazardous medical waste in co mpliance with federal, state, and local regulat ions. In case of contact 
with the powder (eg, from a broken capsule), skin should be washed immediately  with soap and 
copious amounts of water for at least 15 minutes. In case of contact with the eyes, copious amounts 
of water shoul d be used to fl ush the ey es for at least 15 minutes. Medical personnel should be 
notified. 
Patients will  receive instructi ons for hom e storage and administration of TAK -931. 
Patients will  be instructed to return any  unused study  drug in the ori ginal packaging alo ng with 
their com pleted di ary cards at the appropri ate visi ts.
Please refer to the Study  Manual for addit ional instructi ons.
8.13 Other Protocol -Specified Materials
Not applicable. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 54of 99
Protocol Incorporating Amendment 04 16 July 2018
9.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol , Good Clinical Pract ice (GCP), 
applicable regulatory  requi rements, and Internat ional Conference on Harmonisat ion (ICH) 
guidelines.
9.1 Study Personnel and Organizations
The contact informat ion for the Takeda project clinician for this study , the central  laboratory  and 
any addit ional clinical laboratories, the coordinat ing invest igator for each member state/country 
(where applicable), and the contract research organizat ion (CRO) team may be found in the Study 
Manual. A full list of investigators is available in the sponsor’s invest igator database.
9.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for this study may include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruit ment strategy , they  will be reviewed by  the inst itutional review board (IRB)/ 
independent ethics co mmittee (IEC).
9.3 Study Procedures
Refer to the Schedule of Events ( Appendix A) for timing of assessments. Addit ional details are 
provi ded as necessary in the sect ions that fo llow. Evaluat ions during the screening period are to be 
conducted within 28 days before adminis tration of  the first dose of study  drug. Unless otherwi se 
noted, evaluat ions during the treatment period must occur before study drug administration. Tests 
and procedure should be performed on schedule for all visits. The timing of PK assessments is 
specif ied in Appendix A, Table C. All end -of-study  evaluat ions should occur 30 to 40 day s after 
the last dose of study  drug. 
Note: Tests and procedures should be performed on schedule; pat ients may remain on study  with 
occasi onal changes (±3 days) for holidays, vacat ions, and other administrative reasons. 
9.3.1 Informed Consent
Each patient must provide written informed consent befor e any  study -requi red procedures are 
conducted, unless those procedures are performed as part of the patient’s standard care.
9.3.2 Patient Demographics
The date of birth, race, ethnicit y, and sex of the patient are to be recorded during screening.
9.3.3 Medical Histor y
During the Screening period, a complete medical history  will be com piled for each pat ient. The 
history  will emphasize the background and progress of the patient’s malignancy  and include a 
descript ion of prior therapies with a breakdown by treatment inten tion (neoadj uvant, adj uvant, or 
metastati c), line of therapy  for m etastati c disease, regimen, and drug(s). Treatment start and stop 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 55of 99
Protocol Incorporating Amendment 04 16 July 2018
dates (including at least month and year), best response and PD date. Known genetic and blood 
tumor biomarkers previously an alyzed at the site should be recorded. In addit ion, concomitant 
medicat ions will be recorded as specified in Sect ion 9.3.8 . Tobacco smoking history  shoul d be 
collected for patients in the sqEC and sqNSCLC cohorts.
Patients fo llowed by  CT scans (rather than magnetic resonance imaging [MRI]): CT scans 
acqui red for disease assessment in addit ion to the most recent prescreening CT scan, if available, 
willbe submitted to an imaging core laboratory  vendor for tum or growth rate determinat ion (see 
Secti on 13.1.3 ). The date of the scan should be indicated. Availabilit y of the prescreening scan is 
not a prerequisite for study  eligibilit y. 
9.3.4 Physical Examination
A physical examinat ion will be completed per standard of care at the times specified in the 
Schedule of Events ( Appendix A)
. 
9.3.5 Patient Height and Weight
Height will be measured only once, during screening (within 28 days before the first dose of 
TAK -931). Body  weight will be m easured at the visits specified in the Schedule of Eve nts 
(Appendix A). 
9.3.6 Vital Signs
Standard vital signs should be obtained at least once during each visit specified in the Schedule of 
Events 
(Appendix A, Tables A and B) and will include temperature (oral or axillary ), BP, and 
heart rate (HR). 
9.3.7 Pregnancy Test
A serum pregnancy test will be performed for women of childbearing potential at screening and 
within 4 days before the first dose of study  drug. 
Women of childbearing potential will be defined as sexually  mature females who meet the 
following criteria:
Those who have not undergone hysterectomy or bilateral oophorectomy, and
Those who have not had natural menopause for 12 consecut ive months or l onger (eg, 
follicle -stimulat ing horm one >40 IU/L and no menopausal period for at least 12 consecutive 
months). Note that a loss of menopausal periods following chemotherapy  may not rul e out 
childbearing potential. 
The results from these tests must be available and negat ive before the first dose of study  drug i s 
administered. If Cycle 1, Day  1 serum  pregnancy results will not be available before dosing, a 
urine pregnancy test may be performed . 
Pregnancy tests may also be repeated during the study if requested by an IEC/IRB or if required by 
local regulati ons.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 56of 99
Protocol Incorporating Amendment 04 16 July 2018
9.3.8 Concomitant Medications and Procedures
Medicat ions used by the pat ient and therapeutic procedures completed by the pat ient will be 
recorded in the eCRF fro m the ICF signature through the EOT visit or before init iation of new 
anti-cancer therapy , whichever com es first. See Secti ons 8.5and 8.6for a list of m edicat ions and 
therapi es that are prohibited and/or allowe d during the study .
9.3.9 Adverse Events
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specified in 
the Schedule of Events ( Appendix A). Ref er to Secti on 10.0 for details regarding definit ions, 
docum entati on, and reporting of AEs and SAEs.
9.3.10 Enrollment
Enrollment is defined as when the written informed consent has been obtained and the patient’s 
eligibilit y has been confirmed per the inclusio n and exclusio n criteria (Section
 7.0). Procedures for 
completion of the enro llment informat ion are described in the Study  Manual . Inform ation 
regarding patients who do not meet the study  entry cri teria will be collected in a separate log. 
9.3.11 Electrocardiogram
9.3.11.1 Safety ECGs
Standa rd 12 -lead ECGs will be administered at the time points specified in the Schedule of Events 
(Appendix A,
 Tables A and B). All machine -generated tracings should be acqu ired in the supine 
position after pati ents have been resting for 5 minutes. Additional ECGs may  be obtained as 
clinically indicated (see Section 8.4.5 ). 
9.3.11.2 Triplicate ECGs
Patients in the Western safet y cohort and the first 10 US patients in the CRC and pancreat ic cancer 
cohorts will undergo triplicate ECGs matching PK sampling for QTc assessment during Cycle 1 
on Day s 1 and 8 
(Appendix A, Table C). Triplicate ECGs are not required for all other 
patients, including all patients in the sqEC and sqNSCLC cohorts. 
Before each no minal triplicate ECG sampling time point, patients must ma intain a supine posit ion 
for 15 minutes. A Holter monitoring device will be used for triplicate ECG assessment. Three 
ECGs (approximately 1 minute apart) will be extracted at prespecified time points at times that 
match the times of Day  1 and Day  8 postdos e PK/ECG sampling. For these matched PK/ECG 
collect ions, the PK blood sample should be co llected only after complet ion of the triplicate ECG 
collect ion as described below. It is reco mmended that patients refrain from eat ing or limit 
themselves to bl and foo d for 1 hour before and until co mpletion of the 4- hour tri plicate ECG 
measurements. Before each no minal triplicate ECG time po int listing in Appendix A,
 Table C, the 
patient m ust be m aintained at supine bed rest for 15 minutes. The triplicate ECGs will be 
perform ed during the final 10 minutes of that rest period (the ECG extraction 10 -minute window). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 57of 99
Protocol Incorporating Amendment 04 16 July 2018
The PK blood draws will occur immediately  following the complet ion of the ECG extracti ons on 
Cycle 1, Days 1 and 8. 
9.3.12 Eastern Cooperative Oncology Group Performance Status
The ECOG performance status ( Appendix D) will  be assessed at the times specified in the 
Schedule of Events.
9.3.13 Echocardiogram or Multiple Gated Acquisition Scan
A MUGA scan or ECHO will be administered at the time po ints specified in the Schedule of 
Events ( Appendix A).
9.3.14 Clinical Laboratory Evaluations
Clinical laboratory  evaluat ions will be performed locally. Handling of clinical laboratory samples 
will be outlined in the Study Manual. Clinical laboratory evaluat ions wi ll be performed as outlined 
below.
Blood sam ples f or analysis of the clinical chemistry  and hematol ogical parameters shown in 
Table 9.aand urine samples for analysis of the param eters shown in  Table 9.bwill be obtained as 
specified in the Schedule of Events 
(Appendix A).
Table 9.a Clinical Chemistry and Hematology Tests
Hematology Chemistry
Hematocrit
Hemoglobin
Leukocytes with differential
Neutrophils
PlateletsAlanine aminotransferase
Albumin
Alkaline phosphatase 
Aspartate aminotransferase
Bicarbonate
Bilirubin (total)
Blood urea nitrogen
Calcium
Chloride Creatinine
Glucose
Lactate dehydrogenase 
Magnesium
Phosphate
Potassium
Sodium
Urate
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-931
Study No. TAK-931- 2001 Page 58 of 99
Protocol Incorporating Amendment 04 16 July 2018
Table 9.b Clinical Urinalysis Tests
Urinalysis
Bilirubin
Glucose
Ketones
Leukocytes
Nitrite
Occult bloodpH
Protein
Specific gravity
Turbidity and color
Urobilinogen
9.3.15 Disease Assessment
Patients will undergo CT scan, with contrast as appropriate, or MRI scan to monitor and assess 
disease progression, using RECIST, version 1.1 [20] as outlined in the Schedule of Events 
(Appendix A) .
Primary determination of disease status will be based on local investigator assessment. The 
collection and central storage of scans are planned in the event that more detailed analysis of 
imaging data, as determined by the sponsor, is needed. More details can be found in the Imaging 
Review Charter.
A blood sample will be collected during screening for measurement of CEA (CRC) or CA19-9 
(pancreatic adenocarcinoma) and analyzed locally. Tests will be repeated at the frequency 
specified in the Schedule of Events. Other tumor biomarkers that are increased at Baseline should 
be collected and followed at the time points used for CEA and CA19-9 measurement. 
9.3.16 Biomarker and Phar macodynamic Samples
9.3.16.1 Fresh Skin Tissue Biopsy Sample
pMCM2 will be detected semiquantitatively by IH C in histologic sections of formalin-fixed, 
paraffin-embedded (FFPE) fresh skin tissue biopsies . Fresh skin tissue biopsies (2 to 4 mm) will 
be obtained from patients in the Western safe ty cohort either during screening or predose on C1D1 CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef
plic
RI scan tscan 
in the Sn the
local inocal i
the evenhe ev
ded. ed. MoM
eening fening
ed localld loca
her tumher tu
me poe pointin
9.39erty of Takeda: For Non-Commerc
TAK -931
Study No. TAK -931-2001 Page 59of 99
Protocol Incorporating Amendment 04 16 July 2018
and postdose on Day  8 in Cycle 1. If t he skin biopsy cannot be taken during Day 8 visit, it can be 
scheduled at any  other day  from Day  9 to Day  14 while the patient is st ill taking TAK -931. It i s 
strongly  recommended that the postdose skin biopsies are collected 4 to 9 hours after study  drug 
administrati on. For patients who consent to paired tumor biopsies (Sect ion 9.3.16.4 ), it is optiona l 
to collect a skin tissue biopsy simultaneously  with the tum or biopsy . 
For sample retent ion, refer to Section 9.3.16.7 .
9.3.16.2 Archival (Banked) Tumor Tissue Sample
All patients enrolled in the disease -specific cohorts must have an FFPE pretreatment tumor tissue 
biopsy to assess TAK -931 efficacy  in relati on to vari ous bio markers . It is acceptable to use 
archival tumor tissues collected before study  enro llment. An archival sample obtained at the time 
of the last progression, if available, is preferred; however, an archival FFPE sample obtained at the 
time of the init ial diagnosis (eg, surgical specimen) is acceptable. An FFPE block or a minimum o f 
10 unstained slides is required. 
For sample retent ion, refer to Section 9.3.16.7 .
9.3.16.3 Fresh Tumor Tissue Biopsy Sample
If FFPE tumor tissue is not available, a fresh biopsy must be obtained. If a new biopsy is 
perform ed, it shoul d be obtained during the screening period with a nonsignificant risk procedure 
per the treating physician as described in Sect ion9.3.16.4 .
 
9.3.16.4 Paired Fresh Tumor Tissue Biopsy Sample for Pharmacodynamics
Paired tum or biopsies are opti onal from patients in each disease -speci fic cohort to demonstrate 
TAK -931 target engagement and to evaluate possible changes of other potential bio markers 
related to CDC7. The predose biopsy  can be collected any  time before the first dose of TAK -931. 
The postdose biopsy can be collected 4 to 9 h ours postdose on any dosing day after complet ion of 
3consecutive days o f TAK -931 treatm ent (Day  4 and later). It is recommended that the postdose 
biopsy be taken from the same lesio n or, at l east, from  the same organ as at Baseline. 
The invest igator should preselect patients for this procedure and the patient must consent 
specifically to undergoing paired biopsies. Biopsies should meet the characterist ics of 
nonsignificant risk as assessed by the investigator. Failure to obtain a fo llow-up bi opsy  (eg, if the 
patient declines to undergo the second procedure) will not be considered a reason to discont inue a 
patient from the tri al. 
Refer to Section 9.3.16.7 for sam ple retenti on. 
9.3.16.5 Plasma Sample for Circulating Tumor DNA
Plasma shoul d be collected at the time points specified in the Schedule of Events (Appendix A
)
and will be used for iso lation of ctDNA and NGS analysis of ctDNA to ident ify potential 
predi ctive bio markers. A retrospective correlat ive study  may be perf ormed to assess the 
associ ation of the tumor genetic alterations wit h clinical responses to TAK-931. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 60of 99
Protocol Incorporating Amendment 04 16 July 2018
Refer to Section 9.3.16.7 for sam ple retenti on. 
9.3.16.6 Blood Sample for DNA
Who le blood sam ples will be co llected at screening to iso late geno mic DNA for NGS analysis in 
parallel wit h tum or DNA to i dentify potential predict ive biomarkers. 
9.3.16.7 Sample Retention
Tumor tissues, skin tissues, plasma samples for DNA measurements, and blood samples for 
geno mic DNA analyses will be stored at BioStorage Technologies (Indiana USA) f or up to 
15years after the date of study co mpletion as identified in the CSR and will be destroy ed by  a 
third-party  vendor i dentified by  BioStorage Technol ogies per com pany standard operating 
procedures. Tumor tissues and skin t issues will be stored at am bient tem perature and pl asma will 
be stored at -70°C. If a patient withdraws consent, the samples will be discarded fo llowing l ocal 
procedures. Test results should not be discussed with patients unless required by local law. The 
tests performed with these samples are not intended to make determinat ions about a pati ent’s 
healt h or the likelihood that a patient will develop any disease, so no test results will be provided to 
the invest igator or put into a patient’s medical record.
9.3.17 Pharmacokinetic Measurements
Serial blood and urine specimens for PK analysis of TAK -931 will be co llected at the time points 
specified in the Schedule of Events ( Appendix A, Table C). The dates and exact times of 
administration of TAK -931 before collect ion of the blood or urine sample for PK analysis and the 
dates and exact times of the postdose PK sample collect ion will be recorded in the eCRF.
Detailed instructions on the procedure for collect ion, processing, storage, and shipment of the 
urine samples will be provided in the Study  Manual. Plasma and urine samples may be stored for 
possible future analysis of TAK -931 metabo lites and to test for inversio n of the single chiral center 
within TAK -931. 
Intensive PK measurements, as described in Section
 5.2.2 , will be obtained for the first 10 patients 
in the Western safet y cohort and for the first 10 patients from US sites in the CRC and pancreat ic 
cohorts. Sparse PK concentrations will be obtained for all other patients, including pat ients in the 
sqEC and sqNSCLC cohorts, for use in future integrated TAK -931 population PK analyses, which 
will be reported separ ately. 
Across the Western cohort and the CRC and pancreatic cancer cohorts, a total of approximately 32 
US patients will be expected to contribute time -matched PK/triplicate ECG data in this study  to 
contribute to future PK/QTc analyses. If these patients do not complete the protocol -specified data 
collect ions, the PK/ triplicate ECG sampling may be performed in addit ional US pat ients as 
needed to ensure availabilit y of these data in a total o f approximately 32 patients.
If the timing of PK and ECGs co incide, the ECGs should be acquired first fo llowed by the PK 
sample collect ion. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 61of 99
Protocol Incorporating Amendment 04 16 July 2018
9.3.18 EORTC QLQ -C30
HRQOL assessment using the EORTC QLQ- C30 will be co llected from pat ients in the 
disease -specific cohorts at the time points specified in the Schedule of Events 
(Appendix A, Table 
C). The patient should be given the paper versio n of the quest ionnaire to complete at the scheduled 
visit before other clinical assessments are conducte d. The questionnaire should be co mpleted in 
the language most familiar to the patient, at the scheduled visit, before the patient sees the 
investigator for clinical assessments. The patient should be given sufficient space and time to 
complete the questi onnaire. The patient should complete the quest ionnaires on their own without 
any assistance from site staff or a caregiver. The questionnaire is intended to be self -reported and 
shoul d not be interviewer -administered.
The quest ionnaire should be checked for completeness and the patient is encouraged to complete 
any missing response. Detailed instructions relat ing to the administrative procedures of the 
questionnaire will be provided to the sites. Patient’s refusal to complete all or any part of a 
questionnair e shoul d be documented in the eCRF.
The EORTC QLQ C30 was designated to assess HRQOL in a wide range of cancer patient 
popul ations and contains 30 items which incorporates 5 funct ional scales (physical, role, 
cogni tive, em otional, and soci al), 9 symptom  scales (fat igue, nausea and vo miting, pain, dyspnea, 
sleep disturbance, appetite loss, const ipation, diarrhea, and financial difficult ies), and a global 
qualit y of life/healt h status scale. Most of the 30 items have 4 response levels (not at all, a litt le, 
quite a bit, and very much), with 2 questions relying on a 7 -point numeric rating scale. Raw scores 
are converted into scale scores ranging fro m 0 to 100. For the funct ional scales and the global 
healt h status scale, higher scores represent better HRQOL; wh ereas for the symptom scales lower 
scores represent better HRQOL. All items in this questionnaire relate to a recall period of 1 week.
9.4 Completion of Study Treatment (for Individual Patients)
Patients will  be considered to have completed study  treatm ent if they discontinue study  drug for 
any of the reasons outlined in Sect ion
 9.6.
9.5 Completion of Study (for Individual Patients)
Patients will be considered to have co mpleted the study if they wit hdraw from the study for any of 
the reasons outlined in Sect ion 9.7. 
9.6 Discontinuation of Treatment With Study Drug and Patient Replacement
Treatment with study  drug m ay be discont inued for any of the fo llowing reasons:
Adverse event.
Protocol  deviat ion.
Progressive disease.
Withdrawal by pat ient.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 62of 99
Protocol Incorporating Amendment 04 16 July 2018
Lost to follow -up.
Initiation of  another sy stemic ant icancer treatment. 
Treatment complet ion: the patient completes 1 y ear of treatm ent and continuat ion is not 
approved.
Study  terminated by  sponsor.
Once study  drug has been discont inued, all study  procedures outlined for the End -of-Treatment, 
PFS, and OS visits will be co mpleted as specified in the Schedule of Events ( Appendix A). The 
primary  reason for study  drug discont inuat ion will be recorded on the eCRF.
Note that som e pati ents m ay discont inue study  drug for reasons other than PD before complet ing 
the full treatment course; these patients will remain in the study  for posttreatm ent assessments as 
outlined in the Schedule o f Events ( Appendix A) unt il PD occurs. 
Patients in the Western safet y cohort who receive <11 daily  doses of TAK -931 in Cycle 1 for 
reasons other than study  drug -related AEs may be replaced. In the disease -specific cohorts, 
patients not evaluable for response (Section
 13.1.1 ) may be repl aced. 
9.7 Withdrawal of Patients From Study
A pat ient may wi thdraw from  the study  at any  time or be withdrawn fro m the study  for any  of the 
following reasons:
Lost to follow -
up.
Consent withdrawal. 
Death. 
Study  terminated by  sponsor.
Transfer of patient to a long -term safet y study , singl e-patient invest igational new drug 
applicat ion, or similar program.
The consequence of study  withdrawal  is that no new informat ion will be collected from the 
withdrawn pati ent and added to the e xisting data or any database.
9.8 Study Compliance
Study  drug will be administered or dispensed only to eligible pat ients under the supervisio n of the 
investigator or ident ified subinvest igator(s). The appropriate study personnel will maintain records 
of study drug recei pt and dispensing.
Patients are responsible for taking TAK -931 as instructed by  site personnel and will receive a 
sufficient quantit y of study  drug for 1 cy cle of  treatm ent. Pati ents will be given a diary  to record 
study  drug dosing and associ ated events (eg, time of intake, doses missed, vo miting, symptoms). 
The study  center staff will check the patient’s drug diary  versus the patient’s supply o f TAK -931 
capsules to assess co mpliance.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 63of 99
Protocol Incorporating Amendment 04 16 July 2018
9.9 Posttreatment Follow -up Assessments (Progression -Free Survival and Overall 
Survival) 
Patients in the di sease -specific cohorts who stop treatment for any  reason other than PD will 
continue to have PFS and OS follow -up visi ts. Patients in the Western safety  cohort will  be 
followed only  for PFS. The PFS follow -up visi t shoul d be conducted at the site every 12±1 weeks 
from the EOT vi sit until the occurrence of PD, loss to follow up, consent withdrawal, death, the 
start of subsequent sy stemic ant ineoplast ic therapy, study  terminat ion (Section 9.4), or until 
6months after the patient discont inues treatment, whichever occurs first. 
After the occurrence of PD or the start of subsequent anticancer therapy , all pat ients in the 
disease -specific cohorts will cont inue to have OS follow -up visit s. The OS visits should be 
conducted every 12±1 weeks until death, loss to follow -up, consent wit hdrawal, study terminat ion, 
or any  of the ci rcumstances described in Sect ion 9.7. The duration of fo llow-up for OS will be up 
to 1year after the last patient disco ntinues treatment, or until 50% of patients have died, whichever 
occurs first.
Survivor informat ion and death details may be co llected by  methods that include, but are not 
limited to, telephone, e -mail, mail, or retri eved f rom online or other databases (eg , soci al securi ty 
indexes). In addition, the start of another anticancer therapy  for the di sease under study  will be 
collected.
The end -of-study  visit is to be completed when the patient discont inues fro m the fo llow
-up period. 
See the Schedule o f Events ( Appendix A)
 for appropri ate assessments during fo llow-up.
NOTE: Only  study  drug -related SAEs m ust be reported to the Global Pharmacovigilance 
departm ent or designee aft er the EOT visit. Refer to Section 10.0 for details regarding definit ions, 
docum entati on, and reporting of SAEs. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 64of 99
Protocol Incorporating Amendment 04 16 July 2018
10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 Adverse Event Definiti on
AE m eans any  untoward m edical  occurrence in a pati ent administered a pharmaceut ical product; 
the untoward medical occurrence does not necessarily have a causal relat ionship with this 
treatm ent. An AE can therefore be any unfavorable and unintended sign (including an abnorm al 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a m edicinal 
(invest igational) product whether or not it is related to the medicinal product. This includes any 
newly occurring event, or a previous condit ion that has increased in severit y or frequency since the 
administration of study  drug.
An abnormal laboratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or delay in treatment, dose modification, therapeutic intervent ion, or is considered 
by the investigator to be a clinically significant change fro m Baseline.
10.1.2 Serious Adverse Event Definition
SAE m eans any untoward medical occurrence that at any  dose:
Results in death.
Is life-threatening (refers to an AE in which the pat ient was at risk of death at the time of the 
event. It does not refer to an event which hypothetically might have caused death if it were 
more severe).
Requi res inpat ienthospitalization or prolongation of an existing hospitalization (see 
clarificati onin the paragraph in Sect ion 10.2 on planned hospitalizat ions).
Results in persistent or significant disability or incapacity . (Disabilit y is defined as a 
substant ial disrupt ion of a person’s abilit y to conduct normal life functions).
Is a congenital anomaly/birth defect .
Is a medically important event . This refers to an AE that may  not resul t in death, be 
immediately  life threatening, or require hospitalization, but may be considered serious when, 
based on appropriate medical judgment, may  jeopardi ze the pati ent, requi re medical or 
surgi cal interventi on to prevent 1 of the outcomes listed above, or involves suspected 
transmissio n via a medicinal product of an infect ious agent. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsio ns that do not result in inpatient hospita lization, or the 
development of drug dependency  or drug abuse; any  organism , virus, or infecti ous parti cle 
(eg,prion protein transmitt ing transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infect ious agent. 
In thi s study, intensi ty for each AE, including any  lab abnormalit y, will be determined using the 
NCI CTCAE, versio n4.03, effect ive date 14 June 2010 [20].Clarification should be made 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-931
Study No. TAK-931- 2001 Page 65 of 99
Protocol Incorporating Amendment 04 16 July 2018
between an SAE and an AE that is considered severe in intensity (Grade 3 or 4), because the terms 
serious and severe are NOT synonymous. The general term severe is often used to describe the 
intensity (severity) of a specific event; the event itself, however, may be of relatively minor 
medical significance (such as a Grade 3 headache). This is NOT the same as serious , which is 
based on patient/event outcome or action criteria described above, and is usually associated with 
events that pose a threat to a patient’s life or ability to function. A severe AE (Grade 3 or 4) does 
not necessarily need to be considered serious. For example, a WBC count of 1000/mm3to less than 
2000/mm3is considered Grade 3 (severe) but may not be considered serious. Seriousness (not 
intensity) serves as a guide for defining regulatory reporting obligations.
10.2 Procedures for Recording and Reporting Adverse Events and Serious Adverse 
Events
All AEs spontaneously reported by the patient a nd/or in response to an open question from study 
personnel or revealed by observation, physical examination, or other diagnostic procedures will be 
recorded on the appropriate page of the eCRF (see Section 10.3 for the period of observation). Any 
clinically relevant deterioration in laboratory assessments or other clinical finding is considered an 
AE. When possible, signs and symptoms indicating a common underlying pathology should be 
noted as 1 comprehensive event.
Regardless of causality, SAEs (as defined in Section 10.1.2)  must be reported (see Section 10.3 for 
the period of observation) by the investigator to the Takeda Global Pharmacovigilance department
or designee (contact information provided below). Th is should be done by faxing the SAE Form 
within 24 hours after becoming aware of the event. The SAE Form, created specifically by Takeda, 
will be provided to each clinical study site. A sample of the SAE Form may be found in the Study 
Manual. Follow-up information on the SAE may be requested by Takeda. SAE report information 
must be consistent with the data provided on the eCRF. 
SAE Reporting Contact Information
Planned hospital admissions or surgical procedures for an illness or disease that existed before the 
patient was enrolled in the trial are not to be considered AEs unless the condition deteriorated in an CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses 
ed with with
or 4) door 4) d
mto lesto 
ousnessusne
 SeriouSeriou
to an opto an 
other diather d
.33ffor or ffffth
or or otherothe
commoommo
ctioonn101
to ththe eT
belbelow)ow
of fththe evee
dy site.y site
n the SAthe S
ta provia prov
SAESAom
pepeNon-CCCICI
TAK -931
Study No. TAK -931-2001 Page 66of 99
Protocol Incorporating Amendment 04 16 July 2018
unexpected manner during the trial (eg, surgery  was perform ed earlier or l ater than planned).
Prolongati on of  hospitalizat ion as a matter of practical convenience is not to be considered an AE 
unless the patient’s condit ion deteriorated. 
For both serious and nonserious AEs, the invest igator mu st determine both the severit y (toxi city 
grade) of the event and the relat ionship of the event to study drug administration. 
Severit y (toxi city grade) for e ach AE, including any lab oratory abnorm ality, will be determined 
using the NCI CTCAE, v.4.03, effect ive date 14 June 2010 [25].The criteria are provided in the 
Study  Manual.
Relationship of the event to study  drug administrati on(its causalit y) will be determined by  the 
investigator respondi ng yes (rel ated) or no (unrelated) to this quest ion: “Is there a reasonable 
possibilit y that the AE is associated with the study  drug? ”
10.3 Monitoring of Adverse Events and Period of Observation
AEs, both nonserious and serious, will be mo nitored throughout the study  as fo llows: 
AEs will be reported from the signing of the ICF through 30 day s after administration of the 
last dose of study  drug or before init iation of new ant icancer therapy  (whichev er com es first)
and recorded in the eCRF. 
SAEs will be reported to the Takeda Global Pharmacovigilance department or designee from 
the signing of the ICF through 30 day s after administration of the last dose of study  drug or 
before init iation of new antic ancer therapy  (whichever comes first) and recorded in the eCRF. 
After this period, only related SAEs must be reported to the Takeda Global Pharmacovigilance 
departm ent or desi gnee. SAEs shoul d be m onitored until they  are resolved or are clearly 
determined to be due to a patient’s stable or chronic condit ion or intercurrent illness(es).
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
If a woman beco mes pregnant or suspects that she is pregnant while participat ing in this study, she 
must inform  the invest igator immediately and permanent ly discont inue study  drug. The sponsor 
must also be contacted immediately by sending a completed Pregnancy Form to the Takeda Globa l 
Pharmacovigilance department or designee (see Section
 10.2). The pregnancy must be followed 
for the final pregnancy  outcom e.
If a female partner of a male patient becomes pregnant during the male pat ient’s participat ion in 
this study , the sponsor m ust also be contacted immediately by  sending a com pleted Pregnancy  
Form  to the Takeda Global Pharmacovigilance department or designee (see Sect ion 10.2). Every  
effort should be made to fo llow the pregnancy  for the final pregnancy  outcom e.
10.5 Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissat isfaction 
regarding the identit y, strength, puri ty, quali ty, or s tabilit y of a drug product. Individuals who 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-931
Study No. TAK-931- 2001 Page 67 of 99
Protocol Incorporating Amendment 04 16 July 2018
identify a potential product complaint situation should immediately report this via the phone 
numbers or e-mail addresses provided below.
A medication error is a preventable event that invol ves an identifiable patient and that leads to 
inappropriate medication use, which may result in patient harm. Whereas overdoses and 
underdoses constitute medication errors, doses missed inadvertently by a patient do not. 
Individuals who identify a potential medication error (including overdose) situation should immediately report this via the phone numbe rs or e-mail addresses provided below.
Call center Phone number E-mail Fax
Product complaints, in and of themselves, are not AEs. If a product complaint results in an SAE, 
the SAE should be reported (refer to Section  10.2) . 
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, including investigators and 
IRBS and IECs, as applicable, in accordance with national regulations in the countries where the 
study is conducted. Relative to the first awaren ess of the event by/or further provision to the 
sponsor or sponsor’s designee, SUSARs will be s ubmitted to the regulatory authorities as 
expedited reports within 7 days for fatal and life- threatening events and 15 days for other serious 
events, unless otherwise required by national regulations. The sponsor will also prepare an 
expedited report for other safety issues that might materially alter the current benefit-risk 
assessment of an investigational medicinal product or that would be sufficient to consider changes in the investigational medicinal products administration or in the overall conduct of the trial. 
The investigational site also will forward a copy of all expedited reports to his or her IRB or IEC in 
accordance with national regulations.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to thot
oduct cooduct c
ECs, anECs,
uspecteuspect
egulatorgulator
e with nwith 
wareneswarene
Rs will bs will
fatal anatal a
d by natby na
tyy iiyyssuessu
ional mional m
edicinaldicin
site alsoite als
natatplicable Terms of Usehould ould
cap
ioionalnthe App
TAK -931
Study No. TAK -931-2001 Page 68of 99
Protocol Incorporating Amendment 04 16 July 2018
11.0 STUDY- SPECIFIC COMMITTEES
For the Western safet y cohort, patient informat ion will be discussed in regularly scheduled 
meet ings wit h invest igators, other site personnel, and sponsor representatives. The main outcomes 
of these meet ings are DLT evaluat ion, patient allocation, and dose confirmat ion. Meet ings will be 
docum ented in minutes that will be distributed to members. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 69of 99
Protocol Incorporating Amendment 04 16 July 2018
12.0 DATA HANDLING AND RE CORDKEEPING 
The full details of procedures for data handling will be documented in the Data Management Plan. 
If selected for coding, AEs, medic al history , and concurrent condit ions will be coded using the 
Medical Dict ionary for Regulatory  Activities (MedDRA), version 21.0. Drugs will be coded using 
the World Healt h Organizat ion (WHO) Drug Dictionary . 
All available safety, tolerabilit y, efficacy, PK, and pharmacodynamic data will be included in data 
listings and tabulat ions. No imputation of values for missing data will be performed. The relevance 
of missing sample data will be assessed. 
Data that are potentially  spuri ous or erroneous will be exa mined according to standard data 
management operating procedures.
12.1 eCRFs 
Com pleted eCRFs are required for each patient who signed an ICF.
The sponsor or its designee will supply invest igative sites with access to eCRFs and will train 
appropriate site staff in the use of the eCRF. These forms are used to transmit the informat ion 
collected in the performance of this study to the sponsor, CRO partners, and regulatory authorit ies. 
Invest igative sites must complete eCRFs in English.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by the 
investigator or appropriate site personnel . Corrections to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion of the person making the 
correct ion, the date the correction was made, and the reason for change.
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the principal invest igator must retain
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the patient’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized represen tatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
12.2 Record Retention
The fo llowing procedure sapplytoall countri es except Japan. 
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 70of 99
Protocol Incorporating Amendment 04 16 July 2018
participat ing patients, medical records, temporary  media such as thermal -sensit ive paper, source 
worksheets, all original signed and dated ICFs, patient authorizat ion forms regarding the use of 
personal health information (if separate from the ICFs), electronic copy of eCRFs, including the 
audittrail, and detailed records of drug disposit ion to enable evaluat ions or audits fro m 
regul atory  authori ties, the sponsor or its designees. Any  source docum entati on printed on 
degradable thermal -sensi tive paper should be photocopied by  the si te and filed w ith the ori ginal 
in the pat ient’s chart to ensure long- term legibili ty. Furtherm ore, ICH E6 Section 4.9.5 requires 
the invest igator to retain essent ial documents specified in ICH E6 (Section 8) until at least 2 
years after the last approval o f a marketing applicati on for a specified drug indicat ion being 
investigated or, if an applicat ion is not approved, unt il at least 2 years after the invest igation is 
discontinued and regulatory authorit ies are notified. In addit ion, ICH E6 Secti on4.9.5 states that 
the study  records should be retained unt il an amount of time specified by applicable regulatory 
requi rements or for a time specified in the Clinical Study  Site Agreement between the 
investigator and sponsor. 
Refer to the Clinical Study  Site Agreement for the sponsor’s requirements on record retention. 
The invest igator should contact and receive written approval fro m the sponsor before disposing 
of any such documents. 
The fo llowing procedures apply  to Japanese si tes only . 
The invest igator and the head o f the institution agree to keep the records stipulated in 
Secti on12.1 and those documents that include (but are not limited to) the study -specific 
docum ents, the identifi cation log of all part icipating patients, medical records, temporary media 
such as thermal -sensi tive paper, source worksheets, all original signed and dated ICFs, patient 
authori zation forms regarding the use of personal health informat ion (if separate fro m the ICFs), 
electroni c copy  of eCRFs including audit trail, and detailed records of drug disposit ion to enable 
evaluat ions or audits from regulatory  authori ties, the sponsor or i ts desi gnees. Any source 
docum entati on printed on degradable thermal -sensit ive paper should be photocopied by  the si te 
and filed wit h the original in the pat ient’s chart to ensure lo ng-term legibilit y. Furthermore, ICH 
E6 Secti on 4.9.5 requi res the investigator and the head of the inst itution to retain essent ial 
docum ents specified in ICH E6 (Section 8) until at least 3 y ears after the l ast approval o f a 
market ing application for a specified drug indicat ion being investigated or, if an applicat ion is 
not approved, until at least 3 years after the invest igation is discont inued and re gulatory  
authori ties are notified. In addit ion, ICH E6 Secti on 4.9.5 states that the study records should be 
retained unt il an amount of time specified by applicable regulatory requirements or for a time 
specified in the Clinical Study  Site Agreement betwe en the invest igator and/or the head of the 
institution and sponsor.
Refer to the Clinical Study  Site Agreement for the sponsor’s requirements on record retention. 
The invest igator and the head of the inst itution should contact and receive written approval from 
the sponsor before disposing o f any such documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 71of 99
Protocol Incorporating Amendment 04 16 July 2018
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized before database lock. This document will 
provi de further details regarding the definit ion of analysis vari ables and analysis methodology  to 
address all study  object ives. 
13.1.1 Analysis Sets 
The populat ions used for analysis will include the fo llowing:
Safety popul ation:The safet y populati on is defined as all pat ients who receive any  amount of  
study  drug.
Pharmacokinet ic populat ion:The PK popul ation is defined as all patients for whom there are 
sufficient dosing and TAK -931 concentration -time data to reliably estimate the PK parameters. 
This populat ion will be used for analyses of PK parameters. 
DLT -evaluable populat ion:The DLT -evaluable populat ion is defined as all pat ients in the 
Western safet y cohort who receive at least 1 of their planned TAK -931 doses during their first 
cycle of  treatm ent (unl ess interrupted by  related AEs) and who have sufficient fo llow-up data 
to allow the invest igators and sponsor to determine whether a DLT occurred. Patients who 
receive <1 dose of TAK -931 in Cycle 1 for reasons other than relat ed AEs are not eligible for 
DLT evaluat ion and m ay be repl aced. 
Response -evaluable population: The response -evaluable populat ion is defined as pat ients who  
receive at least 1 dose of study  drug, have measurable disease at Baseline, and have at least 1 
postbaseline response assessment. Patients who die (fro m any cause) and patients who 
discontinue due to clinical deterioration before a postbaseline assessment will be considered 
evaluable and as nonresponders.
13.1.2 Analysis of Demographics and Other Baseline Char acteristics
Dem ographic (age, sex, and other parameters as appropriate) and baseline disease characterist ics 
(weight, hei ght, and other parameters as appropriate) will be summarized by cohort.
13.1.3 Efficacy Analysis
The primary  efficacy  parameter i s DCR per REC IST versi on 1.1 (CR+PR+SD; SD has to be ≥6 
weeks fro m treatm ent init iation to qualify for DCR). DCR will be analyzed using the 
response -evaluable population in both tumor -specific cohorts and in the Western safet y cohort . 
Secondary  efficacy parameters are ORR, DOR, PFS, and OS. OS will be evaluated only in the 
tumor-specific cohorts. 
The DCR and ORR will be est imated with 2 -sided 95% exact binomial CIs using the 
response -evaluable population (Sect ion 13.1.1 ). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 72of 99
Protocol Incorporating Amendment 04 16 July 2018
PFS i s defined as the time from the date of first dose to the date of first documentation of PD or 
death due to any  cause, whichever occurs first. The Kaplan -Meier survival curves, 25th, 50th 
(median), and 75th percentiles (if est imable), along with their 2-sided 95% CIs and percentage of 
censored observations will be provided for each disease cohort and for the Western safet y cohort. 
PFS will be analyzed using the safet y popul ation. 
OS is defined as the time fro m the date of first dose of study  drug to de ath due to any  cause. OS 
will be analyzed in the safety  popul ation using Kaplan -Meier est imation. 
DOR i s defined as the time from the date of first documentation of a response to the date of first 
docum entati on of  PD. Pati ents wi thout docum entati on of PD at the time of analysis will be 
censored at the date of their last response assessment that is SD or better. The DOR will be 
analyzed using the Kaplan
-Meier est imation. The DOR will be analyzed using the responders in 
the response -evaluable popul ation.
Themost recent prescreening CT scans (see Section 9.3.15.1 ) collected fro m pat ients (if available) 
may facilitate estimat ion of those patients’ pretreatment tumor gro wth rates to iso late the 
antitumor effect of TAK -931. These exploratory  analyses will be reported separately from the 
final CSR for this study . 
13.1.4 Pharmacokinetic Analysis 
PK parameters in pat ients undergoing intensive PK sampling will be est imated using 
noncompart mental methods wi th WinNonlin Phoenix versi on 6.2 or hi gher (Pharsight Corp, 
Mountain View, California). The plasma PK parameters will be est imated fro m the 
concentration -time profiles for all PK populat ion patients that undergo intensive PK sampli ng. 
The pl asma and urine PK of TAK -931 after the first dose on C1D1 and after mult iple doses on 
C1D8 will be determined based on the PK parameters below, as permitted by  data.
Cmax.
tmax.
AUC 24and AUC lastafter the fi rst dose (C1D1) and after administrat ion of mult iple doses on 
C1D8. 
t1/2z(Day  8 only ).
CL ss/F, R ac(AUC) (C1D8 only).
Amount of TAK -931 excreted over 8 hours (C1D1 only) and CLr (C1D1 only ) for pati ents 
undergo ing urine PK co llection in the Western safety  cohort.
PK parameters will be summar ized using descript ive statist ics. Individual TAK -931 
concentration -versus -time data and individual PK parameters will be presented in list ings and 
tabul ated using summary  stati stics by cohort. Individual and mean plasma concentration- time 
profiles will be plotted by  cohort. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 73of 99
Protocol Incorporating Amendment 04 16 July 2018
The sparse PK concentrations will be used in future integrated TAK -931 popul ation PK analyses, 
which will be reported separately. 
13.1.5 Safety Analysis
The incidence of DLTs in the lead -in safet y cohort in Western patients will be tabulated . In 
addition, to assess the relat ionship between toxicit ies and TAK -931 dose, the preferred term of 
individual toxicit ies will be summarized by  their frequency  and intensi ty.The DLT -evaluable 
popul ation will be used for the analysis o f DLT. 
Safety will be eval uated by  the incidence of TEAEs ( defined as any AEs that occur after 
administration of the first dose of study  drug through 30 days after the last dose of study  drug), 
severit y, and by changes from Baseline in the patient’s vital signs and clinical laboratory  results in 
the safet y populat ion. Exposure to study drug will be summarized, and reasons for discontinuatio n 
and modificat ion will be tabulated. Safet y will be summarized by cohort. 
TEAEs will be tabulated according to the MedDRA by  system  orga n class, high level term, and 
preferred term and will include the following categories:
TEAEs.
Drug -related TEAEs.
Grade ≥3 TEAEs.
Grade ≥3 drug -related TEAEs.
Most commo n TEAEs ( ≥10% of all pat ients).
SAEs.
A listing of TEAEs result ing in study  drug di scontinuat ion will be provided.
Descript ive statistics for the actual values of clinical laboratory parameters (and/or change from 
Baseline in clinical laboratory  parameters) will be presented for all scheduled measurements over 
time. Mean l aboratory  values o ver time will be plo tted for key  laboratory  parameters.
Descript ive statist ics for the actual values (and/or the change fro m Ba seline) of vital signs, weight, 
ECHO, or MUGA scans over time will be tabulated by  scheduled time point.
Shift tables for laborat ory parameters and other safety  parameters deem ed appropri ate will be 
generated to show changes in NCI CTCAE grade from Baseline to the worst postbaseline value. 
Graphical displays o f key safet y parameters, such as scatter plots of baseline versus worst 
postbaseline values, may be used to understand the TAK -931 safet y profile.
Concomitant medications co llected from the first dose of study drug through the study period will 
be coded using the WHO Drug Dict ionary. The number and percentage of patients taking 
concomitant medicat ions will be tabulated by WHO drug generic term using the safet y population.
Addit ional safet y analyses m ay be performed to more clearly enumerate rates of toxicit ies and to 
further define the safet y profile o f TAK -931.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 74of 99
Protocol Incorporating Amendment 04 16 July 2018
Electrocardiogram Analysis
ECG intervals (QT and QTcF, and PR interval), QRS duration, and ventricular rate will be 
summarized at each scheduled t ime point, along wit h mean change from Baseline to each 
posttreatment time po int. The number and percentage of patients with EC G abnormalit ies will be 
summarized at each time po int. Patients in the disease -specific cohorts will undergo ECGs as 
specified in the Schedule of Events ( Appendix A, Tables A and B). Patients in the Western safet y 
cohort and the first 10 US patients in each disease -specific cohort will undergo PK time -matched 
triplicate ECGs during Cycle 1 on Days 1 and 8 (Table C). Triplicate ECGs are not required fo r 
all other patien ts, including patients in the sqEC and sqNSCLC cohorts. The results of the 
PK-pharm acodynamic ECG analysis will be reported separately. 
13.1.6 Pharmacodynamic Analysis
The change from Baseline of pMCM2 (Ser40) levels in skin will be descript ively summarized by 
cohort. The change fro m Baseline of pMCM2 (Ser40) levels in tumor tissue biopsies may also be 
descript ively summarized. 
13.1.7 Biomarker Analysis
At the end of the study , tum or geneti c alterati ons (mutati ons, am plificat ion/delet ions) in ctDNA 
and/or banked tumor tissues may be characterized by NGS and a retrospective correlat ive study of 
these genetic alterations in relat ion to clinical responses may  be perform ed using de script ive 
statist ics, graphical methods, and statistical modeling, whichever is appropriate. MSS status and 
TP53 mutations may  be confirmed in part icipating patients. CRC mo lecular subt ypes may be 
characterized and their relationship to clinical efficacy  may be retrospectively evaluated. 
13.1.8 Analysis of Patient -Reported Outcomes
The PRO analysis will be performed based on subscale scores fro m EORTC QLQ -C30 
(disease -specific cohorts only) . The actual  value and change from  baseline of the subscale scores 
for EORTC QLQ -C30 will be summarized using descript ive statistics by disease -specific cohort 
over time. The EORTC QLQ -C30 subscale scores will also be analyzed using linear mixed models 
by incorporating the measurements across different time po ints. 
13.2 Interim A nalyses and Criteria for Early Termination
Metastatic Pancreatic Cohort and CRC Cohort
Two interim futilit y analyses will be conducted for both cohorts. In the metastatic pancreat ic 
cancer cohort, the first interim fut ility analysis will be carried out aft er the first 16 
response -evaluable pat ients. If no patients with disease control (CR, PR, or SD ≥6 weeks) are 
observed in the first stage, the study will be stopped for futilit y; otherwise, the study will cont inue 
to the second stage. The second interim fu tility analysis will be carried out after 25 
response -evaluable pat ients. If ≤2 patients have achieved disease control, the study will be stopped 
for futility; otherwise, the study  will cont inue into the thi rd stage to m ore fully characteri ze the 
DCR in a total of 33 response -evaluable pat ients and the null hypothesis will be rejected if there 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 75of 99
Protocol Incorporating Amendment 04 16 July 2018
are m ore than 7 pati ents wi th disease control . Similarly , the 2 interim fut ility stopping bounds for 
DCR in the metastatic CRC cohort will be ≤1 of 15 and ≤4 of 25 in a total of 35 response -evaluable 
patients, and the null hypothesis will be rejected if there are more than 11 of 35 patients with 
disease control . 
Squam ous Esophageal Cancer and Squamous Non –Small-Cell Lung Cancer Cohorts 
One interim fut ility analysis w ill be conducted for both cohorts. The interim fut ility stoppi ng 
bound for DCR will be ≤6 patients with disease control in a total of 20 response -evaluable patients, 
and the null hypothesis will be rejected if there are more than 16 of 40 patients with dis ease 
control . 
13.3 Determination of Sample Size
Approximately  12 Western patients with metastatic solid tumors that progressed after appropriate 
prior therapy  are expected to be enro lled in the US only to determine the safet y, tolerabilit y, and 
PK of TAK -931 i n Western patients. Init ially, 6 pati ents will  be enrolled at US sites in the safet y 
lead-in cohort for purposes of safety evaluat ion. If no more than 2 pat ients present with a DLT, the 
remaining 6 pati ents will be enrolled. 
Sample size considerat ions fortumor-specific cohorts are based on a Bayesian predict ive 
probabilit y approach with interim analyses for fut ility (see Secti on 13.2) with the f ollowing 
param eters:
AssumptionsPancreatic Cancer 
CohortMetastatic 
CRC CohortsqEC CohortsqNSCLC 
Cohort
Ineffective DCR (H o) 13% 23% 30% 30%
Effective DCR (H a) 30% 40% 50% 50%
Type 1 erro r 10% 10% 10% 10%
Power 80% 80% 80% 80%
Prior beta distribution 
parametersa0=0.2, b0=0.8 a0=0.2, b0=0.8 a0=0.2, b0=0.8 a0=0.2, b0=0.8
Abbreviations: CRC, colorectal cancer; DCR, disease control rate; H o, null hypothesis; H a, alternative hypothesis; 
sqEC, squamous esophageal cancer; sqNSCLC, squamous non –small - cell lung cancer. 
It is expected that the study  will enroll  up to ~33 response -evaluable pat ients in the m etastati c 
pancreat ic cancer cohort, ~35 response -evaluable patients in the metastatic CRC cohort, up to ~40 
response -evaluable pat ients in the sqEC cohort, and up to ~40 response -evaluable patients in the 
sqNSCLC cohort. With a potential drop- out rate of 10%, as many as approximately 76 pat ients 
may be enro lled in the pancreatic and CRC cohorts . Approximately  80 patients may be enrolled in 
the sqEC cohort and sqNSCLC c ohorts.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 76of 99
Protocol Incorporating Amendment 04 16 July 2018
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verific ation of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (CRO) and by  the IRB or IEC.
All aspects of the study  and its documentation will be subject to review by the sponsor or designee, 
including but not limited to the Invest igator’s Binder, study  medicat ion, pati ent m edical  records, 
inform ed consent docum entati on, docum entati on of  patient authorization to use personal health 
inform ation (if separate from the ICFs), and review of eCRFs and associated source documents. It 
is important that the invest igator and other study  personnel are available during the monitoring 
visits and that sufficient time is devoted to the process.
14.2 Protocol Deviations
The fo llowing procedure sapplytoall countri es except Japan. 
The invest igator should not deviate fro m the protocol , except where necessary  to 
eliminate an immediate hazard to study patients. Should other unexpected circumstances 
arise that will require deviat ion from protocol -specified procedures, the investigator 
shoul d consul t with the sponsor or designee (and IRB or IEC, as required) to determine 
the appropriate course of action. There will be no exempt ions (a pro spectively approved 
deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the patient’s source documents. In the 
event of a significant deviat ion, the site should notify the sponsor or its designee (and IRB 
or EC, as required). Significant deviat ions include, but are not limited to, those that 
involve fraud or misconduct, increase the healt h risk to the patient, or confound 
interpretati on of  primary study  assessment. A Protocol Deviat ion Form  shoul d be 
completed by the site and signed by the sponsor or designee for any significant deviat ion 
from the protocol .
The fo llowing procedures apply  to Japanese si tes only . 
The invest igator can deviate and change fro m the protocol for any medically unavo idable 
reason, for example, to eliminate an immediate hazard to study  patients, without a prior 
written agreem ent wi th the sponsor or a prior approval fro m IRB. In the event of a 
deviat ion or change, the principal invest igator should notify the sponsor and the head of 
the site (when applicable) of the deviat ion or change as well as its reason in a written 
form, and then retain a copy  of the wri tten f orm. When necessary , the principal  
investigator may  consul t and agree wi th the sponsor on a protocol amendment. If the 
protocol  amendment i s appropri ate, the am endment proposal  shoul d be submi tted to the 
head o f the site as soon as possible and an approval fro m IRB should be obtained.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 77of 99
Protocol Incorporating Amendment 04 16 July 2018
The invest igator should document all protocol deviations.
14.3 Quality Assurance Audits and Regula tory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to v isit the f acilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the US FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency  [MHRA], the Pharmaceuticals and Medical Devices Agency of 
Japan [PMDA]). If the study  site is contacted for an inspect ion by a regulatory  body, the sponsor 
shoul d be notified immediately. The invest igator and inst itution guarantee access for qualit y 
assurance auditors to all study  docum ents as described in Sect ion 14.1. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 78of 99
Protocol Incorporating Amendment 04 16 July 2018
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, patients) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with th e “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containin g 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable requirements of each participat ing 
region. The sponsor or designee will require documentation notin g all names and titles of members 
who make up the respect ive IRB or IEC. If any member of the IRB or IEC has direct participat ion 
in this study , written notificat ion regarding his or her abst inence fro m voting must al so be 
obtained. Those American sites un willing to provide names and tit les of all members due to 
privacy  and conflict of interest concerns should instead provide a Federal Wide Assurance 
Number or comparable number assigned by the Department of Health and Human Services. 
The sponsor or designe e will  supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, patient recruitment materials and/or a dvertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
patient ICF m ust be obtained and submitted to the sp onsor or desi gnee before commencement of 
the study  (ie, before shipment of the sponsor -supplied drug or study -specific screening act ivity). 
The IRB or IEC approval must refer to the study by exact protocol t itle, number, and versio n date; 
ident ify versio nsof other documents (eg, ICF) reviewed; and state the approval date. The sponsor 
will notify site once the sponsor has confirmed the adequacy of site regulatory documentation and, 
when applicable, the sponsor has received permission fro m competent authori ty to begin the trial. 
Until the site receives notification, no protocol activit ies including screening may occur. 
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding pr otocol  amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  patients, local safet y reporti ng requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submi ssion of the invest igator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the sponsor or its 
designee. 
Patient incent ives should not exert undue influence for participation. Pay ments to patients must be 
approved by  the IRB or IEC and the sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 79of 99
Protocol Incorporating Amendment 04 16 July 2018
15.2 Patient Information, Informed Consent, and Patient Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and th e ICH Gui delines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, patient authorizat ion form (if applicable), and patient 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the patient’s personal and personal health informat ion for purposes of conducting 
the study. The ICF and the patient informat ion sheet (if applicable) further explain the nature of the 
study , its object ives, and potential risks and benefit s, as well as the date informed consent is given. 
The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any  time wi thout giving a reason and without prejudice to his or her further medical 
care.
The invest igator i s responsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicable, the patient authorizat ion form. The ICF, patient authorizat ion form (if 
applicable), and patient information sheet (if applicable) must be approved by both the IRB or IEC 
and the sponsor before use.
The ICF, patient authorization form (if applicable), and patient informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective pat ient. It is the 
responsibilit y of the inves tigator to explain the detailed elements of the ICF, patient authorizat ion 
form (if applicable), and patient informat ion sheet (if applicable) to the patient. Information should 
be given in both oral and wr itten form whenever possible and in the manner dee med appropriate by 
the IRB or IEC. In the event the patient is not capable of rendering adequate written informed 
consent, then the patient’s legally  acceptable representati ve m ay provi de such consent for the 
patient in accordance with applicable laws and regul ations. 
The patient, or the patient’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
patient, or the pati ent’s l egally ac ceptable representative, determines he or she will part icipate in 
the study , then the ICF and pat ient authorizat ion form (if applicable) must be signed and dated by 
the patient, or the patient’s legally acceptable representative, at the time of consent and before the 
patient entering into the study. The pat ient or the patient’s legally acceptable representative should 
be instructed to sign using their legal names, not nicknames, using blue or black ballpo int ink. The 
investigator must also sign and date the ICF and patient authorization (if applicable) at the time o f 
consent and before the patient enters into the study; however, the sponsor may allow a designee o f 
the invest igator to sign to the extent permitted by applicable law. 
Once signed, the original ICF, pati ent authori zation form (if applicable), and pat ient informat ion 
sheet (if applicable) will be stored in the investigator’s site file. The investigator must document 
the date the patient signs the informed consent in the patient’s medical record. C opies of the signed 
ICF, the si gned patient authorizat ion form (if applicable), and pat ient information sheet (if 
applicable) shall be given to the patient. 
All revised ICFs must be reviewed and signed by relevant patients or the relevant patient’s legall y 
acceptable representative in the same manner as the original informed consent. The date the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 80of 99
Protocol Incorporating Amendment 04 16 July 2018
revised consent was obtained should be recorded in the patient’s medical record, and the patient 
shoul d receive a copy  of the revised ICF.
15.3 Patient Confidentiality
The sponsor and designees affirm and upho ld the principle of the patient’s right to protection 
against invasio n of privacy. Throughout this study , a pati ent’s source data will be linked to the 
sponsor’s clinical study  database or documentation only via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited patient attributes, such as sex, age, or date 
of birth, and patient initials may be used to verify the pat ient and accuracy  of the pati ent’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, US FDA, MHRA, PMDA), the sponsor’ s designated auditors, and the 
appropriate IRBs and IECs to review the patient’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a patient’s study  parti cipat ion, 
and autopsy  reports. Access to a patient’s original medical records requires the specific 
authori zation of the patient as part of the informed consent process (see Section 15.2).
Copi es of  any patient source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (eg, pati ent name, address, an d other i dentifier fields 
not collected on the patient’s eCRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication 
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical st udy site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish an y data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
15.4.2 Clinical Trial Registration
To ensure that information on clinical trials reaches the public in a timely manner and to comply 
with applicable laws, regulat ions and guidance, Takeda will, at a minimum register intervent ional 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 81of 99
Protocol Incorporating Amendment 04 16 July 2018
clinical trials it sponsors anywhere in the world on ClinicalTrials.gov or other publicly accessible 
websites on or before start of study , as defined in Takeda Policy/Standard . Takeda contact 
inform ation, along wi th invest igator’s cit y, state (for Amer ican invest igators), country , and 
recrui ting status will be registered and available for public viewing. 
As needed Takeda and Investigator/site contact information may be made public to support 
participant access to trials via registries. In certain situa tions/registri es, Takeda m ay assist 
participants or potential participants to find a clinical trial by helping them locate trial sites closest 
to their homes by providing the investigator name, address, and phone number via email/phone or 
other m ethods cal lers requesting trial informat ion. Once pat ients receive invest igator contact 
inform ation, they  may call the si te request ing enro llment into the trial. The invest igative sites are 
encouraged to handle the trial inquiries according to their established pati ent screening process. If 
the caller asks addit ional questions beyo nd the topic of trial enro llment, they should be referred to 
the sponsor. 
Any invest igator who objects to Takeda providing this informat ion to callers must provide Takeda 
with a wri tten no tice request ing that their informat ion not be listed on the registry site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov or other publicly  accessible 
websites (including the Takeda corporate site) and registries, as required by Takeda Policy/
Standard, applicable laws, and/or regulat ions. 
Data Sharing
The sponsor is committed to responsible sharing of clinical data with the goal of advancing 
medical science and improving pat ient care. Qualified ind ependent researchers will be permitted 
to use data collected from pat ients during the study to conduct addit ional scient ific research, which 
may be unrelated to the study  drug or the patient’s disease. The data provided to external 
researchers will not inc lude informat ion that i dentifies pat ients personally.
15.5 Insurance and Compensation for Injury
Each patient in the study  must be insured in accordance with the regulat ions applicable to the site 
where the patient is participat ing. If a local underwriter is re quired, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study pat ients. 
Refer to the Clinical Study Site Agreement regarding the sponsor’s policy on patient compensat ion 
and treatment for i njury . If the invest igator has questions regarding this po licy, he or she should 
contact the sponsor or sponsor’s designee. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 82of 99
Protocol Incorporating Amendment 04 16 July 2018
16.0 REFERENCES
1. Labib K. How do Cdc7 and cyclin- dependent kinases trigger the init iation of chromosome 
replicat ion in eukaryotic cells? Genes & Development 2010;24(12):1208-19.
2. Masai H, Matsui E, You Z, Ishimi Y, Tamai K, Arai K. Human Cdc7 -related kinase 
complex. In vitro phosphorylat ion of MCM by  concerted acti ons of Cdks and Cdc7 and 
that of a crit icial threonine residue of Cdc7 bY Cdks. Journal of Bio logical Chemistry  
2000;275(37):29042-52.
3. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus 
paclitaxel versus placebo plus paclitaxel in pat ients with previ ously treated advanced 
gastric or gastro -oesophageal junct ion adenocarcinoma (RAINBOW): a double -blind, 
rando mised phase 3 trial. Lancet Onco l 2014;15(11):1224 -35.
4. Bousset K, Diffley JF. The Cdc7 protein kinase is required for origin firing during S phase. 
Genes Dev 1998;12(4): 480-90.
5. Furuya K, Miyabe I, Tsutsui Y, Paderi F, Kakusho N, Masai H, et al. DDK phosphorylates 
checkpoint clamp co mponent Rad9 and promotes its release from damaged chromatin. 
Molecular Cell 2010;40(4):606 -
18.
6. Swords R, Mahalingam D, O'Dwyer M, Santo canale C, Kelly K, Carew J, et al. Cdc7 
kinase -a new target for drug development. European Journal of Cancer 2010;46(1):33-40.
7. Montagnoli A, Moll J, Co lotta F. Targeting cell divisio n cycle 7 kinase: a new approach for 
cancer therapy . Clinical Cancer Research 2010;16(18):4503-8.
8. Yam ada M, Watanabe K, Mistrik M, Vesela E, Protivankova I, Mailand N, et al. 
ATR -Chk1 -APC/CCdh1 -dependent stabilization of Cdc7 -ASK (Dbf4) kinase is required 
for DNA lesio n bypass under replicat ion stress. Genes & Developmen t 
2013;27(22):2459 -72.
9. Hou Y, Wang HQ, Ba Y. Effects of CDC7 gene silencing and Rituximab on apoptosis in 
diffuse large B cell lympho ma cells. Journal of Cancer Research & Clinical Onco logy 
2012;138(12):2027 -34.
10. Cheng AN, Jiang SS, Fan CC, Lo YK, Ku o CY, Chen CH, et al. Increased Cdc7 expressio n 
is a marker of oral squamous cell carcino ma and overexpression of Cdc7 contributes to the 
resistance to DNA -damaging agents. Cancer Letters 2013;337(2):218-25.
11. Bonte D, Lindvall C, Liu H, Dy kema K, Furge K, Weinreich M. Cdc7- Dbf4 kinase 
overexpressio n in mult iple cancers and tumor cell lines is correlated with p53 inact ivation. 
Neopl asia (New York) 2008;10(9):920 -31.
12. Kulkarni AA, Kingsbury  SR, Tudzarova S, Hong HK, Loddo M, Rashid M, et al. Cdc7 
kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian 
carcino ma. Clinical Cancer Research 2009;15(7):2417 -25.
13. Chen HJ, Zhu Z, Wang XL, Feng QL, Wu Q, Xu ZP, et al. Expressio n of huCdc7 in 
colorectal  cancer. Worl d Journal  of Gastroenterol ogy 2013;19(20):3130-3.
14. Malumbres M. Physio logical  relevance of cell  cycle kinases. Physio logical Reviews 
2011;91(3):973 -1007.
15. Yam ada M, Masai  H, Bartek J. Regul ation and roles of Cdc7 kinase under replicat ion 
stress. Cell Cycle 2014;13(12):1859 -66.
16. Kastan MB, Bartek J. Cell -cycle checkpoints and cancer. Nature 2004;432(7015):316 -23.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 83of 99
Protocol Incorporating Amendment 04 16 July 2018
17. Sawa M, Masai H. Drug design with Cdc7 kinase: a potential novel cancer therapy  target. 
Drug Desi gn, Development and Therapy  2008;2:255 –64.
18. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib 
monotherapy  for previ ously treated m etastati c col orectal  cancer (CORRECT): an 
internat ional, mult icentre, randomised, placebo -
controlled, phase 3 trial. Lancet 
2013;381:303 -12.
19. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garci a-Carbonero R, Mizunuma N, et al. 
Randomized trial o f TAS -102 f or refractory  metastati c col orectal  cancer. New England 
Journal  of Medicine 2015;372(20):1909 -19.
20. Lagergren J, Smyt h E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet 
2017;390(10110):2383-96.
21. Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, McCusker ME. Real -world 
treatm ent patterns for patients receiving second -line and third- line treatment for advanced 
non-small  cell lung cancer: A systemat ic review o f recently published studies. PLoS One 
2017;12(4):e0175679.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluat ion criteria in so lid tumours: revised RECIST guideline ( versio n 1.1). Eur 
J Cancer 2009;45(2):228 -47.
23. Rizzo JD, Brouwers M, Hurley  P, Sei denfeld J, Arcasoy  MO, Spivak JL, et al. American 
Society of Clinical  Oncol ogy/American Soci ety of Hem atology clinical pract ice gui deline 
update on the use of epoetin and darbepoetin in adult patients with cancer. Journal of 
Clinical Onco logy 2010;28(33):4996-5010.
24. NCCN.  NCCN Clinical Practice Guidelines in Oncology  (NCCN Guidelines).
25. Commo n Termino logy Criteria f or Adverse Events (CTCAE). National Cancer Inst itute, 
National Inst itutes of Healt h, U.S. Department of Health and Human Services  Series 
v4.03. June 14, 2010. Publication No. 09 -5410.
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicit y 
and response criteria of the Eastern Co operative Onco logy Group. Am erican Journal of 
Clinical Onco logy 1982;5(6):649-55.
27. Cockcroft DW, Gault MH. Prediction of creat inine clearance fro m serum  creat inine. 
Nephron 1976;16(1):31 -41.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 84of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALAppendix ASchedule of Events
Table A S chedule of Events for Cycle 1
Screening aDay
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Informed consent X
Inclusion/exclusion criteria X
Demographics X
Medical historybX X
Physical examinationbX X X X
Height X
Weight X
Vital signscX X X X
ECOG performance status X
12-Lead Safety ECG dX X X X
Triplicate ECG eX X
ECHO/MUGA X
Disease assessment fX
Monitoring of concomitant 
medications and proceduresRecorded from ICF signature through the EOT visit or initiation of
new anticancer therapy (whichever comes first).
Adverse event reporting Recorded from ICF signature through 30 days after administration of the last dose of study drug or before initiation of
new anticancer therapy (whichever comes first).
Serious adverse eventsgwill be reported from signing of the ICF through the EOT visit or initiation of
new anticancer therapy (whichever comes first).
TAK -931 administrationhX X X X X X X X X X X X X X
See footnotes on the last table page. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 85of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALTable A Schedule of Events for Cycle 1 (continued)
Screening aDay
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Samples/Laboratory Assessments
Pregnancy test iX X
Hematology/chemistry jX X X X
CA-19-9 (pancreatic cancer patients only) kX
CEA (CRC patients only) kX
Urinalysis lX X
Plasma sample for ctDNA nX
Whole blood sample oX X
Archival (banked) tumor tissue sample pX
Fresh skin tissue biopsy sample qX (or C1D1) (X)
Fresh tumor tissue biopsy sample rX (or C1D1)
Fresh tumor tissue biopsy pairs for 
pharmacodynamics s X (or C1D1) X
EORTC QLQ -C30 tX X
Plasma sample for TAK -931 PK See Table C, below.
Urine sample for TAK -931 PK See Table C, below.
See footnotes on the following page.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 86of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALAbbreviations: C1D1, Cycle 1 Day 1; CEA, carcinoembryonic antigen; CRC, colorectal cancer; CT, computed tomography; ctDNA, ci rculating tumor DNA; CxDx, Cycle x Day x; 
ECG, electrocardiogram; ECHO, echocardiogram; ECOG, Eastern Cooperative Oncology Group; E ORTC QLQ -C30, European Organisation for Research and Treatment of Care 
Core Quality of Life Questionnaire; EOT, end of treatment; FFPE, formalin -fixed, paraffin -embedded; HRQOL, health -related quality of life; IEC/IRB; independent ethics 
committee /institut ional review board; ICF, informed consent form; MRI, magnetic resonance imaging; MUGA, multiple gated acquisition (scan); PK, pharmacokinetic(s); QD, once 
daily; sqEC, squamous esophageal cancer; sqNSCLC, squamous non–small -cell lung cancer . 
aUnless othe rwise noted, the Screening visit must occur within 28 days before administration of the first dose of study drug (C1D1). The ICF may be signed more than 28 days before 
C1D1.
bThe C1D1 medical history should focus on study disease and changes since the scr eening medical history. For patients in sqEC and sqNSCLC cohorts, collect tobacco smoking 
history. The C1D1 physical examination is not required if the screening physical examination was conducted within 4 days befo re administration of the first dose of st udy drug 
(C1D1). 
cPerform vital sign measurements, including HR and BP measurements, before dosing on C1D1, C1D8, and on C1D15. Also, for all p atients in Western safety cohort and the first 10 
US patients in CRC and pancreatic cancer cohorts, repeat HR a nd BP measurements on C1D1and C1D8 at 2, 4, and 6 hours postdose just before PK sampling. 
dAll 12 -lead safety ECG recordings should be made with the patient in a supine position. On C1D1, C1D8, and C1D15, a 12- lead safety ECG should be recorded after vit al sign 
measurements and before any specified predose PK sampling. 
eTriplicate ECGs: Refer to Table C in this appendix for triplicate ECG/PK collection on C1D1 and C1D8. Patients in the Western safety cohort and the first 10 US patients in the 
pancreatic cancer and CRC cohorts will undergo triplicate ECGs matching PK sampling for QTc assessment during Cycle 1 on Days 1 and 8. Triplicate ECGs are not required 
for all other patients, including patients in the sqEC and sqNSCLC cohorts. Before each nominal triplicate ECG sampling time point, patients must maintain at supine 
position for 15 minutes. A Holter monitoring device will be used for triplicate ECG assessment. Three ECGs (approximately 1 m inute apart) will be extracted at prespecified time 
points at ti mes that match the times of Day 1 and Day 8 postdose PK/ECG sampling. 
fBaseline CT (with contrast) or MRI scan of the chest, abdomen, and pelvis must be obtained within 4 weeks before the first do se of TAK -931, according to standard of care. Bone 
scans m ay be performed rather than CT or MRI on patients with bone metastases. See Section 9.3.15 for more details
gIncluding serious pretreatment events; see Section 10.1.1 .
 
hTAK -931 will be administered orally daily for 14 days of a 21 -day cycle followed by 7 days of rest. S tudy drug will be administered to patients on an empty  stomach. Patients should 
not eat for 2 hours before taking the study drug with 8 ounces of water. See Section 8.1. 
iA serum β -human chorionic gonadotropin pregnancy test will be performed only for women of childbearing potential during screening and a gain at C1D1 (Baseline) if the screening 
test was performed more than 4 days before the first do se of study drug. The results must be negative within 4 days before the first dose of TAK -931 is administered (within the 4 days 
before C1D1), or as otherwise required by local regulations. If C1D1 serum pregnancy results will not be available before dos ing, a urine pregnancy test may be performed. 
Additional pregnancy testing may be performed during the study at the discretion of the investigator, upon request of an IEC/ IRB, or if required by local regulations.
jThe hematology and chemistry blood samples for C1D1 may be collected within 4 days before dosing to ensure patient eligibility on C1D1. If screening clinical laboratory testing 
was performed within 4 days before the C1D1 dose, then testing does not need to be repeated on C1D1. See Section
 9.3.14 for an analyte listing. For patients in the DLT observation 
window (C1, safety lead -in cohort), any symptomatic or asymptomatic Grade 3 laboratory abnormalities need to be retested every 2 days until the event is ≤Grade 2. For patients in 
the disease specific cohorts in Cycle 1, new clinically significant Grade ≥3 laboratory results should be repeated a minimum of every 3 days until recovered to Grade ≤2. Safety 
laboratory measurements outside C1D1 can be collected up to 2 days before the actual visit date. 
kIf another biomarker is elevated, it must be followed and collected according to the schedule for CEA (CRC) and CA -19-9 (pancreatic cancer) measu rements. 
lComplete urinalysis with qualitative analysis for protein at Screening and C1D1. Refer to Section 9.3.14 for required clinical urinalysi s tests. If screening urinalysis was performed 
within 4 days before the C1D1 dose, urinalysis does not need to be repeated on C1D1. 
nA blood sample will be obtained before administration of TAK -931 at C1D1, C3D1, C5D1, and EOT/relapse for plasma and subs equent ctDNA isolation.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 87of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALoThe whole blood sample can be taken at Screening OR before dosing on C1D1. This sample will be used as reference DNA for tumo r mutation detection. 
pAll patients enrolled in disease -specific cohorts must have an archival/banked FFPE pretreatment tumor biopsy to assess TAK -931 efficacy in relation to various biomarkers. An 
archival sample obtained at the time of the last progression, if available, is p referred; however, an archival FFPE sample obtained at the time of the initial diagnosis (eg, surgical 
specimen) is acceptable. An FFPE blocks or ≥10 unstained slides are required. 
q A fresh skin tissue biopsy sample (2 to 4 mm) will be obtained from all patients in the Western safety cohort either during screening or predose on C1D1 and postdose on Day 8 in 
Cycle 1. In the event that the skin biopsy cannot be taken on the Day 8 visit, it can be scheduled on any other day from Day 9 to Day 14 while the pat ient is still receiving TAK -931. 
It is strongly recommended that postdose skin biopsies are collected from 4 to 9 hours after study drug administration. For a ll patients in the Western safety cohort and for those in the 
disease -specific cohorts who consent to have paired (predose and on -treatment) tumor biopsies, an optional skin tissue biopsy will be collected simultaneously, if possible, with the 
tumor collection. 
rIf FFPE tumor tissue is not available (see footnote p), a fresh tumor tissue biopsy sampl e must be obtained. If a new biopsy is performed, it should be obtained during the screening 
period with a nonsignificant risk procedure in the opinion of the investigator. For patients in the Western safety cohort, th is biopsy is optional. 
sPaired tumor biopsies (predose and postdose on any dosing day after the completion of 3 consecutive days in Cycle 1 [Day 4 and after]) are optional and the patient needs to consent 
specifically for them (see Section 9.3.16.4 ). The predose biopsy can be collected any time before the first dose of TAK -931. The postdose biopsy can be collected 4 to 9 hours 
postdose on any dosing day after completion of 3 consecutive days of TAK -931 treatment (Day 4 and later). It is recommended that the postdose biopsy be taken from the same lesion 
or, at least, from the same organ as at Baseline. Fresh tumor biopsies are optional for patients enrolled in the Western safety  cohort. F resh biopsies should meet the characteristics of 
nonsignificant risk, in the opinion of the investigator. 
t Patient -reported outcomes (HRQOL) should be completed before any other study procedures are performed. 
Note: Tests and procedures should be performed on schedule; patients may remain on study with occasional changes (±3 days) for holidays, vacations, and other administra tive 
reasons. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 88of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALTable B Schedule of Events for Treatment Cycle 2 Through PFS Follow -up
Cycle 2 and Subsequent Cycles
EOTaPFSFU OSFU aDay 1 Day 8 Day 15 Day 18
Symptom -directed phy sical 
examination bX X
Weight X cX
Vital signs dX X dX dX
ECOG performance status fX X
12-Lead ECG gX X
ECHO/MUGA hX X
Disease assessment iX
(±4 day s starting C2 
and every other cycle 
thereafter)XjXk
(Q 12 weeks)
Monitoring of concomitant 
medications and proceduresRecorded from ICF signature through the EOT visit or initiation of
new anticancer therapy (whichever comes first).
Adverse event reporting Recorded from ICF signature through 30 days after administration of the last dose of study drug or before 
initiation of new anticancer therapy (whichever comes first).
Serious adverse events lwill be reported from signing of the informed consent form through 30 days after the 
last dose of study drug or before initiation of new anti -cancer therapy (whichever comes first).X m
TAK -931 administrationnDays 1 through 14 of each treatment cycle
Samples/Laboratory Assessments
Pregnancy test oX
Hematology/chemistry e,pX X eX
CA-19-9 (pancreatic patients only) qX X
CEA (CRC patients only) qX X
Urinalysis rX
Plasma sample for DNA sX X
EORTC QLQ -C30 tX X
Blood samples for PK dSee Table C, below. 
Footnotes are on the following page.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 89of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALAbbreviations: BP, blood pressure; C, cycle; CEA, carcinoembryonic antigen; CRC, colorectal cancer; CxDx , Cycle x Day x; CT, computed tomography; ctDNA, circulating tumor 
DNA; ECG, electrocardiogram; ECHO, echocardiogram; ECOG, Eastern Cooperative Oncology Group; EORTC QLQ -C30, European Organisation for Research and Treatment of 
Care Core Quality of Life Que stionnaire; EOT, end of treatment; FIT, fusion- inferred threshold; HR, heart rate; HRQOL, health -related quality of life; IEC/IRB; independent ethics 
committee /institutional review board; MRI, magnetic resonance imaging; MUGA, multiple gated acquisition (scan); OSFU, overall survival follow -up; PD, progression of disease; 
PFS, progression -free survival; PFSFU, progression -free survival follow -up; Q, every; QD, once daily; SAE, serious adverse event. 
aFor patients in disease -specific cohorts, survival stat us is to be assessed every 12±1 weeks after the occurrence of PD or the start of subsequent anticancer therapy. These OS visi ts 
should continue until death, loss to follow -up, consent withdrawal, study termination, or any of the circumstances described in Section 9.7. 
bThe symptom -directed physical examination will be conducted within 3 days prior to dosing on Day 1 of each treatment cycle and at the EOT visit. Th e symptom -directed physical 
examination may be performed at other visits during the treatment cycle at the discretion of the investigator.
cWeight will be measured every other cycle beginning with Cycle 3, and at EOT.
dPerform vital sign measurements pri or to dosing. For all patients in the Western safety cohort and first 10 US patients in the pancreatic cancer and CRC cohorts , BP will be measured 
predose and at 2 and 4 hours postdose on Days 1 and 8 of Cycle 2 only and before the PK blood draw. From Cycl e 3 to Cycle 5 if the investigator considers that there is no hypotension 
risk based on previous determinations, only standard vital signs will be performed (BP, HR, and temperature) on Day 1. For th e remaining patients, collect BP, HR, and temperature 
only on Day 1 of each cycle and at EOT. 
eSafety laboratory values can be collected up to 2 days before the actual visit date. From Cycle 6 and beyond, hematology and chemistry tests will only be conducted on Day 1 of each 
cycle if, in the opinion of the inv estigator, this is safe. 
fECOG performance status will be performed within 3 days before the beginning (Day 1) of each treatment cycle and at the EOT visit.
gPredose, single safety ECGs will be collected on Day 1 of Cycle 2 and at the EOT visit. Additional ECGs may be obtained as clinically indicated at the discretion of the investigator. 
ECG assessments are to be performed with the patient supine and rested for 5 minutes.
hECHO and/or MUGA should be performed predose on C2D1, C3D1, every 3rd cyc le thereafter (C6D1, C9D1, etc.), and at the EOT visit. From Cycle 3 (inclusive) onwards, a 
window of ±2 weeks is allowed for the ECHO and/or MUGA procedures. The same modality should be used as on the Screening visit . 
iContrast -enhanced baseline CT or M RI scan of the chest, abdomen, and pelvis must be acquired at Screening, after which contrast -enhanced CT or MRI should be acquired starting 
on C2D18 (±4 days) and every other cycle thereafter or as clinically indicated. The same imaging modality (CT or MR I) should be used on a patient as at the Screening visit and 
throughout the study. Additional bone scans may be performed on patients with bone metastases rather than CT or MRI. See Sect ion 9.3.15 for more details.
jAt EOT, tumor assessments will be done only on patients who have not previously demonstrated disease progression in the study unless completed within the previous 4 weeks.
kPatients who discontinue study treatment for reasons other than PD will undergo CT/MRI scans every 12±1 weeks from EOT until the occurrenc e of PD, loss to follow -up, consent 
withdrawal, death, the start of subsequent systemic antineoplastic therapy, study termination ( Section 9.4), or until 6 months after the patient discontinued study treatment, whichever 
occurs first.
lIncluding serious pretreatment events; see Section 10.2.
mAfter EOT, only study drug -related SAEs must be reported to the sponsor’s Department of Pharmacovigilance or designee.
nTAK -931 will be administe red orally daily for 14 days of a 21 -day cycle followed by 7 days of rest. Study drug will be administered to patients on an empty  stomach. Patients should 
not eat for 2 hours before taking the study drug with 8 ounces of water. Patients should be instruct ed to eat a meal or snack >1 hour after taking study drug. See Section 8.1. 
oAdditional pregnancy testing may be performed at the discretion of th e investigator, upon request of an IEC/IRB, or if required by local regulations. See Section 8.7.1 . 
pAny new Grade ≥3 results should be repeated at investigator discretion until recovered to Grade ≤2.
qIf another biomarker is elevated, it has to be followed and collected according to th e schedule for CEA (CRC) and CA -19-9 (pancreatic cancer) measurements.
rComplete urinalysis with qualitative analysis for protein will be performed at C2D1 and every other cycle thereafter. Positiv e results may require quantitative analysis (assessment 
ofurine protein –to-creatinine ratio). Refer to Section 9.3.14 for the required clinical urinalysis tests.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 90of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALs A blood sample will be obtained before ad ministration of TAK -931 at C1D1, C3D1, C5D1, and EOT/relapse for plasma and subsequent ctDNA isolation.
tPatient -reported outcomes (HRQOL) should be completed before any other study procedures are performed. 
Note: Tests and procedures should be performed on schedule; patients may remain on study with occasional changes (±3 days) for holidays, vacations, and other 
administrative reasons.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 91of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALTable C Pharmacokinetic Sampling Schedule
Cycle 1 Cycle 2
Day 1 Day 8 Day 1 Day 8
Plasma Triplicate 
ECG aUrine Plasma Triplicate 
ECG aPlasma Plasma
Intensive PK Sampling 
Predose (within 1 hour before study drug) X X X b,cX X X d
30 min postdose ( 5 min) X X
1 hour postdose ( 10 min) X X X eX
2 hours postdose ( 20 min) X X X X
4 hours postdose ( 30 min) X X X X
6 hours postdose ( 1 hr) X X X X
8 hours postdose ( 1 hr) X X X eX
24 hours postdose ( 3 hr) (f) X X
Sparse PK Sampling (All patients enrolled 
from Amendment 03 onward)
Predose X X X X
1 hour postdose ( 10 min) X
2 hours postdose ( 20 min) X X X X
4 hours postdose ( 30 min) X
Footnotes are on the following page.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 92of 99
Protocol Incorporating Amendment 04 16 July 2018
CONFIDENTIALAbbreviations: AE, adverse event; ECG, electrocardiogram; hr, hour(s); min, minute(s); PK, pharmacokinetic(s); sqEC, squamous esophageal cancer; sqNSCLC, squam ous non –
small -cell lung cancer; US, United States .
aLimited to all patients in Western safety cohort and the first 10 US patients in the pancreatic cancer and CRC cohorts (target a total of ~32 patients). Triplicate ECGs are not 
required for all other patients, including patients in the sqEC and sqNSCLC cohorts. A Holter device will be used for collecting triplicate ECGs. Collection of PK time -matched 
triplicate ECGs begins after the patient has rested in the supine position for approximately 15 minutes. It is recommended that patients refrain from eating or limit themselves to bland 
food for 1 hour before and until completion of the 4-hour triplicate ECG measurements. Three Holter ECGs (approximately 1 minute apart) will be extracted at prespecified time 
points. Before each nominal triplicate ECG time point, the patient must be maintained at supine bed rest for 15 minutes. The tripli cate ECGs will be extracted during the final 10 
minutes of that rest period (the ECG extraction 10 -minute window). The PK blood draws will occur immediately following the completion of the ECG extractions on Cycle 1, Days 
1 and 8. 
Note: For any patient wh o experiences hypotension or other AEs on non -PK sampling days considered to be possibly related to study drug, an additional PK plasma specimen should 
(if feasible) be collected at the time of the event. 
bThe first 10 patients from US sites in the CRC a nd pancreas cancer cohorts do not require urine collection. 
cThe 8 -hour urine collection begins on Day 1 at the time of TAK -931 administration and ends 8 hours later. For the timed 8 -hour urine collection on C1D1 in the Western safety 
cohort, patients sh ould be asked to void completely in a container approximately 30 minutes before administration of the first dose of study drug. An aliquot of this spot urine 
specimen will be a predose sample. The volume of the urine collected during the 8 -hour period on C 1D1 will be recorded. 
dThe scheduling of the time of the study visit and PK sample on Cycle 2, Day 8 should be encouraged to occur at approximately the same time as dosing on 
Days 1 to 7. 
eThese plasma samples from Western safety cohorts may also be u sed for TAK -931 protein binding measurement.
fThe PK plasma sample is collected before administration of the morning dose of TAK -
931.
Note: Further details about sample collection, processing, storage, and shipment can be found in the Study Manual.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 93of 99
Protocol Incorporating Amendment 04 16 July 2018
Appendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are patient to ICH GCP and all the applicable 
local laws and regulat ions. 
The invest igator agrees to assume the fo llowing responsibilit ies:
1.Conduct the study  in accordance wit h the protocol.
2.Personally co nduct or supervise the staff who will assist in the protocol.
3.Ensure that study -related procedures, including study -specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potent ial patients before the receipt of written 
approval from relevant governing bodies/authorit ies.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory requirements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to pati ents. Make at l east y early  reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
7.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH, and local 
regul ations, are met.
8.Obtain valid informed consent from each pat ient who participates in the study , and document 
the date of consent in the patient’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each ICF should contain a pa tient authorization sect ion that 
describes the uses and disclosures of a patient’s personal informat ion (including personal 
healt h informat ion) that will take place in connect ion with the study. If an ICF does not include 
such a patient authorizat ion, then the invest igator must obtain a separate patient authorization 
form from each patient or the patient’s legally acceptable representative.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc., and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator shoul d 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
11.Maintain current records of the receipt, administratio n,and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. This responsibilit y lies on 
the appropriate individual, designated by the site in Japan. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 94of 99
Protocol Incorporating Amendment 04 16 July 2018
12.Report adverse reactions to the sponsor prompt ly. In the even t of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 95of 99
Protocol Incorporating Amendment 04 16 July 2018
Appendix CInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and othe r personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its a ffiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and ve rification of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regul atory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regula tory authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly acc essible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 96of 99
Protocol Incorporating Amendment 04 16 July 2018
Appendix DEastern Cooperative Oncology Group (ECOG) Scale for Perf ormance Status
Grade Description
0 Normal activity. Fully active, able to carry on all predisease performance without restriction.
1 Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to 
carry  out work of a light or sedentary nature (eg, light housework, office work).
2 In bed <50% of the time. Ambulatory and capable of all self -care, but unable to carry out any work 
activities. Up and about more than 50% of waking hours.
3 In bed >50% of the time. Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair.
5 Dead
Source: [26]
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 97of 99
Protocol Incorporating Amendment 04 16 July 2018
Appendix ECockcroft -Gault Equation
For m en:
Creatinine Clearance =(140- age [y ears] )weight [kg]
72(serum creat inine [mg/dL] )
OR
Creatinine Clearance =(140- age [y ears] )weight [kg]
0.81(serum creatinine [µmo l/L])
For wom en:
Creatinine Clearance =0.85 (140- age [y ears] )weight [kg]
72(serum creat inine [mg/dL] )
OR
Creatinine Clearance =0.85 (140- age [y ears] )weight [kg]
0.81(serum creatinine [µmo l/L])
Source: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16(1):31 -41 [27]. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -931
Study No. TAK -931-2001 Page 98of 99
Protocol Incorporating Amendment 04 16 July 2018
Appendix FDetailed Description of Amendments to Text
The primary sect ion(s) of the prot ocol affected by the changes in Amendment 0 4are indicated. 
The corresponding text has been revised throughout the protocol.
Change 1: SAE reporting requirements were changed fro m EDC -based reporting to 
paper/e -mail/fax -based reporting.  
The primary  change occurs in Secti on 10.2 Procedures for Recording and Repo rting Adverse 
Events and Serious Adverse Events :
Initial 
wording: …
Regardless of causalit y, SAEs m ust be reported (see Section 10.3 for the period of 
observat ion) by the invest igator to the Takeda Global Pharmacovigilance 
departm ent or desi gnee wi thin 24 hours of beco ming aware of the event. 
Invest igators should transmit an electronic data capture (EDC) SAE report; 
however, if transmissio n of an EDC SAE report is not feasible, a facsimile of the 
completed Takeda paper -based SAE fo rm may be sent. A sample o f the paper -based 
SAE form and processing directions are found in the Study  Manual . Informati on in 
the SAE report or form must be consistent with the data provided on the eCRF. 
If informat ion not available at the time o f the first report becomes available at a later 
date, the invest igator will transmit a fo llow-up EDC SAE report (or a paper -based 
SAE form if an EDC SAE report is not feasible) or provide other documentation 
immediately  within 24 hours of receipt. Copies of any rele vant data from the 
hospi tal notes (eg, ECGs, laboratory  tests, di scharge summary , postm ortem  resul ts) 
shoul d be sent to the addressee, if requested. 
All SAEs should be fo llowed up unt il reso lution or permanent outcome o f the event. 
The timelines and proce dure for follow- up reports are the same as those for the 
initial report. 
…
Amended 
or new 
wording:…
Regardless of causalit y, SAEs (as defined in Section 10.1.2) must be reported (see 
Secti on10.3 for the peri od of  observati on) by  the investi gator to the Taked aGlobal 
Pharmacovigilance department or desi gnee (contact information provided below). 
This should be done by faxing the SAE Form within 24 hours ofafter beco ming 
aware of the event. Invest igators should transmit an electronic data capture (EDC) 
SAE report; however, if transmissio n of an EDC SAE report is not feasible, a 
facsimile of the co mpleted Takeda paper -based SAE form may be sent. A sample of 
the paper -based SAE form and processing direct ions are found in the Study  Manual . 
Inform ation in the SAE re port or form must be consistent with the data provided on 
the eCRF. The SAE Form, created specifically by Takeda, will be provided to 
each clinical study site. A sample of the SAE Form may be found in the Study 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-931
Study No. TAK-931- 2001 Page 99 of 99
Protocol Incorporating Amendment 04 16 July 2018
Manual. Follow-up information on the SAE may be requested by Takeda. SAE 
report information must be consistent with the data provided on the eCRF. 
SAE Reporting Contact Information
If information not available at the time of the first report becomes available at a later 
date, the investigator will transmit a follow-up EDC SAE report (or a paper-based 
SAE form if an EDC SAE report is not feasible) or provide other documentation 
immediately within 24 hours of receipt. Copies of any relevant data from the 
hospital notes (eg, ECGs, laboratory tests, discharge summary, postmortem results) 
should be sent to the addressee, if requested. 
All SAEs should be followed up until resoluti on or permanent outcome of the event. 
The timelines and procedure for follow-up reports are the same as those for the 
initial report. 
…
Prolongation of hospitalization as a matter of practical convenience is not to be 
considered to be an AE unless the patient’s condition deteriorated.
…
Rationale for Change: EDC SAE reporting is intended for new studies. EDC systems are not in 
place yet for this study.  CCI
Property of Takeda: For Non-Commercial Use Only and SdSof tf the fihe fanfofollollowlyis not fis not fOn of receipreceieOaboratorboratoUsdressee, dresseeal
followedlloweerc d procedprocem
ngationgatio
sideredidere
……
ale for Cle for 
 yet foryet fodTerms of Useof
dda
fTSubject to the Applicable T
䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GGG䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢶䢢䣶䣱䢢䣃䣰䢢䣑䣲䣧䣰䢯䣮䣣䣤䣧䣮䢮䢢䣒䣪䣣䣵䣧䢢䢴䢮䢢䣒䣣䣴䣣䣮䣮䣧䣮䢢䣃䣴䣯䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇 䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣕䣣䣨䣧䣶䣻䢮䢢䣖䣱䣮䣧䣴䣣䣤䣫䣮䣫䣶䣻䢮䢢䣣䣰䣦䢢䣃䣥䣶䣫䣸䣫䣶䣻
䣱䣨䢢䣖䣃䣍䢯䢻䢵䢳䢢䣕䣫䣰䣩䣮䣧䢢䣃䣩䣧䣰䣶䢢䣫䣰䢢䣒䣣䣶䣫䣧䣰䣶䣵䢢䣙䣫䣶䣪䢢䣏䣧䣶䣣䣵䣶䣣䣶䣫䣥䢢䣒䣣䣰䣥䣴䣧䣣䣶䣫䣥䢢 䣅䣣䣰䣥䣧䣴䢢䣱䣴䢢䣏䣧䣶䣣䣵䣶䣣䣶䣫䣥䢢䣅䣱䣮䣱䣴䣧䣥䣶䣣䣮䢢䣅䣣䣰䣥䣧䣴
6WDWLVWLFDO$SSURYDO -XO87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO -XO87&
&OLQLFDO$SSURYDO -XO87&PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

-XOXO